
<html lang="en"     class="pb-page"  data-request-id="a9c40b17-bbf3-42f5-b113-c62bfd9e4b30"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-5;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.0c01957;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="64Cu/177Lu-DOTA-diZD, a Small-Molecule-Based Theranostic Pair for Triple-Negative Breast Cancer" /></meta><meta name="dc.Creator" content="Yuqian  Huang" /></meta><meta name="dc.Creator" content="Zhen  Yang" /></meta><meta name="dc.Creator" content="Feng  Li" /></meta><meta name="dc.Creator" content="Hong  Zhao" /></meta><meta name="dc.Creator" content="Chun  Li" /></meta><meta name="dc.Creator" content="Nam  Yu" /></meta><meta name="dc.Creator" content="Dale J.  Hamilton" /></meta><meta name="dc.Creator" content="Zheng  Li" /></meta><meta name="dc.Description" content="Despite advances in targeted therapies, the prognosis for patients with triple-negative breast cancer (TNBC) is poor because there are few actionable molecular targets. The dependence of solid tumo..." /></meta><meta name="Description" content="Despite advances in targeted therapies, the prognosis for patients with triple-negative breast cancer (TNBC) is poor because there are few actionable molecular targets. The dependence of solid tumo..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 1, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01957" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01957" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01957" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01957" /></link>
        
    
    

<title>64Cu/177Lu-DOTA-diZD, a Small-Molecule-Based Theranostic Pair for Triple-Negative Breast Cancer | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01957" /></meta><meta property="og:title" content="64Cu/177Lu-DOTA-diZD, a Small-Molecule-Based Theranostic Pair for Triple-Negative Breast Cancer" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0008.jpeg" /></meta><meta property="og:description" content="Despite advances in targeted therapies, the prognosis for patients with triple-negative breast cancer (TNBC) is poor because there are few actionable molecular targets. The dependence of solid tumor growth on angiogenesis prompted our development of angiogenic-receptor-targeted radionuclide therapy (TRT) to treat TNBC by targeted delivery of therapeutic doses of ionizing radiation to tumors. A high-affinity vascular endothelial growth factor receptor (VEGFR)-targeted agent, diZD, was synthesized and labeled with 177Lu and 64Cu by 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator giving the TRT agent, 177Lu-DOTA-diZD, and PET imaging agent, 64Cu-DOTA-diZD. We showed that “64Cu/177Lu”-DOTA-diZD radiotracers are a promising theranostic pair for TNBC. 4T1-bearing mice treated with 177Lu-DOTA-diZD-based TRT survived with a median of 28 days, which was significantly longer than that of control mice as 18 days. Anti-PD1 immunotherapy resulted in a shorter median survival of 16 days. This work presents for the first time that small-molecule VEGFR-oriented TRT is a promising therapeutic option to treat “immunogenic cold” TNBC." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01957"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01957">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01957&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01957&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01957&amp;href=/doi/10.1021/acs.jmedchem.0c01957" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2705-2713</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01922" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c01992" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title"><sup>64</sup>Cu/<sup>177</sup>Lu-DOTA-diZD, a Small-Molecule-Based Theranostic Pair for Triple-Negative Breast Cancer</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yuqian Huang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yuqian Huang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Bioenergetics, Houston Methodist Research Institute, Houston, Texas 77030, United States</div><div class="loa-info-affiliations-info">Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yuqian++Huang">Yuqian Huang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhen Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhen Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Bioenergetics, Houston Methodist Research Institute, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhen++Yang">Zhen Yang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9763-6766" title="Orcid link">http://orcid.org/0000-0001-9763-6766</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Feng Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Feng Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Bioenergetics, Houston Methodist Research Institute, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Feng++Li">Feng Li</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hong Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Cancer Center, Houston Methodist Hospital, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Zhao">Hong Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chun Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chun Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Departments of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chun++Li">Chun Li</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2376-4703" title="Orcid link">http://orcid.org/0000-0002-2376-4703</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nam Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nam Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Houston Radiology Associates and Department of Radiology, Houston Methodist Hospital, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nam++Yu">Nam Yu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dale J. Hamilton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dale J. Hamilton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicine, Weil Cornell Medicine, New York, New York 10065, United States</div><div class="loa-info-affiliations-info">Center for Bioenergetics, Houston Methodist Research Institute, Houston, Texas 77030, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dale+J.++Hamilton">Dale J. Hamilton</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Zheng Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zheng Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Radiology, Weil Cornell Medicine, New York, New York 10065, United States</div><div class="loa-info-affiliations-info">Center for Bioenergetics, Houston Methodist Research Institute, Houston, Texas 77030, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#8bd1e7e2cbe3e4fef8ffe4e5e6eeffe3e4efe2f8ffa5e4f9ec"><span class="__cf_email__" data-cfemail="b6ecdadff6ded9c3c5c2d9d8dbd3c2ded9d2dfc5c298d9c4d1">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zheng++Li">Zheng Li</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6118-9175" title="Orcid link">http://orcid.org/0000-0001-6118-9175</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01957&amp;href=/doi/10.1021%2Facs.jmedchem.0c01957" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2705–2713</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 1, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 November 2020</li><li><span class="item_label"><b>Published</b> online</span>1 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 March 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01957" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01957</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2705%26pageCount%3D9%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYuqian%2BHuang%252C%2BZhen%2BYang%252C%2BFeng%2BLi%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D5%26contentID%3Dacs.jmedchem.0c01957%26title%3D64Cu%252F177Lu-DOTA-diZD%252C%2Ba%2BSmall-Molecule-Based%2BTheranostic%2BPair%2Bfor%2BTriple-Negative%2BBreast%2BCancer%26numPages%3D9%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2713%26publicationDate%3DMarch%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01957"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">703</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01957" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;64Cu/177Lu-DOTA-diZD, a Small-Molecule-Based Theranostic Pair for Triple-Negative Breast Cancer&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yuqian&quot;,&quot;last_name&quot;:&quot;Huang&quot;},{&quot;first_name&quot;:&quot;Zhen&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Feng&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Chun&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Nam&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Dale&quot;,&quot;last_name&quot;:&quot;J. Hamilton&quot;},{&quot;first_name&quot;:&quot;Zheng&quot;,&quot;last_name&quot;:&quot;Li&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;2705-2713&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01957&quot;},&quot;abstract&quot;:&quot;Despite advances in targeted therapies, the prognosis for patients with triple-negative breast cancer (TNBC) is poor because there are few actionable molecular targets. The dependence of solid tumor growth on angiogenesis prompted our development of angiogenic-receptor-targeted radionuclide therapy (TRT) to treat TNBC by targeted delivery of therapeutic doses of ionizing radiation to tumors. A high-affinity vascular endothelial growth factor receptor (VEGFR)-targeted agent, diZD, was synthesized and labeled with 177Lu and 64Cu by 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator giving the TRT agent, 177Lu-DOTA-diZD, and PET imaging agent, 64Cu-DOTA-diZD. We showed that “64Cu/177Lu”-DOTA-diZD radiotracers are a promising theranostic pair for TNBC. 4T1-bearing mice treated with 177Lu-DOTA-diZD-based TRT survived with a median of 28 days, which was significantly longer than that of control mice as 18 days. Anti-PD1 immunotherapy resulted in a shorter median survival of 16 days. This work &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01957&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01957" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01957&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01957" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01957&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01957" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01957&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01957&amp;href=/doi/10.1021/acs.jmedchem.0c01957" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01957" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01957" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01957%26sid%3Dliteratum%253Aachs%26pmid%3D33646782%26genre%3Darticle%26aulast%3DHuang%26date%3D2021%26atitle%3D64Cu%252F177Lu-DOTA-diZD%252C%2Ba%2BSmall-Molecule-Based%2BTheranostic%2BPair%2Bfor%2BTriple-Negative%2BBreast%2BCancer%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D5%26spage%3D2705%26epage%3D2713%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292519" title="Cancer therapy">Cancer therapy</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/jmcmar.2021.64.issue-5/20210311/jmcmar.2021.64.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Despite advances in targeted therapies, the prognosis for patients with triple-negative breast cancer (TNBC) is poor because there are few actionable molecular targets. The dependence of solid tumor growth on angiogenesis prompted our development of angiogenic-receptor-targeted radionuclide therapy (TRT) to treat TNBC by targeted delivery of therapeutic doses of ionizing radiation to tumors. A high-affinity vascular endothelial growth factor receptor (VEGFR)-targeted agent, diZD, was synthesized and labeled with <sup>177</sup>Lu and <sup>64</sup>Cu by 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator giving the TRT agent, <sup>177</sup>Lu-DOTA-diZD, and PET imaging agent, <sup>64</sup>Cu-DOTA-diZD. We showed that “<sup>64</sup>Cu/<sup>177</sup>Lu”-DOTA-diZD radiotracers are a promising theranostic pair for TNBC. 4T1-bearing mice treated with <sup>177</sup>Lu-DOTA-diZD-based TRT survived with a median of 28 days, which was significantly longer than that of control mice as 18 days. Anti-PD1 immunotherapy resulted in a shorter median survival of 16 days. This work presents for the first time that small-molecule VEGFR-oriented TRT is a promising therapeutic option to treat “immunogenic cold” TNBC.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71244" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71244" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Triple-negative breast cancer (TNBC), which represents 10–20% of patients with breast cancer, is characterized by the loss of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a> Compared to other breast cancer subtypes, TNBC is more aggressive and occurs more frequently in young women of African origin and BRCA1 mutation carriers.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Despite advances in clinical and molecular understanding of breast cancer, treatment options and outcome still rely primarily on targeting the three markers: ER, PR, and HER2.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The dearth of clinically relevant targets hinders application of tailored therapy to treat TNBC.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> The extremely aggressive and metastatic nature of TNBC, coupled with limited treatment options, has led to an unacceptably high patient mortality rate and urgent calls for the development of more effective therapeutic strategies.</div><div class="NLM_p">Targeted radionuclide therapy (TRT) utilizes targeted agents labeled with radiotherapeutic isotopes, such as <sup>131</sup>I (β-emitter, <i>t</i><sub>1/2</sub> = 8.03 d), <sup>90</sup>Y (β-emitter, <i>t</i><sub>1/2</sub> = 2.66 d), <sup>177</sup>Lu (β-emitter, <i>t</i><sub>1/2</sub> = 6.65 d), and <sup>225</sup>Ac (α-emitter, <i>t</i><sub>1/2</sub> = 9.95 d) to deliver the ionizing energy to tumors, allowing for targeted therapy through systemic administration.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8−10)</a> In contrast to external-beam radiotherapy, TRT offers reduced collateral damage to normal tissues. Moreover, a major advantage of TRT over conventional radiotherapy is its ability to act not only on primary tumors but also on multiple metastatic lesions that are not accessible with external radiation therapy. For instance, <sup>177</sup>Lu-DOTATATE shows favorable outcomes to adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors with respect to overall survival, objective response rate, and quality-of-life measures, prompting food and drug administration (FDA) approval in January 2018 for clinical use.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a><sup>177</sup>Lu-labeled prostate-specific membrane antigen (PSMA) has emerged as an effective treatment to metastatic castration-resistant prostate cancer and is currently being evaluated in multicenter trials.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Likewise, α-particle-emitting radionuclide conjugating with melanoma-targeting peptides has greatly benefited clinical management of metastatic melanoma.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">Another remarkable progress in oncology has been the development of immune checkpoint blockade therapies, which are effective and now FDA-approved for the treatment of a broad range of tumor types.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The success of a variety of immune checkpoint inhibitors has drastically revolutionized the landscape of cancer treatment. Yet the responses to the immunotherapies are currently limited to a minority of patients and indications. It will be interesting to see how the aggressive TNBC responds to the clinically viable anti-PD1-oriented checkpoint inhibitor immunotherapy and how the newly emerged TRT would benefit the TNBC treatment versus the anti-PD1 immunotherapy.</div><div class="NLM_p last">Herein, we radiolabeled diZD, a vascular endothelial growth factor receptor (VEGFR)-targeting agent previously reported by us,<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> with <sup>177</sup>Lu for an angiogenesis-based TRT and <sup>64</sup>Cu for PET imaging in a preclinical mouse model of TNBC. A remarkable antitumor efficacy was observed on orthotopic murine 4T1 tumor model, resulting in both improved local tumor control and prolonged survival. On the contrary, the murine TNBC exhibited poor response to the anti-PD1 immunotherapy. This study reveals a potentially promising small-molecule-based TRT treatment strategy for “immunogenic cold” TNBC.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Preparation of the VEGFR-Targeting Radionuclide</h3><div class="NLM_p">In this work, we prepared the VEGFR-targeting radiotracer using a previously identified VEGFR-targeting agent, diZD, to conjugate with radiotherapeutic β-emitter isotope, <sup>177</sup>Lu, via 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelation as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Previously, we have shown that the <sup>64</sup>Cu-DOTA-diZD specifically binds to VEGFR-positive cells with <i>K</i><sub>d</sub> of 0.45 nM.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> To further validate the binding affinity of the reported targeting agent to VEGFR2, we performed the cell-free binding assay using the VEGFR2 kinase assay by measuring the inhibition of the diZD compound to VEGFR2 kinase activity. <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A shows the IC<sub>50</sub> of the synthetic diZD to VEGFR2 protein as 0.31 ± 0.09 nM, which was consistent with the previously reported 100-fold improvement of binding affinity as compared to the parental drug ZD6474 (vandetanib) as measured IC<sub>50</sub> of 40 nM with the same assay.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> A similar cell-binding assay was also employed to validate the <i>K</i><sub>d</sub> of <sup>177</sup>Lu-DOTA-diZD. <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B shows the saturation curves of the <sup>177</sup>Lu-DOTA-diZD binding to VEGFR-positive HUVECs cells, and the one-site binding mathematical model calculated the <i>K</i><sub>d</sub> of <sup>177</sup>Lu-DOTA-diZD as 0.54 ± 0.05 nM, which was comparable to the <sup>64</sup>Cu-DOTA-diZD. Meanwhile, the blocking assay using excessive “cold” DOTA-diZD showed a significantly diminished cell uptake of the “hot” <sup>177</sup>Lu-DOTA-diZD due to the competitive binding (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C), validating the specificity of the <sup>177</sup>Lu-DOTA-diZD to cell VEGFR. The similar binding properties of “<sup>64</sup>Cu/<sup>177</sup>Lu”-labeled DOTA-diZD suggests a theranostic pairing of the two agents for diagnostic imaging and radiotherapy in VEGFR cancer targeting.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Binding affinity of the targeting agent to VEGFR2 validated by measuring the inhibition of diZD to VEGFR2 protein using VEGFR2 kinase assay (A), saturation binding of <sup>177</sup>Lu-DOTA-diZD to VEGFR2-expressed HUVEC cells (B), and blocking of excessive cold DOTA-diZD to specific binding of <sup>177</sup>Lu-DOTA-diZD to VEGFR2-expressed HUVEC cells (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Structures of <sup>64</sup>Cu-DOTA-diZD and <sup>177</sup>Lu-DOTA-diZD<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Blue color highlights the targeting moieties to VEGFR.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> PET Imaging and Biodistribution of <sup>64</sup>Cu-DOTA-diZD in 4T1 Tumor-Bearing Mice</h3><div class="NLM_p">We first performed small-animal PET/CT imaging studies of the <sup>64</sup>Cu-DOTA-diZD to investigate the in vivo behavior of the VEGFR-targeting radionuclide in Balb/c mice bearing 4T1 TNBC tumors as shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A. The in vivo images clearly showed a clearance trend of the radiotracer in the metabolic tissues and organs, such as blood, liver, and GI, with prolonged post injection (pi) time. On the contrary, accumulation of the radiotracer in the tumor was gradually increased from 6 to 24 h and peaked at 48 h pi indicated by tumor/blood ratio during the study time window. Heterogeneous tumor uptake of radiotracer demonstrated heterogeneity of VEGFR expression and angiogenesis in TNBC. Specifically, tumor/blood ROI reading revealed a median tumor uptake of <sup>64</sup>Cu-DOTA-diZD as 1.67 ± 0.11 at 6 h pi, and increased uptake to 1.83 ± 0.06 at 24 h pi and peaked uptake to 2.25 ± 0.09 at 48 h pi (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Diagnostic MIP (maximum intensity projection) images of <sup>64</sup>Cu-DOTA-diZD in 4T1 tumor-bearing mice obtained by in vivo PET/CT imaging at 6, 24, and 48 h pi (A), tumor/blood ROI-derived uptake of the radiotracer in the in vivo imaging (B), and biodistribution of the radiotracer among major organs at 48 h pi (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last"><a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C shows the biodistribution of <sup>64</sup>Cu-DOTA-diZD in the 4T1 tumor-bearing mice at 48 h pi, corresponding to representative image presented in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A. Medium uptake in the liver (4.6 ± 0.8% ID/g) suggested a predominantly hepatic clearance of the <sup>64</sup>Cu-DOTA-diZD due to a slight hydrophobicity of the synthetic diZD molecule. Tumor uptake was measured as 2.0 ± 0.5% ID/g by the 48 h pi biodistribution. Notably, a prominent lesion uptake was observed in the 48 h pi lung of the imaged tumor-bearing mouse, which suggested a metastatic lesion of the 4T1 tumor in the lung. Correspondingly, a relative higher lung uptake of the <sup>64</sup>Cu-DOTA-diZD was observed in the biodistribution study as compared to our previously identified <sup>64</sup>Cu-DOTA-diZD PET imaging of U87-bearing mice.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> VEGFR-Based TRT and Anti-PD1 Antibody for the 4T1 Tumor</h3><div class="NLM_p">Given the specific tumor-targeting behavior and excellent pharmacokinetic properties of <sup>64</sup>Cu-DOTA-diZD in the 4T1 tumor, a therapy study was performed to examine the antitumor efficacy of its theranostic counterpart <sup>177</sup>Lu-DOTA-diZD, alone and in combination with anti-PD1 immunotherapy. To verify there is minimal therapy effect of cold diZD when binding to VEGFR in the treatment at an extremely low dose, additional control groups treated with radiotherapeutic dose cold diZD were also included in the study design. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A shows the therapy protocol designed in the study.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Therapies for the 4T1 tumor-bearing Balb/c mice: (A) schematic illustration of the therapy protocol; (B) body weight change; (C) local tumor volume change; and (D) survival of mice treated with saline (group A), cold diZD (group B), anti-PD1 antibody (group C), and <sup>177</sup>Lu-DOTA-diZD (group D) (<i>p</i> < 0.001).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Slight weight loss was observed in animals that received either anti-PD1 antibody or radioactive <sup>177</sup>Lu-DOTA-diZD on the first week of the therapy (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B), but no systemic toxicity of the therapies was suggested. <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C illustrates rapid tumor growth observed in mice treated with saline (group A) and cold diZD (group B) after 8 days of therapy. The animals were euthanized when tumor reached 2 cm in length, as described in the study endpoint established by the IACUC protocol. As calculated from the survival curve shown in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>D, median survival for groups A and B were 18 and 20 days, respectively. No significant differences were observed in groups A and B for either tumor volume or median survival, suggesting negligible antitumor effect of the cold diZD at a dosage as low as that used in the radiotherapy. For mice treated with anti-PD1 antibody with (group C), local tumor control as indicated by decreased rate of tumor growth relative to the control group did not translate to significant improvement in median survival (16 days for group C). Treatment with <sup>177</sup>Lu-DOTA-diZD (group D) yielded a significant improvement in tumor volume reduction compared to the other groups.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Histopathological Study of the Antitumor Efficacy</h3><div class="NLM_p">We then examined the tumor tissues and immune cells to explore the possible mechanism underlying the antitumor efficacy of the treatments. We first examined the proliferation biomarker, Ki67, in tumor tissues from the mice that received various therapies (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). Predominant Ki67 expression was observed in the control group (group A) and the diZD group (group B), suggesting active tumor growth in the two groups. However, the Ki67 level was still prominent in the group treated with anti-PD1 immunotherapy (group C). When the tumor was treated with <sup>177</sup>Lu-DOTA-diZD radiotherapy (group D), the Ki67 expression was dramatically decreased. It supported the notion that tumor growth was suppressed upon the TRT treatment. The observation was concordant with tumor volume and median survival data presented in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>. In addition, we examined the VEGFR2 expression level on the tumor tissues and compared the levels across groups treated with various therapies, and no difference on the VEGFR expression level was observed (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Immunohistochemistry staining of Ki67 on tumor tissues collected from various therapies; (B) western blotting assay for VEGFR2 expression on tumor tissues; (C) flow analyses of PD1 expression on T cells from spleens of healthy Balb/c and 4T1 tumor-bearing Balb/c mice; and (D) flow analyses of CD4<sup>+</sup> and CD8<sup>+</sup> cells activation in tumors treated with various therapies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Further, T cells of the groups of treated Balb/c mouse were identified by positive staining of CD3 marker, showing negligible expression of PD1 immune checkpoint marker on the T cells of the Balb/c mouse strain with and without the 4T1 tumor inoculation (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). This supports our observation that 4T1 tumor-bearing mice responded poorly to the anti-PD1 antibody treatment. Moreover, population of CD4<sup>+</sup> and CD8<sup>+</sup> cells doubled after treatment with <sup>177</sup>Lu-DOTA-diZD radiotherapy (group D) compared to the control group (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D), while only mild increase over control was observed in the diZD-treated group (group B) and anti-PD1 antibody-treated group (group C). These results suggest that <sup>177</sup>Lu-DOTA-diZD modulates the tumor microenvironment and facilitates adaptive immune response, which may partially account for the observed antitumor efficacy of <sup>177</sup>Lu-DOTA-diZD radiotherapy on 4T1 breast tumor.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43048" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43048" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Advances in molecular biology have spawned vast development of tailored therapy and precision medicine for cancer treatment.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> However, lack of clinically recognized molecular targets impedes such effort for TNBC. Angiogenesis is a well-recognized and ubiquitous process in various pathologic states including growth of malignant tumors, providing a promising therapeutic target to treat both primary and metastatic TNBC.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Tremendous clinical attempts have been made to curtail angiogenesis by targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFR) with varying levels of success in nearly every type of solid tumors.<a onclick="showRef(event, 'ref24 ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27">(24−27)</a> However, the success of angiogenesis-targeted chemotherapy was limited by the existence of multiple complimentary mechanisms.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Alternatively, angiogenic-receptor-targeting radionuclide radiation therapy was proposed to eradicate tumor cells using radiation energy. For instance, Cai and his colleagues piloted the antitumor efficacy of angiogenesis-targeting antibody (anti-CD105) conjugated with <sup>177</sup>Lu on murine 4T1 TNBC model.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> It showed effective suppression of tumor growth and significant survival benefits with negligible off-target toxicity. However, the efficacy of antibody-based TRT is still challenged by its limited penetration into solid tumors along with concerns of high cost and immunogenicity.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> With this in mind, we developed a synthetic small-molecule-based TRT strategy to treat TNBC. The binding assay at both protein level and VEGFR2-expressed cell level collectively showed superior binding affinity of the synthetic compounds to VEGFR2 and significant improvement compared to its parental drug compound ZD6474.</div><div class="NLM_p">As observed in our PET imaging of the 4T1 tumor, medium <sup>64</sup>Cu-DOTA-diZD uptake was observed in the tumor at the 6 h pi with progressive accumulation over time, whereas pharmacokinetics of the radiotracer exhibited a trend for decreased clearance in the metabolic organs such as liver and GI tract. This supports that specific tumor targeting increased accumulation of the diZD-based radiotracer was originated by its specific targeting to the tumor. Also, the positive validation of VEGFR2 expression in the 4T1 tumor supported the tumor-targeting nature of diZD agents via the angiogenic target. There was continuous increase in tumor uptake of the tracer at the end of the 48 h PET imaging window which was limited by the 12.7 h half-life of <sup>64</sup>Cu. This implies robust prolonged retention of <sup>177</sup>Lu-DOTA-diZD for optimal therapeutic exposure of the tumor to the radionuclide radiation.</div><div class="NLM_p">There were studies suggesting that metal ions across different radiolabeling may alter binding properties of the TRT agents. Using in vitro cell VEGFR-binding assay, we demonstrated that the binding affinity and specificity of the therapeutic <sup>177</sup>Lu-DOTA-diZD to VEGFR are similar to those of the diagnostic <sup>64</sup>Cu-DOTA-diZD. Indeed, the good uptake of radiotracer observed on imaging can be correlated with antitumor efficacy in the VEGFR-TRT-treated 4T1 tumor-bearing mice, advocating for the small-molecule “<sup>64</sup>Cu/<sup>177</sup>Lu”-DOTA-diZD pair as a promising theranostic strategy in TNBC. Worth noting was that the diagnostic imaging of <sup>64</sup>Cu-DOTA-diZD showed prominent uptake in a lung metastatic lesion and relatively high lung uptake of the 4T1-bearing mouse, suggesting that tumor angiogenesis-targeted <sup>177</sup>Lu-DOTA-diZD radionuclide radiation therapy can treat both primary and metastatic tumor lesions simultaneously.</div><div class="NLM_p last">Furthermore, we investigated antitumor efficacy of the developed VEGFR-targeting TRT in the murine 4T1 TNBC breast cancer model and its comparison with the clinically viable anti-PD1 checkpoint inhibitor immunotherapy. Our result showed that the murine 4T1 breast tumor responded poorly to anti-PD1 immunotherapy, which is correlated with other reported studies, due to low infiltrating T cells in the tumor.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> Similarly, treatment of angiogenesis-targeting agent, diZD at a very low dosage (2 nmol/mouse), posed little benefit to the treatment of murine 4T1 tumor. It indicated that no VEGFR2-associated downstream signal pathway was agitated by the low dosage employed in this study. To our delight, the newly developed <sup>177</sup>Lu-DOTA-diZD radionuclide radiation therapy yielded remarkable antitumor efficacy on the murine 4T1 tumor with effective local tumor control and prolonged survival on 4T1 TNBC breast tumors. The distinctive antitumor efficacy displayed between the cold diZD group and hot <sup>177</sup>Lu-DOTA-diZD group demonstrated the radionuclide radiation therapeutic effect underlying the <sup>177</sup>Lu-DOTA-diZD therapy rather than the targeted diZD chemotherapeutic effect. When we examined the population of CD4<sup>+</sup> and CD8<sup>+</sup> in the various treated cohorts, it showed that only the <sup>177</sup>Lu-DOTA-diZD radiotherapy significantly increased the activated T cells. In addition, a number of studies have suggested to combine radiotherapy to modulate the tumor microenvironment to promote effectiveness of the immunotherapy.<a onclick="showRef(event, 'ref9 ref31'); return false;" href="javascript:void(0);" class="ref ref9 ref31">(9,31)</a> It was proposed that the ionizing energy delivered by the radiotherapy modulates the tumor environment, stimulates adaptive immune response and facilitates infiltration of activated immune cells, and thereby promoting response to immunotherapy. However, such synergistic effect was not observed in our study when combing the <sup>177</sup>Lu-DOTA-diZD TRT with the anti-PD1 immunotherapy concurrently (data not shown). Mixed results of combination therapy of TRT were reported. For instance, a clinical study by Baum and colleagues showed that <sup>177</sup>Lu-PSMA TRT offers significant survival benefits to patients with metastatic prostate cancer when administered first line but was associated with worse prognosis in patients who had been previously treated with chemotherapy or Ra-223 treatment.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> In addition, Chen and his group showed that the time window for combined integrin α<sub>v</sub>β<sub>3</sub>-based TRT with anti-PD-L1 antibody therapy was critical to outcome, as the concurrent administration was more effective than sequential therapy in terms of overall survival and long-term tumor control in an immunoresponsive colon cancer model.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> These reports and our work suggest that TNT has great potential to treat immunogenic cold TNBC, and further study is needed to optimize combination strategies with TNT, bearing in mind the elusive window for synergy and potential for added toxicity.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83344" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83344" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we report here the development and evaluation of a synthetic small-molecule-based angiogenic TRT to treat TNBC. We have shown the “<sup>64</sup>Cu/<sup>177</sup>Lu”-DOTA-diZD radiotracers as a promising theranostic pair for TNBC: (1) similar VEGFR-targeting property was exhibited between the “<sup>64</sup>Cu/<sup>177</sup>Lu”-DOTA-diZD radiotracers; (2) the diagnostic <sup>64</sup>Cu-DOTA-diZD specifically accumulated in the murine 4T1 tumor in the microPET/CT imaging; (3) the therapeutic <sup>177</sup>Lu-DOTA-diZD displayed excellent antitumor efficacy in the murine 4T1 breast cancer model as indicated by both local tumor growth and prolonged median survival. Therefore, the angiogenic-receptor-targeted TRT poses a promising therapeutic strategy in TNBC.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77555" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77555" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Reagents and Equipment</h3><div class="NLM_p last">All chemical reagents and solvents were purchased from Millipore Sigma (St. Louis, MO) and used without further purification unless otherwise stated. ZD6474 was purchased from FDU, Inc. (Shanghai, China). DOTA was purchased from Macrocyclics (Dallas, TX). <sup>177</sup>LuCl<sub>3</sub> was ordered from Advanced Accelerator Applications, Inc. Water was purified using Milli-Q ultrapure water system from Millipore (Milford, MA). VEGFR2 antibody (VEGF Receptor 2 Rabbit mAb #2479) was purchased from Cell Signaling Technology (MA). All solvents were of HPLC grade from Sigma-Aldrich (St. Louis MO).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Synthesis of diZD (<b>3</b>, ZD-G2)</h3><div class="NLM_p">The VEGFR-targeting agent, diZD, was synthesized as previously reported by our group.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The synthetic scheme is shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Briefly, triethylamine (28 mmol, 4.0 mL) was added to a stirred solution of triethanolamine (3 mmol, 0.45 g) in 50 mL of anhydrous dichloromethane. Then, 1,1′-carbonyldiinidazole (CDI, 24 mmol, 4.06 g) was supplemented and the mixture was stirred at room temperature to react for 12 h. Afterward, the mixture was cooled down to 0 °C and kept stirred with supplement of 50 mL for an additional 30 min. The organic layer was collected and washed with ice-cold water (2 × 50 mL) and brine (50 mL) and then dried with MgSO<sub>4</sub> prior to reduced-pressure evaporation to retrieve 2,2′,2″-nitrilotris(ethane-2,1-diyl)-tris(1H-imidazole-1-carboxylate) intermediate <b>2</b> as a colorless oil (1.16 g, 2.69 mmol, 90% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 8.07 (s, 3H), 7.32 (t, 3H, <i>J</i> = 1.5), 7.05 (m, 3H), 4.47 (t, 6H, <i>J</i> = 5.7), 3.05 (d, 6H, <i>J</i> = 5.7).</div><figure id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Scheme of Precursor DOTA-diZD</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Afterward, ZD6474 (0.42 mmol, 210 mg) was added to 2 mL of DMSO solution containing <b>2</b> (0.22 mmol, 85 mg). The solution was stirred overnight at ambient temperature upon addition of triethylamine (2.80 mmol, 400 μL). Then, 50 μL of ethyldiamine was added into the stirred solution and the reaction was kept for an additional 24 h and then quenched by adding 20 μL of trifluoroacetic acid. The purification of the crude product was carried out on a semipreparative reversed-phase high-performance liquid chromatography (HPLC) system (Agilent 1200 series) using a Phenomenex Luna C18(2) column 100R (250 × 10.00 mm<sup>2</sup>). Compound <b>3</b> was collected by monitoring optical absorbance at 254 nm and then lyophilized and characterized prior to further use. Mass spectrum and <sup>1</sup>H NMR were performed to validate the compound chemical structure and purity. MS spectrum of <b>3</b>: <i>m</i>/<i>z</i> 1210.5 (100, [M + H]<sup>+</sup>, calculated 1209.92); 606.0 ([M + 2H]<sup>2+</sup>). <sup>1</sup>H NMR (500 MHz, DMSO): 8.715 (s, 2H, Ph–NH), 7.963 (s, 2H), 7.796 (d, 2H, <i>J</i> = 2), 7.786 (d, 2H, <i>J</i> = 2), 7.796 (d, 2H, <i>J</i> = 2), 7.547 (m, 4H), 7.502 (s, 1H, CONH), 7.265 (s, 2H), 4.272 (m, 4H, −OCH<sub>2</sub>−), 4.058 (m, 8H), 3.975 (s, 6H, −OCH<sub>3</sub>), 3.345 (m, 6H), 2.876 (m, 8H), 1.96 (s, 2 h, −NH<sub>2</sub>), 2.095 (m, 2H), 1.824 (m, 4 h), 1.242 (m, 4 h).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Synthesis of DOTA-diZD (<b>4</b>, ZD-G2)</h3><div class="NLM_p last">The synthesis of DOTA-diZD <b>4</b> was performed as follows: DOTA-<i>N</i>-hydroxysuccinimide (NHS)-ester (3 mg, 6 μmol) was added to 0.5 mL of diZD DMSO solution (10 μmol/mL, 6 μmol) with supplement of 50 μL of triethylamine. The reaction mixture was stirred in the dark at ambient temperature overnight and then quenched with an addition of 200 μL of trifluoroacetic acid. The crude product was purified by semipreparative reversed-phase HPLC using a Phenomenex Luna C18 column (250 × 10 mm<sup>2</sup>). Fractions containing DOTA-diZD <b>5</b> were collected, lyophilized, and stored with protection of light at −20 °C until further use. MS was performed to characterize the compound: <i>m</i>/<i>z</i> 1596.32 ([M + H]<sup>+</sup>, calculated 1596.3); 789.6 ([M + 2H]<sup>2+</sup>).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Radiochemistry</h3><div class="NLM_p">DOTA-diZD was radiolabeled with <sup>177</sup>Lu using the procedures as follows. Briefly, 700 MBq (19 mCi) <sup>177</sup>LuCl<sub>3</sub> in 0.1 M HCl was diluted by adding 950 μL of 0.1 M ammonium acetate (pH 5.6) to obtain <sup>177</sup>Lu (OAc)<sub>3</sub>. DOTA-diZD (10 μmol/mL, 100 nmol) in 10 μL of DMSO was mixed with 400 μL of <sup>177</sup>Lu (OAc)<sub>3</sub>. The mixture was vortexed and incubated at 50 °C for 1 h. <sup>177</sup>Lu-labeled DOTA-diZD (<sup>177</sup>Lu-DOTA-diZD) was purified by semipreparative radio-HPLC, and the collected fraction containing <sup>177</sup>Lu-DOTA-diZD was evaporated and reconstituted in PBS. It was filtered into a sterile dose vial for use in animal experiments by passing through a 0.22 μm Millipore filter. The radiochemical yield and chemical purity were determined by HPLC. The radiochemical yield was 70% with purity above 99%. The specific activity was 2.53 MBq/nmol. The stability of <sup>177</sup>Lu-DOTA-diZD was also evaluated by incubating with Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) at 37 °C for up to 24 h. Aliquots at 3, 24, and 48 h were analyzed by radio-HPLC (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_001.pdf" class="ext-link">Figure S5</a>).</div><div class="NLM_p last">A similar procedure was followed to radiolabel DOTA-diZD with <sup>64</sup>Cu. Generally, 185 MBq (5 mCi) <sup>64</sup>CuCl<sub>2</sub> in 0.1 M HCl was diluted by adding 300 μL of 0.1 M ammonium acetate (pH 5.6) to obtain <sup>64</sup>Cu(OAc)<sub>2</sub>. Then, 200 μL of 0.1 M ammonium acetate containing 100 nmol DOTA-diZD was mixed with ∼2 to 3 mCi <sup>64</sup>Cu(OAc)<sub>2</sub> to incubate and vortex at 50 °C for 1 h for the radiolabeling. The radiolabeled <sup>64</sup>Cu-DOTA-diZD was purified by semipreparative radio-HPLC, and the collected fraction of <sup>64</sup>Cu-DOTA-diZD was evaporated to remove the organic solvents and reconstituted in PBS for in vivo imaging study. Prior to animal injection, the reconstituted imaging probe solution was filtered through a 0.22 μm Millipore filter to derive a final sterile dose for animal imaging study. The radiolabeled yield was determined as 75% by HPLC, and the specific activity was calibrated as 2.40 MBq/nmol. The stability of <sup>64</sup>Cu-DOTA-diZD was evaluated by incubating with Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS). Aliquots of the solution at 3, 24, and 48 h were extracted and analyzed by radio-HPLC for stability evaluation (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_002.csv" class="ext-link">Figure S6</a>).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> In Vitro Cell VEGFR-Binding Assay</h3><div class="NLM_p">Binding affinity and specificity of the synthetic diZD compound to VEGFR2 were performed using both cell-free assay and cell-binding assay. The cell-free assay was performed using the VEGFR2 Kinase Assay Kit (BPS Bioscience, cat# 40325), which was designated to profile inhibitors to VEGFR2 at the protein level. Briefly, the assay was performed using the kit as instructed by measuring inhibition of diZD to VEGFR2 at concentrations (nM): 1 × 10<sup>–5</sup>, 5 × 10<sup>–4</sup>, 1 × 10<sup>–3</sup>, 5 × 10<sup>–3</sup>, 1 × 10<sup>–2</sup>, 5 × 10<sup>–2</sup>, 0.1, 0.5, 1, 5, 10, 50, and 100. The inhibitory effect was gauged by measuring the VEGFR2 kinase activity upon the addition of various concentrations of diZD, and Kinase-GloMAX (Promega, cat# V6711) was used as a detection reagent.</div><div class="NLM_p">For cell-binding assay, human umbilical vein endothelial cells (HUVECs) were purchased from Lonza (cat# C2519AS) and maintained in endothelial cell growth medium-2 (Lonza, cat# CC-3162). The cells were cultured in 5% CO<sub>2</sub> atmosphere in a 37 °C incubator and used for the binding experiments when they reached approximately 75% confluence.</div><div class="NLM_p last">The binding affinity and specificity of <sup>177</sup>Lu-DOTA-diZD were evaluated by saturation and displacement assay as previously reported.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> Briefly, the cells were seeded in 12-well plates at a density of 5 × 105 cells/well the day before the experiment. For receptor-saturation assay, the cells were incubated at 37 °C for 1 h with increased concentrations of <sup>177</sup>Lu-DOTA-diZD. Then, the cells were washed with PBS three times, trypsinized, and collected into γ counter tubes by centrifuging at 500<i>g</i> for 5 min. The cell pellet-associated radioactivity was measured using a PerkinElmer Packard γ counter. For specific binding assay, 37 kBq (1 μCi, 0.014 nmol) <sup>177</sup>Lu-DOTA-diZD was added to each well of cells with and without 100-fold excess amount of nonradioactive DOTA-diZD, and 500 μL volume was maintained to yield 7.3 nM concentration of the investigated compounds for the binding assay. After incubation at 37 °C for 1 h, the cells were washed and collected for the radioactivity counting as described above.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Murine TNBC Model</h3><div class="NLM_p">4T1 murine breast cancer cells were obtained from American Type Culture Collection and maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum supplementation. The cells were cultured in 5% CO<sub>2</sub> atmosphere in a 37 °C incubator and used for in vivo experiments when they reached about 75% confluence.</div><div class="NLM_p last">All animal studies were performed under approval protocol by the Institutional Animal Care and Use Committee (IACUC) of the Houston Methodist Research Institute. To generate breast tumor model, 1 × 105 4T1 cells were harvested and suspended into 100 μL of Matrigel (Corning, #354248) diluted with 1:1 PBS, and then injected into the mammary fat pad of 8 week old female Balb/c purchased from Charles River for tumor inoculation. The tumor-bearing mice were closely monitored and randomly grouped for therapy study when tumors reached a palpable size (10–12 days after inoculation).</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> PET/CT Imaging and Biodistribution</h3><div class="NLM_p last">Small-animal PET/CT scans were performed and analyzed using a Siemens Inveon PET/CT imaging system. Approximately 3.7 MBq <sup>64</sup>Cu-DOTA-diZD (100 μCi, 1.5 nmol) was intravenously injected into the 4T1-bearing mice (<i>n</i> = 5) with tumor size reaching up to 10 mm in length via tail vein. In-line PET and CT scans were acquired at 6, 24, and 48 h post injection (pi), and images were obtained using manufacturer’s two-dimensional ordered-subsets expectation maximum algorithm. For each PET scan, regions of interest (ROIs) were drawn over the tumor on decay-corrected whole-body coronal images to derive tumor accumulation of the targeting agent. After the 48 h pi imaging scans, the mice were sacrificed to evaluate radiotracer biodistribution among the major organs, including blood, heart, lung, liver, kidney, spleen, tumor, gastrointestinal (GI), and muscle. The radioactivity accumulated in each tissue was measured using a 2470 Wizard2 Automatic γ counter (PerkinElmer, Wallac) and calculated as radioactivity divided by tissue weight and decay-corrected injected dose to express as %ID/g.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> In Vivo Antitumor Efficacy</h3><div class="NLM_p">Each mouse was inoculated with 1 × 10<sup>5</sup> cells of 4T1 cells in the mammary fat pad. When tumors had grown to be palpable (∼4 mm in diameter), the tumor-bearing mice were randomized into four treatment groups of 10–15 mice per group: group A, control receiving saline; group B, cold treatment control receiving cold DOTA-diZD on days 0 and 8 at a dose of 2 nmol by intravenous (iv) injection; group C, individual immunotherapy receiving anti-PD1 mAb intraperitoneally (ip) on days 0, 3, 6, and 9 at a dose of 100 μg/mouse; group D, individual radiotherapy receiving iv injection of <sup>177</sup>Lu-DOTA-diZD on days 0 and 8 at a dose of 3.7 MBq (1.46 nmol) per injection.</div><div class="NLM_p last">To evaluate the antitumor efficacy of the treatment, tumor size and body weight were monitored every other day. The tumor growth and animals were continuously monitored until the study reached the endpoint measured by any of the following criteria: weight loss over 15%, tumor size reached 2 cm in length, active tumor ulceration, and abnormal behavior indicating pain or unease. Individual tumor volume was calculated by the formula (length × width<sup>2</sup>/2). Median survival for each treatment group was calculated using the Kaplan–Meier analysis.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Flow Cytometry after the Therapy</h3><div class="NLM_p">The tumor tissue was obtained and ground into pieces in 2% FBS supplemented RPMI1640 medium. The cell suspension was then filtered through a 40 μm cell strainer, washed with 1% BSA supplemented phosphate-buffered saline solution (PBS), and centrifuged at 500<i>g</i> for 5 min. The cell pellet was collected and resuspended for the subsequent antibody staining.</div><div class="NLM_p last">Two groups of staining were performed: (1) 100 μL/tube of 10<sup>6</sup> cells suspended in 1% BSA PBS was incubated with fluorescent mAbs specific to mouse CD3 (PE anti-mouse CD3, BioLegend, cat# 100205) and PD1 (FITC anti-mouse PD1, BioLegend, cat# 135214) at RT for 30 min; (2) similarly, cells from the mice of various treatment groups were incubated to with the mAbs specific to mouse CD4+ (APC anti-mouse CD4, BD Bioscience, cat# 561091) and CD8+ (FITC anti-mouse CD8, BD Bioscience, cat# 553030). Then, the tubes were washed twice in 1 mL of 1% BSA PBS and centrifuged at 500<i>g</i> for 5 min. The stained cells were data acquired and analyzed using BD LSRFortessa Flow Cytometer.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Histopathological Staining and Western Blotting after the Therapy</h3><div class="NLM_p">The 4T1 tumor samples from groups A–D were collected and fixed in 4% formalin immediately after harvesting and then processed, embedded, and sectioned following the routine pathology core procedure. Briefly, 4–5 μm tissue sections were obtained. For Ki67 antibody staining, the sections were deparaffinized in xylene, a series of ethanol solution, treated with 0.3% hydrogen peroxide for 20 min, followed by incubation in 5% horse serum block for 10 min to inhibit the nonspecific binding of the primary antibody. Then, the sections were stained with Ki67 antibody (Rabbit mAb, 1:500 dilution). Detection was performed with HRP-conjugated respective secondary system followed by diaminobenzidine and counter-staining with hematoxylin solution. Images were captured using an inverted microscope.</div><div class="NLM_p last">Meanwhile, the tumor samples were collected for western blotting assay of the expression level of VEGFR2. Generally, fresh tumor samples were collected, homogenized, and lysed in 0.1% Triton X-100 buffer. The lysed samples were electrophoresed in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels (Bio-Rad) following protein quantification by BCA Protein Assay (Thermo Fisher Scientific) according to manufacturer’s protocol and equivalent protein amounts were loaded for each group. Proteins were blotted onto poly(vinylidene difluoride) (PVDF) membranes by wet transfer. The membranes were probed with VEGFR2 antibody (rabbit mAb) and secondary antibody and developed using enhanced chemiluminescence reagent, and images were acquired using a ChemiDoc gel documentation system.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Statistics</h3><div class="NLM_p last">Quantitative data were expressed as mean ± SD. Means were compared using Student’s <i>t</i> test; 95% confidence level was chosen to determine the significance between groups; and <i>P</i> value < 0.05 was considered statistically significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01957" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46866" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46866" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01957?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01957</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">NMR and MS spectra of representative compounds and stability validation of the investigated radiotracers (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES formula of each tested compound and associated biochemical data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Scheme 1 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_003.cdx" class="ext-link">CDX</a>)</p></li><li><p class="inline">Scheme 2 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_004.cdx" class="ext-link">CDX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_001.pdf">jm0c01957_si_001.pdf (694.86 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_002.csv">jm0c01957_si_002.csv (1.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_003.cdx">jm0c01957_si_003.cdx (25.25 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_004.cdx">jm0c01957_si_004.cdx (24.53 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01957" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14830" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14830" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zheng Li</span> - <span class="hlFld-Affiliation affiliation">Department of Radiology, 
     and , Weil Cornell Medicine, New York, New York 10065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Center
for Bioenergetics, Houston Methodist Research
Institute, Houston, Texas 77030, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6118-9175" title="Orcid link">http://orcid.org/0000-0001-6118-9175</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#91cbfdf8d1f9fee4e2e5fefffcf4e5f9fef5f8e2e5bffee3f6"><span class="__cf_email__" data-cfemail="461c2a2f062e2933353229282b23322e29222f353268293421">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuqian Huang</span> - <span class="hlFld-Affiliation affiliation">Center
for Bioenergetics, Houston Methodist Research
Institute, Houston, Texas 77030, United
States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Neurology, Xiangya Hospital, Central
South University, Changsha, Hunan 410008, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhen Yang</span> - <span class="hlFld-Affiliation affiliation">Center
for Bioenergetics, Houston Methodist Research
Institute, Houston, Texas 77030, United
States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9763-6766" title="Orcid link">http://orcid.org/0000-0001-9763-6766</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feng Li</span> - <span class="hlFld-Affiliation affiliation">Center
for Bioenergetics, Houston Methodist Research
Institute, Houston, Texas 77030, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Zhao</span> - <span class="hlFld-Affiliation affiliation">Cancer
Center, Houston Methodist Hospital, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chun Li</span> - <span class="hlFld-Affiliation affiliation">Departments
of Cancer Systems Imaging, The University
of Texas MD Anderson Cancer Center, Houston, Texas 77030, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2376-4703" title="Orcid link">http://orcid.org/0000-0002-2376-4703</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nam Yu</span> - <span class="hlFld-Affiliation affiliation">Houston
Radiology Associates and Department of Radiology, Houston Methodist Hospital, Houston, Texas 77030, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dale J. Hamilton</span> - <span class="hlFld-Affiliation affiliation">Department of Medicine, 
     and , Weil Cornell Medicine, New York, New York 10065, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Center
for Bioenergetics, Houston Methodist Research
Institute, Houston, Texas 77030, United
States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.H. and Z.Y. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e1218-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17477" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17477" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the Houston Methodist Research Institute (HMRI) and foundation. The authors thank the preclinical imaging core facility of HMRI. This research was funded in part through DoD BCRP Breakthrough Award (BC141561P1) (Z.L.) and Finger Distinguished Endowed Chair (D.H.).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">DOTA</td><td class="NLM_def"><p class="first last">1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">food and drug administration</p></td></tr><tr><td class="NLM_term">HER2</td><td class="NLM_def"><p class="first last">human epidermal growth factor receptor 2</p></td></tr><tr><td class="NLM_term">PR</td><td class="NLM_def"><p class="first last">progesterone receptor</p></td></tr><tr><td class="NLM_term">PSMA</td><td class="NLM_def"><p class="first last">prostate-specific membrane antigen</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple-negative breast cancer</p></td></tr><tr><td class="NLM_term">TRT</td><td class="NLM_def"><p class="first last">targeted radionuclide therapy</p></td></tr><tr><td class="NLM_term">VEGFR</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42846" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42846" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foulkes, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span> <span> </span><span class="NLM_article-title">Triple-negative breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1948</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1001389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1056%2FNEJMra1001389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=21067385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1938-1948&author=W.+D.+Foulkesauthor=I.+E.+Smithauthor=J.+S.+Reis-Filho&title=Triple-negative+breast+cancer&doi=10.1056%2FNEJMra1001389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer</span></div><div class="casAuthors">Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1938-1948</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiN8P8IsovvLVg90H21EOLACvtfcHk0lgUpej7yUSHow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P&md5=641fe4726e6a7118208aa6b3502c9df6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1001389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1001389%26sid%3Dliteratum%253Aachs%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26atitle%3DTriple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1938%26epage%3D1948%26doi%3D10.1056%2FNEJMra1001389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cedolini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Londero, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seriau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risaliti, A.</span></span> <span> </span><span class="NLM_article-title">Type of breast cancer diagnosis, screening, and survival</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2014.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1016%2Fj.clbc.2014.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=24703317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BC2cngslGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=235-240&author=C.+Cedoliniauthor=S.+Bertozziauthor=A.+P.+Londeroauthor=S.+Bernardiauthor=L.+Seriauauthor=S.+Concinaauthor=F.+Cattinauthor=A.+Risaliti&title=Type+of+breast+cancer+diagnosis%2C+screening%2C+and+survival&doi=10.1016%2Fj.clbc.2014.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Type of breast cancer diagnosis, screening, and survival</span></div><div class="casAuthors">Cedolini Carla; Bertozzi Serena; Seriau Luca; Concina Serena; Cattin Federico; Risaliti Andrea; Londero Ambrogio P; Bernardi Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical breast cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Breast cancer screening is known to reduce mortality.  In the present study, we analyzed the prevalence of breast cancers detected through screening, before and after introduction of an organized screening, and we evaluated the overall survival of these patients in comparison with women with an extrascreening imaging-detected breast cancer or those with palpable breast cancers.  MATERIALS AND METHODS:  We collected data about all women who underwent a breast operation for cancer in our department between 2001 and 2008, focusing on type of tumor diagnosis, tumor characteristics, therapies administered, and patient outcome in terms of overall survival, and recurrences.  Data was analyzed by R (version 2.15.2), and P < .05 was considered significant.  RESULTS:  Among the 2070 cases of invasive breast cancer we considered, 157 were detected by regional mammographic screening (group A), 843 by extrascreening breast imaging (group B: 507 by mammography and 336 by ultrasound), and 1070 by extrascreening breast objective examination (group C).  The 5-year overall survival in groups A, B, and C were, respectively, 99% (95% CI, 98%-100%), 98% (95% CI, 97%-99%), and 91% (95% CI, 90%-93%), with a significant difference between the first 2 groups and the third (P < .05) and a trend between groups A and B (P = .081).  CONCLUSION:  The diagnosis of invasive breast cancer with screening in our population resulted in a survival gain at 5 years from the diagnosis, but a longer follow-up is necessary to confirm this data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmYGo-TAdgM8AKB7Fa-xrUfW6udTcc2eb5rCUAeQl2Krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cngslGhug%253D%253D&md5=5bad0adebd713661b082b0a4ad66c9f1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2014.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2014.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DCedolini%26aufirst%3DC.%26aulast%3DBertozzi%26aufirst%3DS.%26aulast%3DLondero%26aufirst%3DA.%2BP.%26aulast%3DBernardi%26aufirst%3DS.%26aulast%3DSeriau%26aufirst%3DL.%26aulast%3DConcina%26aufirst%3DS.%26aulast%3DCattin%26aufirst%3DF.%26aulast%3DRisaliti%26aufirst%3DA.%26atitle%3DType%2520of%2520breast%2520cancer%2520diagnosis%252C%2520screening%252C%2520and%2520survival%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D235%26epage%3D240%26doi%3D10.1016%2Fj.clbc.2014.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auguste, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, M. A.</span></span> <span> </span><span class="NLM_article-title">Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">18295</span>– <span class="NLM_lpage">18303</span>, <span class="refDoi"> DOI: 10.1073/pnas.1904697116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1073%2Fpnas.1904697116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=31451668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslOhsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=18295-18303&author=P.+Guoauthor=J.+Yangauthor=J.+Huangauthor=D.+T.+Augusteauthor=M.+A.+Moses&title=Therapeutic+genome+editing+of+triple-negative+breast+tumors+using+a+noncationic+and+deformable+nanolipogel&doi=10.1073%2Fpnas.1904697116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel</span></div><div class="casAuthors">Guo, Peng; Yang, Jiang; Huang, Jing; Auguste, Debra T.; Moses, Marsha A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">18295-18303</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC), which has the highest mortality rate of all breast cancer, is in urgent need of a therapeutic that hinders the spread and growth of cancer cells.  CRISPR genome editing holds the promise of a potential cure for many genetic diseases, including TNBC; however, its clin. translation is being challenged by the lack of safe and effective nonviral delivery systems for in vivo therapeutic genome editing.  Here we report the synthesis and application of a noncationic, deformable, and tumor-targeted nanolipogel system (tNLG) for CRISPR genome editing in TNBC tumors.  We have demonstrated that tNLGs mediate a potent CRISPR knockout of Lipocalin 2 (Lcn2), a known breast cancer oncogene, in human TNBC cells in vitro and in vivo.  The loss of Lcn2 significantly inhibits the migration and the mesenchymal phenotype of human TNBC cells and subsequently attenuates TNBC aggressiveness.  In an orthotopic TNBC model, we have shown that systemically administered tNLGs mediated &gt;81% CRISPR knockout of Lcn2 in TNBC tumor tissues, resulting in significant tumor growth suppression (&gt;77%).  Our proof-of-principle results provide exptl. evidence that tNLGs can be used as a safe, precise, and effective delivery approach for in vivo CRISPR genome editing in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjqqx58aJhMbVg90H21EOLACvtfcHk0lhG9K5kHiT6qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslOhsbjP&md5=8c6b27fc6fa491c81ed757fd096a38ff</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1904697116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1904697116%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DAuguste%26aufirst%3DD.%2BT.%26aulast%3DMoses%26aufirst%3DM.%2BA.%26atitle%3DTherapeutic%2520genome%2520editing%2520of%2520triple-negative%2520breast%2520tumors%2520using%2520a%2520noncationic%2520and%2520deformable%2520nanolipogel%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2019%26volume%3D116%26spage%3D18295%26epage%3D18303%26doi%3D10.1073%2Fpnas.1904697116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dent, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudeau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawka, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lickley, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narod, S. A.</span></span> <span> </span><span class="NLM_article-title">Triple-negative breast cancer: clinical features and patterns of recurrence</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4429</span>– <span class="NLM_lpage">4434</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-3045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1158%2F1078-0432.CCR-06-3045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=17671126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BD2svltlShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4429-4434&author=R.+Dentauthor=M.+Trudeauauthor=K.+I.+Pritchardauthor=W.+M.+Hannaauthor=H.+K.+Kahnauthor=C.+A.+Sawkaauthor=L.+A.+Lickleyauthor=E.+Rawlinsonauthor=P.+Sunauthor=S.+A.+Narod&title=Triple-negative+breast+cancer%3A+clinical+features+and+patterns+of+recurrence&doi=10.1158%2F1078-0432.CCR-06-3045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer: clinical features and patterns of recurrence</span></div><div class="casAuthors">Dent Rebecca; Trudeau Maureen; Pritchard Kathleen I; Hanna Wedad M; Kahn Harriet K; Sawka Carol A; Lickley Lavina A; Rawlinson Ellen; Sun Ping; Narod Steven A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15 Pt 1</span>),
    <span class="NLM_cas:pages">4429-34</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">PURPOSE:  To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer.  EXPERIMENTAL DESIGN:  We studied a cohort of 1,601 patients with breast cancer, diagnosed between January 1987 and December 1997 at Women's College Hospital in Toronto.  Triple-negative breast cancers were defined as those that were estrogen receptor negative, progesterone receptor negative, and HER2neu negative.  The prognostic significance of triple-negative breast cancer was explored.  RESULTS:  The median follow-up time of the 1,601 women was 8.1 years.  One hundred and eighty of 1,601 patients (11.2%) had triple-negative breast cancer.  Compared with other women with breast cancer, those with triple-negative breast cancer had an increased likelihood of distant recurrence (hazard ratio, 2.6; 95% confidence interval, 2.0-3.5; P < 0.0001) and death (hazard ratio, 3.2; 95% confidence interval, 2.3-4.5; P < 0.001) within 5 years of diagnosis but not thereafter.  The pattern of recurrence was also qualitatively different; among the triple-negative group, the risk of distant recurrence peaked at approximately 3 years and declined rapidly thereafter.  Among the "other" group, the recurrence risk seemed to be constant over the period of follow-up.  CONCLUSIONS:  Triple-negative breast cancers have a more aggressive clinical course than other forms of breast cancer, but the adverse effect is transient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgv_jWdHp-NeIHSmpohpd0fW6udTcc2eb5rCUAeQl2Krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svltlShtQ%253D%253D&md5=7ee3954fe80ef97f1966768b115e6050</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-3045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-3045%26sid%3Dliteratum%253Aachs%26aulast%3DDent%26aufirst%3DR.%26aulast%3DTrudeau%26aufirst%3DM.%26aulast%3DPritchard%26aufirst%3DK.%2BI.%26aulast%3DHanna%26aufirst%3DW.%2BM.%26aulast%3DKahn%26aufirst%3DH.%2BK.%26aulast%3DSawka%26aufirst%3DC.%2BA.%26aulast%3DLickley%26aufirst%3DL.%2BA.%26aulast%3DRawlinson%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DNarod%26aufirst%3DS.%2BA.%26atitle%3DTriple-negative%2520breast%2520cancer%253A%2520clinical%2520features%2520and%2520patterns%2520of%2520recurrence%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D4429%26epage%3D4434%26doi%3D10.1158%2F1078-0432.CCR-06-3045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fleisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ait-Oudhia, S.</span></span> <span> </span><span class="NLM_article-title">Current advances in biomarkers for targeted therapy in triple-negative breast cancer</span>. <i>Breast Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.2147/BCTT.S114659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.2147%2FBCTT.S114659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovFOjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=183-197&author=B.+Fleisherauthor=C.+Clarkeauthor=S.+Ait-Oudhia&title=Current+advances+in+biomarkers+for+targeted+therapy+in+triple-negative+breast+cancer&doi=10.2147%2FBCTT.S114659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Current advances in biomarkers for targeted therapy in triple-negative breast cancer</span></div><div class="casAuthors">Fleisher, Brett; Clarke, Charlotte; Ait-Oudhia, Sihem</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">183-197</span>CODEN:
                <span class="NLM_cas:coden">BCTTA9</span>;
        ISSN:<span class="NLM_cas:issn">1179-1314</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a complex heterogeneous disease characterized by the absence of three hallmark receptors: human epidermal growth factor receptor 2, estrogen receptor, and progesterone receptor.  Compared to other breast cancer subtypes, TNBC is more aggressive, has a higher prevalence in African-Americans, and more frequently affects younger patients.  Currently, TNBC lacks clin. accepted targets for tailored therapy, warranting the need for candidate biomarkers.  BiomarkerBase, an online platform used to find biomarkers reported in clin. trials, was utilized to screen all potential biomarkers for TNBC and select only the ones registered in completed TNBC trials through clinicaltrials.gov.  The selected candidate biomarkers were classified as surrogate, prognostic, predictive, or pharmacodynamic (PD) and organized by location in the blood, on the cell surface, in the cytoplasm, or in the nucleus.  Blood biomarkers include vascular endothelial growth factor/vascular endothelial growth factor receptor and interleukin-8 (IL-8); cell surface biomarkers include EGFR, insulin-like growth factor binding protein, c-Kit, c-Met, and PD-L1; cytoplasm biomarkers include PIK3CA, pAKT/S6/p4E-BP1, PTEN, ALDH1, and the PIK3CA/AKT/mTOR-related metabolites; and nucleus biomarkers include BRCA1, the glucocorticoid receptor, TP53, and Ki67.  Candidate biomarkers were further organized into a "cellular protein network" that demonstrates potential connectivity.  This review provides an inventory and ref. point for promising biomarkers for breakthrough targeted therapies in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEVZUacaLXTLVg90H21EOLACvtfcHk0ljpAv71_HKusw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovFOjtbY%253D&md5=3d9f5f9599f1e3700c7c04a518fc527e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2147%2FBCTT.S114659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FBCTT.S114659%26sid%3Dliteratum%253Aachs%26aulast%3DFleisher%26aufirst%3DB.%26aulast%3DClarke%26aufirst%3DC.%26aulast%3DAit-Oudhia%26aufirst%3DS.%26atitle%3DCurrent%2520advances%2520in%2520biomarkers%2520for%2520targeted%2520therapy%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2016%26volume%3D8%26spage%3D183%26epage%3D197%26doi%3D10.2147%2FBCTT.S114659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span> <span> </span><span class="NLM_article-title">Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">12890</span>– <span class="NLM_lpage">12908</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.18632%2Foncotarget.3849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=25973541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BC2Mfjs12msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=12890-12908&author=F.+Le%0ADuauthor=B.+L.+Eckhardtauthor=B.+Limauthor=J.+K.+Littonauthor=S.+Moulderauthor=F.+Meric-Bernstamauthor=A.+M.+Gonzalez-Anguloauthor=N.+T.+Ueno&title=Is+the+future+of+personalized+therapy+in+triple-negative+breast+cancer+based+on+molecular+subtype%3F&doi=10.18632%2Foncotarget.3849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?</span></div><div class="casAuthors">Le Du Fanny; Eckhardt Bedrich L; Lim Bora; Litton Jennifer K; Moulder Stacy; Gonzalez-Angulo Ana M; Ueno Naoto T; Le Du Fanny; Lim Bora; Litton Jennifer K; Moulder Stacy; Meric-Bernstam Funda; Gonzalez-Angulo Ana M; Ueno Naoto T; Litton Jennifer K; Meric-Bernstam Funda; Gonzalez-Angulo Ana M</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">12890-908</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Significant research has been conducted to better understand the extensive, heterogeneous molecular features of triple-negative breast cancer (TNBC).  We reviewed published TNBC molecular classifications to identify major groupings that have potential for clinical trial development.  With the ultimate aim to streamline translational medicine, we linked these categories of TNBC according to their gene-expression signatures, biological function, and clinical outcome.  To this end, we define five potential clinically actionable groupings of TNBC: 1) basal-like TNBC with DNA-repair deficiency or growth factor pathways; 2) mesenchymal-like TNBC with epithelial-to-mesenchymal transition and cancer stem cell features; 3) immune-associated TNBC; 4) luminal/apocrine TNBC with androgen-receptor overexpression; and 5) HER2-enriched TNBC.  For each defined subtype, we highlight the major biological pathways and discuss potential targeted therapies in TNBC that might abrogate disease progression.  However, many of these potential targets need clinical validation by clinical trials.  We have yet to know how we can enrich the targets by molecular classifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZdPdM90gD3_3jf77P2BG3fW6udTcc2eZAxzeH5Cujrrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mfjs12msA%253D%253D&md5=64bd5a0e4eb949f45eceed1a4a2a5fdd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3849%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BDu%26aufirst%3DF.%26aulast%3DEckhardt%26aufirst%3DB.%2BL.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26aulast%3DMoulder%26aufirst%3DS.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DIs%2520the%2520future%2520of%2520personalized%2520therapy%2520in%2520triple-negative%2520breast%2520cancer%2520based%2520on%2520molecular%2520subtype%253F%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D12890%26epage%3D12908%26doi%3D10.18632%2Foncotarget.3849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietenpol, J. A.</span></span> <span> </span><span class="NLM_article-title">New strategies for triple-negative nreast cancer—deciphering the heterogeneity</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1158%2F1078-0432.CCR-13-0583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=24536073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVejsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=782-790&author=I.+A.+Mayerauthor=V.+G.+Abramsonauthor=B.+D.+Lehmannauthor=J.+A.+Pietenpol&title=New+strategies+for+triple-negative+nreast+cancer%E2%80%94deciphering+the+heterogeneity&doi=10.1158%2F1078-0432.CCR-13-0583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies for Triple-Negative Breast Cancer-Deciphering the Heterogeneity</span></div><div class="casAuthors">Mayer, Ingrid A.; Abramson, Vandana G.; Lehmann, Brian D.; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">782-790</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) is a heterogeneous disease; gene expression analyses recently identified six distinct TNBC subtypes, each displaying a unique biol.  Exploring novel approaches to treatment of these subtypes is crit. because less than 30% of women with metastatic breast cancer survive five years and virtually all women with metastatic TNBC will ultimately die of their disease despite systemic therapy.  To date, not a single targeted therapy has been approved for the treatment of TNBC and cytotoxic chemotherapy remains the std. treatment.  We discuss the current and upcoming therapeutic strategies being explored in an attempt to "target" TNBC.  Clin Cancer Res; 20(4); 782-90. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdvsR_JjXMyLVg90H21EOLACvtfcHk0ljpAv71_HKusw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVejsb0%253D&md5=4ce0876cb914096f913a7a637d7b63d5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0583%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DNew%2520strategies%2520for%2520triple-negative%2520nreast%2520cancer%25E2%2580%2594deciphering%2520the%2520heterogeneity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D782%26epage%3D790%26doi%3D10.1158%2F1078-0432.CCR-13-0583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uribe, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bénard, F.</span></span> <span> </span><span class="NLM_article-title">Enhancing treatment efficacy of 177Lu-PSMA-617 with the conjugation of an albumin-binding motif: preclinical dosimetry and endoradiotherapy studies</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5183</span>– <span class="NLM_lpage">5191</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.8b00720</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.8b00720" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOhsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=5183-5191&author=H.-T.+Kuoauthor=H.+Merkensauthor=Z.+Zhangauthor=C.+F.+Uribeauthor=J.+Lauauthor=C.+Zhangauthor=N.+Colpoauthor=K.-S.+Linauthor=F.+B%C3%A9nard&title=Enhancing+treatment+efficacy+of+177Lu-PSMA-617+with+the+conjugation+of+an+albumin-binding+motif%3A+preclinical+dosimetry+and+endoradiotherapy+studies&doi=10.1021%2Facs.molpharmaceut.8b00720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies</span></div><div class="casAuthors">Kuo, Hsiou-Ting; Merkens, Helen; Zhang, Zhengxing; Uribe, Carlos F.; Lau, Joseph; Zhang, Chengcheng; Colpo, Nadine; Lin, Kuo-Shyan; Benard, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5183-5191</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We designed and evaluated a novel albumin-binder-conjugated 177Lu-PSMA-617 deriv., 177Lu-HTK01169, with an extended blood retention time to maximize the radiation dose delivered to prostate tumors expressing prostate-specific membrane antigen (PSMA).  PSMA-617 and HTK01169 that contained N-[4-(p-iodophenyl)butanoyl]-Glu as an albumin-binding motif were synthesized using the solid-phase approach.  Binding affinity to PSMA was detd. by in vitro competition-binding assay.  77Lu labeling was performed in acetate buffer (pH 4.5) at 90 °C for 15 min.  SPECT/CT imaging, biodistribution, and endoradiotherapy studies were conducted in mice bearing PSMA-expressing LNCaP tumor xenografts.  Radiation dosimetry was calcd. using OLINDA software.  Lu-PSMA-617 and Lu-HTK01169-bound PSMA with high affinity (Ki values = 0.24 and 0.04 nM, resp.).  SPECT imaging and biodistribution studies showed that 177Lu-PSMA-617 and 177Lu-HTK01169 were excreted mainly via the renal pathway.  With fast blood clearance (0.68%ID/g at 1 h postinjection), the tumor uptake of 177Lu-PSMA-617 peaked at 1 h postinjection (15.1%ID/g) and gradually decreased to 7.91%ID/g at 120 h postinjection.  With extended blood retention (16.6 and 2.10%ID/g at 1 and 24 h, resp.), the tumor uptake of 177Lu-HTK01169 peaked at 24 h postinjection (55.9%ID/g) and remained at the same level by the end of the study (120 h).  Based on dosimetry calcns., 177Lu-HTK01169 delivered an 8.3-fold higher radiation dose than 177Lu-PSMA-617 to LNCaP tumor xenografts.  For the endoradiotherapy study, the mice treated with 177Lu-PSMA-617 (18.5 MBq) all reached humane end point (tumor vol. >1000 mm3) by Day 73 with a median survival of 58 days.  Mice treated with 18.5, 9.3, 4.6, or 2.3 MBq of 177Lu-HTK01169 had a median survival of >120, 103, 61, and 28 days, resp.  With greatly enhanced tumor uptake and treatment efficacy compared to 177Lu-PSMA-617 in preclin. studies, 177Lu-HTK01169 warrants further investigation for endoradiotherapy of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJkVyN6KqoFbVg90H21EOLACvtfcHk0liIizUZVpW25Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOhsLjP&md5=3bf3bad467088ab84b51b65285f9db7a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.8b00720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.8b00720%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DH.-T.%26aulast%3DMerkens%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DUribe%26aufirst%3DC.%2BF.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DColpo%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DK.-S.%26aulast%3DB%25C3%25A9nard%26aufirst%3DF.%26atitle%3DEnhancing%2520treatment%2520efficacy%2520of%2520177Lu-PSMA-617%2520with%2520the%2520conjugation%2520of%2520an%2520albumin-binding%2520motif%253A%2520preclinical%2520dosimetry%2520and%2520endoradiotherapy%2520studies%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2018%26volume%3D15%26spage%3D5183%26epage%3D5191%26doi%3D10.1021%2Facs.molpharmaceut.8b00720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">7948</span>– <span class="NLM_lpage">7960</span>, <span class="refDoi"> DOI: 10.7150/thno.39203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.7150%2Fthno.39203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=31695808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFams7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=7948-7960&author=H.+Chenauthor=L.+Zhaoauthor=K.+Fuauthor=Q.+Linauthor=X.+Wenauthor=O.+Jacobsonauthor=L.+Sunauthor=H.+Wuauthor=X.+Zhangauthor=Z.+Guoauthor=Q.+Linauthor=X.+Chen&title=Integrin+%CE%B1v%CE%B23-targeted+radionuclide+therapy+combined+with+immune+checkpoint+blockade+immunotherapy+synergistically+enhances+anti-tumor+efficacy&doi=10.7150%2Fthno.39203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy</span></div><div class="casAuthors">Chen, Haojun; Zhao, Liang; Fu, Kaili; Lin, Qiuming; Wen, Xuejun; Jacobson, Orit; Sun, Long; Wu, Hua; Zhang, Xianzhong; Guo, Zhide; Lin, Qin; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">7948-7960</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Radiotherapy combined with immunotherapy has revealed promising outcomes in both preclin. studies and ongoing clin. trials.  Targeted radionuclide therapy (TRT) is a branch of radiotherapy concerned with the use of radioisotopes, radiolabeled mols. or nanoparticles that deliver particulate radiation to cancer cells.  TRT is a promising approach in cases of metastatic disease where conventional treatments are no longer effective.  The increasing use of TRT raises the question of how to best integrate TRT with immunotherapy.  In this study, we proposed a novel therapeutic regimen that combined programmed death ligand 1 (PD-L1)-based immunotherapy with peptide-based TRT (177Lu as the radionuclide) in the murine colon cancer model.  To explore the most appropriate timing of immunotherapy after radionuclide therapy, the anti-PD-L1 antibody (αPD-L1 mAb) was delivered in a concurrent or sequential manner when 177Lu TRT was given.  The results demonstrated that TRT led to an acute increase in PD-L1 expression on T cells, and TRT in combination with αPD-L1 mAb stimulated the infiltration of CD8+ T cells, which improved local tumor control, overall survival and protection against tumor rechallenge.  Moreover, our data revealed that the time window for this combination therapy may be crit. to outcome.  This therapeutic combination may be a promising approach to treating metastatic tumors in which TRT can be used.  Clin. translation of the result would suggest that concurrent rather than sequential blockade of the PD-1/PD-L1 axis combined with TRT improves overall survival and long-term tumor control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsr0E0ceG7HrVg90H21EOLACvtfcHk0liIizUZVpW25Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFams7%252FP&md5=ec320e3cccd676df412d96656f144667</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.7150%2Fthno.39203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.39203%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DJacobson%26aufirst%3DO.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DIntegrin%2520%25CE%25B1v%25CE%25B23-targeted%2520radionuclide%2520therapy%2520combined%2520with%2520immune%2520checkpoint%2520blockade%2520immunotherapy%2520synergistically%2520enhances%2520anti-tumor%2520efficacy%26jtitle%3DTheranostics%26date%3D2019%26volume%3D9%26spage%3D7948%26epage%3D7960%26doi%3D10.7150%2Fthno.39203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehlerding, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacognata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theuer, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, W.</span></span> <span> </span><span class="NLM_article-title">Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1007/s00259-017-3793-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1007%2Fs00259-017-3793-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=28821931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKnurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=123-131&author=E.+B.+Ehlerdingauthor=S.+Lacognataauthor=D.+Jiangauthor=C.+A.+Ferreiraauthor=S.+Goelauthor=R.+Hernandezauthor=J.+J.+Jefferyauthor=C.+P.+Theuerauthor=W.+Cai&title=Targeting+angiogenesis+for+radioimmunotherapy+with+a+177Lu-labeled+antibody&doi=10.1007%2Fs00259-017-3793-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody</span></div><div class="casAuthors">Ehlerding, Emily B.; Lacognata, Saige; Jiang, Dawei; Ferreira, Carolina A.; Goel, Shreya; Hernandez, Reinier; Jeffery, Justin J.; Theuer, Charles P.; Cai, Weibo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">123-131</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Increased angiogenesis is a marker of aggressiveness in many cancers.  Targeted radionuclide therapy of these cancers with angiogenesis-targeting agents may curtail this increased blood vessel formation and slow the growth of tumors, both primary and metastatic.  CD105, or endoglin, has a primary role in angiogenesis in a no. of cancers, making this a widely applicable target for targeted radioimmunotherapy.  The anti-CD105 antibody, TRC105 (TRACON Pharmaceuticals), was conjugated with DTPA for radiolabeling with 177Lu (t1/2 6.65 days).  Balb/c mice were implanted with 4T1 mammary carcinoma cells, and five study groups were used: 177Lu only, TRC105 only, 177Lu-DTPA-IgG (a nonspecific antibody), 177Lu-DTPA-TRC105 low-dose, and 177Lu-DTPA-TRC105 high-dose.  Toxicity of the agent was monitored by body wt. measurements and anal. of blood markers.  Biodistribution studies of 177Lu-DTPA-TRC105 were also performed at 1 and 7 days after injection.  Ex vivo histol. studies of various tissues were conducted at 1, 7, and 30 days after injection of high-dose 177Lu-DTPA-TRC105.  Biodistribution studies indicated steady uptake of 177Lu-DTPA-TRC105 in 4T1 tumors between 1 and 7 days after injection (14.3 ± 2.3%ID/g and 11.6 ± 6.1%ID/g, resp.; n = 3) and gradual clearance from other organs.  Significant inhibition of tumor growth was obsd. in the high-dose group, with a corresponding significant increase in survival (p < 0.001, all groups).  In most study groups (all except the nonspecific IgG group), the body wts. of the mice did not decrease by more than 10%, indicating the safety of the injected agents.  Serum alanine transaminase levels remained nearly const. indicating no damage to the liver (a primary clearance organ of the agent), and this was confirmed by ex vivo histol. analyses.  177Lu-DTPA-TRC105, when administered at a sufficient dose, is able to curtail tumor growth and provide a significant survival benefit without off-target toxicity.  Thus, this targeted agent could be used in combination with other treatment options to slow tumor growth allowing the other agents to be more effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosYqSvEDxgebVg90H21EOLACvtfcHk0ljtJQk-cUJqVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKnurrL&md5=066ae34a2a9074e63b5d4067897476eb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00259-017-3793-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-017-3793-2%26sid%3Dliteratum%253Aachs%26aulast%3DEhlerding%26aufirst%3DE.%2BB.%26aulast%3DLacognata%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DFerreira%26aufirst%3DC.%2BA.%26aulast%3DGoel%26aufirst%3DS.%26aulast%3DHernandez%26aufirst%3DR.%26aulast%3DJeffery%26aufirst%3DJ.%2BJ.%26aulast%3DTheuer%26aufirst%3DC.%2BP.%26aulast%3DCai%26aufirst%3DW.%26atitle%3DTargeting%2520angiogenesis%2520for%2520radioimmunotherapy%2520with%2520a%2520177Lu-labeled%2520antibody%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2018%26volume%3D45%26spage%3D123%26epage%3D131%26doi%3D10.1007%2Fs00259-017-3793-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mittra, E. S.</span></span> <span> </span><span class="NLM_article-title">Neuroendocrine tumor therapy: 177Lu-DOTATATE</span>. <i>Am. J. Roentgenol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>211</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.2214/AJR.18.19953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.2214%2FAJR.18.19953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FisVyisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=2018&pages=278-285&author=E.+S.+Mittra&title=Neuroendocrine+tumor+therapy%3A+177Lu-DOTATATE&doi=10.2214%2FAJR.18.19953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroendocrine Tumor Therapy: (177)Lu-DOTATATE</span></div><div class="casAuthors">Mittra Erik S</div><div class="citationInfo"><span class="NLM_cas:title">AJR. American journal of roentgenology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-285</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  The purposes of this article are to increase understanding of the concepts of theranostics and peptide receptor radionuclide therapy (PRRT) as they apply to neuroendocrine tumors (NETs); review the key 1, 2, and 3 clinical trial data leading to the approval of (177)Lu-tetraazacyclododecanetetraacetic acid-octreotide ((177)Lu-DOTATATE); and foster understanding of the practical aspects and future directions of PRRT for NETs.  CONCLUSION:  In January 2018, (177)Lu-DOTATATE therapy was approved in the United States (previously approved in Europe in September 2017) for adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including those of the foregut, midgut, and hindgut.  The results of the phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial show favorable outcomes with respect to the primary endpoint of progression-free survival and a host of secondary objectives, including overall survival, objective response rate, and quality of life measures.  Patient selection is based on a number of specific factors and should be sequenced carefully with respect to other available therapies, ideally in multidisciplinary cancer conferences.  Establishing the therapy at a new institution can be somewhat involved, but once it is established, the therapy is fairly straightforward to administer and is well tolerated with limited side-effects and toxicity.  A number of approaches and issues are still to be worked out, and this therapy will continue to be studied and optimized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVZWXuXntqS_6BottYdIAWfW6udTcc2eamsuH28VL2Bbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FisVyisw%253D%253D&md5=bc9e9550a927a2fa425d63c18f779f5c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2214%2FAJR.18.19953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2214%252FAJR.18.19953%26sid%3Dliteratum%253Aachs%26aulast%3DMittra%26aufirst%3DE.%2BS.%26atitle%3DNeuroendocrine%2520tumor%2520therapy%253A%2520177Lu-DOTATATE%26jtitle%3DAm.%2520J.%2520Roentgenol.%26date%3D2018%26volume%3D211%26spage%3D278%26epage%3D285%26doi%3D10.2214%2FAJR.18.19953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strosberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Haddad, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendifar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chasen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulke, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacene, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushnell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dorisio, T. M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1607427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1056%2FNEJMoa1607427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=28076709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSnsLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=125-135&author=J.+Strosbergauthor=G.+El-Haddadauthor=E.+Wolinauthor=A.+Hendifarauthor=J.+Yaoauthor=B.+Chasenauthor=E.+Mittraauthor=P.+L.+Kunzauthor=M.+H.+Kulkeauthor=H.+Jaceneauthor=D.+Bushnellauthor=T.+M.+O%E2%80%99Dorisio&title=Phase+3+trial+of+177Lu-dotatate+for+midgut+neuroendocrine+tumors&doi=10.1056%2FNEJMoa1607427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors</span></div><div class="casAuthors">Strosberg, J.; El-Haddad, G.; Wolin, E.; Hendifar, A.; Yao, J.; Chasen, B.; Mittra, E.; Kunz, P. L.; Kulke, M. H.; Jacene, H.; Bushnell, D.; O'Dorisio, T. M.; Baum, R. P.; Kulkarni, H. R.; Caplin, M.; Lebtahi, R.; Hobday, T.; Delpassand, E.; Van Cutsem, E.; Benson, A.; Srirajaskanthan, R.; Pavel, M.; Mora, J.; Berlin, J.; Grande, E.; Reed, N.; Seregni, E.; Oeberg, K.; Sierra, M. Lopera; Santoro, P.; Thevenet, T.; Erion, J. L.; Ruszniewski, P.; Kwekkeboom, D.; Krenning, E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-135</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analog therapy have limited therapeutic options.  This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-pos. midgut neuroendocrine tumors.  METHODS We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either 177Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 wk (four i.v. infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered i.m. at a dose of 30 mg) (177Lu-Dotatate group) or octreotide LAR alone (113 patients) administered i.m. at a dose of 60 mg every 4 wk (control group).  The primary end point was progression-free survival.  Secondary end points included the objective response rate, overall survival, safety, and the side-effect profile.  The final anal. of overall survival will be conducted in the future as specified in the protocol; a prespecified interim anal. of overall survival was conducted and is reported here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKr440jwrnEbVg90H21EOLACvtfcHk0ljtJQk-cUJqVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSnsLnM&md5=58f9b06cf2877e354899a6a26af138fd</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1607427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1607427%26sid%3Dliteratum%253Aachs%26aulast%3DStrosberg%26aufirst%3DJ.%26aulast%3DEl-Haddad%26aufirst%3DG.%26aulast%3DWolin%26aufirst%3DE.%26aulast%3DHendifar%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DChasen%26aufirst%3DB.%26aulast%3DMittra%26aufirst%3DE.%26aulast%3DKunz%26aufirst%3DP.%2BL.%26aulast%3DKulke%26aufirst%3DM.%2BH.%26aulast%3DJacene%26aufirst%3DH.%26aulast%3DBushnell%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Dorisio%26aufirst%3DT.%2BM.%26atitle%3DPhase%25203%2520trial%2520of%2520177Lu-dotatate%2520for%2520midgut%2520neuroendocrine%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D125%26epage%3D135%26doi%3D10.1056%2FNEJMoa1607427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barber, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niepsch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, R. P.</span></span> <span> </span><span class="NLM_article-title">Clinical outcomes of 177Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">955</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.2967/jnumed.118.216820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.2967%2Fjnumed.118.216820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=30683770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpslaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=955-962&author=T.+W.+Barberauthor=A.+Singhauthor=H.+R.+Kulkarniauthor=K.+Niepschauthor=B.+Billahauthor=R.+P.+Baum&title=Clinical+outcomes+of+177Lu-PSMA+radioligand+therapy+in+earlier+and+later+phases+of+metastatic+castration-resistant+prostate+cancer+grouped+by+previous+taxane+chemotherapy&doi=10.2967%2Fjnumed.118.216820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical outcomes of 177Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy</span></div><div class="casAuthors">Barber, Thomas W.; Singh, Aviral; Kulkarni, Harshad R.; Niepsch, Karin; Billah, Baki; Baum, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">955-962</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy using PSMA-617 and PSMA-I&T ligands (177Lu-PRLT) is an emerging treatment in metastatic castration-resistant prostate cancer (mCRPC).  This retrospective study evaluates clin. outcomes of 177Lu-PRLT in earlier and later phases of mCRPC grouped by previous taxane chemotherapy.  A retrospective anal. was performed on 167 patients with mCRPC who underwent 177Lu-PRLT between March 2013 and Dec. 2016.  Patients were classified as either taxane chemotherapy pretreated (T-pretreated) or naive (T-naive) depending on whether they had received taxane-based chemotherapy prior to 177Lu-PRLT.  Clin. outcome for T-pretreated and T-naive patients was assessed by overall survival (OS), radiog. progression- free survival, and prostate-specific antigen (PSA) response rate.  Univariate and multivariable analyses were performed for both Tpretreated and T-naive patients to det. predictors of outcome.  Toxicity was categorized by the Common Terminol. Criteria for Adverse Events (version 4.03).  Of the 167 patients treated with 177Lu-PRLT, 83 were T-pretreated and 84 were T-naive.  At baseline, T-pretreated patients had overall poorer performance status, a higher prevalence of bone metastases, higher PSA levels, lower Hb levels, higher alk. phosphatase (ALP) levels and had received more addnl. therapies compared with T-naive patients.  Median OS was 10.7 mo for T-pretreated patients and 27.1 mo for T-naive patients.  Median radiog. progression-free survival was 6.0 mo for T-pretreated patients and 8.8 mo for T-naive patients.  PSA response assessment was evaluable in 132 patients and seen in 25 of 62 (40%) T-pretreated patients and 40 of 70 (57%) T-naive patients.  Significant determinates of inferior OS in multivariable anal. for T-pretreated patients were poorer performance status, lower cumulative administered activity, and lower baseline Hb.  Higher baseline alk. phosphatase was the only significant determinate of inferior OS in multivariable anal. for T-naive patients.  Overall 177Lu-PRLT was safe, with minimal adverse effects evident during follow-up in both T-pretreated and T-naive patients.  177Lu-PRLT is a promising therapy in mCRPC, with encouraging outcomes and minimal assocd. toxicity seen in both our T-naive and heavily pretreated patient cohorts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQlOH_-eDNvLVg90H21EOLACvtfcHk0lgW3jJSfeYdNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpslaqtw%253D%253D&md5=f042fc9d466570e85bfac4465a8d5df6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.216820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.216820%26sid%3Dliteratum%253Aachs%26aulast%3DBarber%26aufirst%3DT.%2BW.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DKulkarni%26aufirst%3DH.%2BR.%26aulast%3DNiepsch%26aufirst%3DK.%26aulast%3DBillah%26aufirst%3DB.%26aulast%3DBaum%26aufirst%3DR.%2BP.%26atitle%3DClinical%2520outcomes%2520of%2520177Lu-PSMA%2520radioligand%2520therapy%2520in%2520earlier%2520and%2520later%2520phases%2520of%2520metastatic%2520castration-resistant%2520prostate%2520cancer%2520grouped%2520by%2520previous%2520taxane%2520chemotherapy%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D60%26spage%3D955%26epage%3D962%26doi%3D10.2967%2Fjnumed.118.216820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szajek, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiesewetter, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Single low-dose injection of evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3213</span>– <span class="NLM_lpage">3221</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.8b00556</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.8b00556" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVylsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=3213-3221&author=Z.+Wangauthor=R.+Tianauthor=G.+Niuauthor=Y.+Maauthor=L.+Langauthor=L.+P.+Szajekauthor=D.+O.+Kiesewetterauthor=O.+Jacobsonauthor=X.+Chen&title=Single+low-dose+injection+of+evans+blue+modified+PSMA-617+radioligand+therapy+eliminates+prostate-specific+membrane+antigen+positive+tumors&doi=10.1021%2Facs.bioconjchem.8b00556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors</span></div><div class="casAuthors">Wang, Zhantong; Tian, Rui; Niu, Gang; Ma, Ying; Lang, Lixin; Szajek, Lawrence P.; Kiesewetter, Dale O.; Jacobson, Orit; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3213-3221</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide.  Prostate-specific membrane antigen (PSMA) is a surface mol. specifically expressed by prostate tumors that has been shown to be a valid target for internal radionuclide therapy in both preclin. and clin. settings.  The most common radiotherapeutic agent is the small mol. 177Lu-PSMA-617, which is under clin. evaluation in multiple countries.  Nevertheless, its efficacy in causing tumor regression is still suboptimal, even when administered in several cycles per patient, perhaps due to poor pharmacokinetics (PK), which limits uptake by the tumor cells.  We postulated that the addn. of the Evans blue (EB) moiety to PSMA-617 would improve the PK by extending circulation half-life, which would increase tumor uptake and improve radiotherapeutic efficacy.  PSMA-617 was modified by conjugation of a 2-thiol acetate group onto the primary amine and thereafter reacted with a maleimide functional group of an EB deriv., to give EB-PSMA-617.  The PK and radiotherapeutic efficacy of 90Y- or 177Lu-EB-PSMA-617 was compared to the clin. used radiopharmaceutical 90Y- or 177Lu- PSMA-617 in PC3-PIP tumor-bearing mice.  EB-PSMA-617 retained binding to serum albumin as well as a high internalization rate by tumor cells.  Upon injection, metal-labeled EB-PSMA-617 demonstrated an extended blood half-life compared to PSMA-617 and, thereby, prolonged the time window for binding to PSMA.  The improved PK of EB-PSMA-617 resulted in significantly higher accumulation in PSMA+ tumors and highly effective radiotherapeutic efficacy.  Remarkably, a single dose of 1.85 MBq of 90Y- or 177Lu-EB-PSMA-617 was sufficient to eradicate established PMSA+ tumors in mice.  No significant body wt. loss was obsd., suggesting little to no gross toxicity.  The construct described here, EB-PSMA-617, may improve the radiotherapeutic efficacy for patients with PSMA-pos. tumors by reducing both the amt. of activity needed for therapy as well as the frequency of administration, as compared to PSMA-617.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVIct9lbcQfrVg90H21EOLACvtfcHk0lgW3jJSfeYdNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVylsrvO&md5=66a04f13d479e0fc7c4d7097ce148d31</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.8b00556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.8b00556%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DR.%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DLang%26aufirst%3DL.%26aulast%3DSzajek%26aufirst%3DL.%2BP.%26aulast%3DKiesewetter%26aufirst%3DD.%2BO.%26aulast%3DJacobson%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DSingle%2520low-dose%2520injection%2520of%2520evans%2520blue%2520modified%2520PSMA-617%2520radioligand%2520therapy%2520eliminates%2520prostate-specific%2520membrane%2520antigen%2520positive%2520tumors%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D3213%26epage%3D3221%26doi%3D10.1021%2Facs.bioconjchem.8b00556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, T. P.</span></span> <span> </span><span class="NLM_article-title">Peptide-targeted radionuclide therapy for melanoma</span>. <i>Crit. Rev Oncol./Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2008.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1016%2Fj.critrevonc.2008.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=18387816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BD1cnis1Ckuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2008&pages=213-228&author=Y.+Miaoauthor=T.+P.+Quinn&title=Peptide-targeted+radionuclide+therapy+for+melanoma&doi=10.1016%2Fj.critrevonc.2008.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-targeted radionuclide therapy for melanoma</span></div><div class="casAuthors">Miao Yubin; Quinn Thomas P</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">213-28</span>
        ISSN:<span class="NLM_cas:issn">1040-8428</span>.
    </div><div class="casAbstract">Melanocortin-1 receptor (MC1-R) and melanin are two attractive melanoma-specific targets for peptide-targeted radionuclide therapy for melanoma.  Radiolabeled peptides targeting MC1-R/melanin can selectively and specifically target cytotoxic radiation generated from therapeutic radionuclides to melanoma cells for cell killing, while sparing the normal tissues and organs.  This review highlights the recent advances of peptide-targeted radionuclide therapy of melanoma targeting MC1-R and melanin.  The promising therapeutic efficacies of 188Re-(Arg(11))CCMSH (188Re-[Cys(3,4,10), D-Phe(7),Arg(11)]-alpha-MSH(3-13)), 177Lu- and 212Pb-labeled DOTA-Re(Arg(11))CCMSH (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-[ReO-(Cys(3,4,10), D-Phe(7), Arg(11))]-alpha-MSH(3-13)) and 188Re-HYNIC-4B4 (188Re-hydrazinonicotinamide-Tyr-Glu-Arg-Lys-Phe-Trp-His-Gly-Arg-His) in preclinical melanoma-bearing models demonstrate an optimistic outlook for peptide-targeted radionuclide therapy for melanoma.  Peptide-targeted radionuclide therapy for melanoma will likely contribute in an adjuvant setting, once the primary tumor has been surgically removed, to treat metastatic deposits and for treatment of end-stage disease.  The lack of effective treatments for metastatic melanoma and end-stage disease underscores the necessity to develop and implement new treatment strategies, such as peptide-targeted radionuclide therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiJPWW4Lb-mMuCWE5mhx1RfW6udTcc2eZetrFuABFd17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnis1Ckuw%253D%253D&md5=f1b8b2536ade387be4ce52e369b54637</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2008.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2008.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DY.%26aulast%3DQuinn%26aufirst%3DT.%2BP.%26atitle%3DPeptide-targeted%2520radionuclide%2520therapy%2520for%2520melanoma%26jtitle%3DCrit.%2520Rev%2520Oncol.%252FHematol.%26date%3D2008%26volume%3D67%26spage%3D213%26epage%3D228%26doi%3D10.1016%2Fj.critrevonc.2008.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span> <span> </span><span class="NLM_article-title">Fundamental mechanisms of immune checkpoint blockade therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1086</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1158%2F2159-8290.CD-18-0367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=30115704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ovV2lug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1069-1086&author=S.+C.+Weiauthor=C.+R.+Duffyauthor=J.+P.+Allison&title=Fundamental+mechanisms+of+immune+checkpoint+blockade+therapy&doi=10.1158%2F2159-8290.CD-18-0367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Fundamental Mechanisms of Immune Checkpoint Blockade Therapy</span></div><div class="casAuthors">Wei Spencer C; Duffy Colm R; Allison James P; Allison James P</div><div class="citationInfo"><span class="NLM_cas:title">Cancer discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1069-1086</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Immune checkpoint blockade is able to induce durable responses across multiple types of cancer, which has enabled the oncology community to begin to envision potentially curative therapeutic approaches.  However, the remarkable responses to immunotherapies are currently limited to a minority of patients and indications, highlighting the need for more effective and novel approaches.  Indeed, an extraordinary amount of preclinical and clinical investigation is exploring the therapeutic potential of negative and positive costimulatory molecules.  Insights into the underlying biological mechanisms and functions of these molecules have, however, lagged significantly behind.  Such understanding will be essential for the rational design of next-generation immunotherapies.  Here, we review the current state of our understanding of T-cell costimulatory mechanisms and checkpoint blockade, primarily of CTLA4 and PD-1, and highlight conceptual gaps in knowledge.Significance: This review provides an overview of immune checkpoint blockade therapy from a basic biology and immunologic perspective for the cancer research community.  Cancer Discov; 8(9); 1069-86. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQlpKqONKSUIwqdek-gHSrIfW6udTcc2eZetrFuABFd17ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ovV2lug%253D%253D&md5=fceabad6a29a522d25051d90ed3a3c44</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0367%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DS.%2BC.%26aulast%3DDuffy%26aufirst%3DC.%2BR.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26atitle%3DFundamental%2520mechanisms%2520of%2520immune%2520checkpoint%2520blockade%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D1069%26epage%3D1086%26doi%3D10.1158%2F2159-8290.CD-18-0367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettigrew, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Single-molecule force measurement guides the design of multivalent ligand with picomolar affinity</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">5326</span>– <span class="NLM_lpage">5330</span>, <span class="refDoi"> DOI: 10.1002/ange.201814347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1002%2Fange.201814347" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2019&pages=5326-5330&author=Z.+Yangauthor=S.+Jiangauthor=F.+Liauthor=Y.+Qiuauthor=J.+Guauthor=R.+I.+Pettigrewauthor=M.+Ferrariauthor=D.+J.+Hamiltonauthor=Z.+Li&title=Single-molecule+force+measurement+guides+the+design+of+multivalent+ligand+with+picomolar+affinity&doi=10.1002%2Fange.201814347"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fange.201814347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fange.201814347%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DPettigrew%26aufirst%3DR.%2BI.%26aulast%3DFerrari%26aufirst%3DM.%26aulast%3DHamilton%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DSingle-molecule%2520force%2520measurement%2520guides%2520the%2520design%2520of%2520multivalent%2520ligand%2520with%2520picomolar%2520affinity%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D131%26spage%3D5326%26epage%3D5330%26doi%3D10.1002%2Fange.201814347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">A tyrosine kinase inhibitor–based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1525</span>– <span class="NLM_lpage">1531</span>, <span class="refDoi"> DOI: 10.2967/jnumed.114.138925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.2967%2Fjnumed.114.138925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=24970912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSrurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1525-1531&author=F.+Liauthor=S.+Jiangauthor=Y.+Zuauthor=D.+Y.+Leeauthor=Z.+Li&title=A+tyrosine+kinase+inhibitor%E2%80%93based+high-affinity+PET+radiopharmaceutical+targets+vascular+endothelial+growth+factor+receptor&doi=10.2967%2Fjnumed.114.138925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor</span></div><div class="casAuthors">Li, Feng; Jiang, Sheng; Zu, Youli; Lee, Daniel Y.; Li, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1525-1531</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Tyrosine kinase receptors including vascular endothelial growth factor receptor (VEGFR) have gained significant attention as pharmacol. targets.  However, clin. evaluation of small-mol. drugs or biologics that target these pathways has so far yielded mixed results in a variety of solid tumors.  The reasons for response variability remain unknown, including the temporal and spatial patterns of receptor tyrosine kinase expression.  Methods to detect and quantify the presence of such cellular receptors would greatly facilitate drug development and therapy response assessment.  We aimed to generate specific imaging agents as potential companion diagnostics that could also be used for targeted radionuclide therapy.  Here, we report on the synthesis and initial preclin. performance of 64Cu-labeled probes that were based on the kinase inhibitor already in clin. use, vandetanib (ZD6474), as a VEGFR-selective theranostic radiopharmaceutical.  Methods: A monomeric (ZD-G1) and a dimeric (ZD-G2) deriv. of ZD6474 were synthesized and conjugated with DOTA for chelation with 64Cu to produce the probes 64Cu-DOTA-ZD-G1 and 64Cu-DOTA-ZD-G2.  The binding affinity and specificity to VEGFR were measured using U-87 MG cells known to overexpress VEGFR.  Small-animal PET and biodistribution studies were performed with 64Cu-labeled probes (3-4 MBq) i.v. administered in U-87 MG tumor-bearing mice with or without coinjection of unlabeled ZD-G2 for up to 24 h after injection.  Results: Receptor-binding assays yielded a mean equil. dissocn. const. of 44.7 and 0.45 nM for monomeric and dimeric forms, resp., indicating a synergistic effect in VEGFR affinity by multivalency.  Small-animal PET/CT imaging showed rapid tumor accumulation of 64Cu-DOTA-ZD-G2, with excellent tumor-to-normal tissue contrast by 24 h.  Coinjection of the 64Cu-DOTA-ZD-G2 with 50 nmol (60 μg) of nonradioactive ZD-G2 effectively blocked tumor uptake.  Conclusion: A 64Cu-labeled probe derived from an approved oncol. drug selective for VEGFR demonstrates excellent tumor targeting, particularly for the dimeric form.  The multivalent probe yielded a 100-fold improvement in receptor affinity while maintaining pharmacokinetic and biodistribution properties well suited for PET imaging in our preclin. model.  These results indicate that a clin. relevant theranostic platform can be rapidly developed from known small mols. that target key cellular receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiDkS3tF9BU7Vg90H21EOLACvtfcHk0licz7rPX-OOmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSrurrN&md5=2fe2cbca18a5366002a0ab70e450ced2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.114.138925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.114.138925%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DZu%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DD.%2BY.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DA%2520tyrosine%2520kinase%2520inhibitor%25E2%2580%2593based%2520high-affinity%2520PET%2520radiopharmaceutical%2520targets%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D1525%26epage%3D1531%26doi%3D10.2967%2Fjnumed.114.138925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span> <span> </span><span class="NLM_article-title">177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">800</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1021/mp4005047</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp4005047" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=800-807&author=Z.+Liuauthor=T.+Maauthor=H.+Liuauthor=Z.+Jinauthor=X.+Sunauthor=H.+Zhaoauthor=J.+Shiauthor=B.+Jiaauthor=F.+Liauthor=F.+Wang&title=177Lu-labeled+antibodies+for+EGFR-targeted+SPECT%2FCT+imaging+and+radioimmunotherapy+in+a+preclinical+head+and+neck+carcinoma+model&doi=10.1021%2Fmp4005047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">177Lu-Labeled Antibodies for EGFR-Targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma Model</span></div><div class="casAuthors">Liu, Zhaofei; Ma, Teng; Liu, Hao; Jin, Zhongxia; Sun, Xianlei; Zhao, Huiyun; Shi, Jiyun; Jia, Bing; Li, Fang; Wang, Fan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">800-807</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) has been well characterized as an important target for cancer therapy.  Immunotherapy based on EGFR-specific antibodies (e.g., panitumumab and cetuximab) has shown great clin. promise.  However, increasing evidence has indicated that only a subgroup of patients receiving these antibodies will benefit from them, and even patients who do initially experience a major response may eventually develop therapeutic resistance.  In this study, we investigated whether panitumumab and cetuximab can serve as delivery vehicles for tumor-targeted radionuclide therapy in a preclin. tumor model that did not respond to immunotherapy.  The in vitro toxicity and cell binding properties of panitumumab and cetuximab were characterized.  Both antibodies were conjugated with 1,4,7,10-tetraazadodecane-N,N',N'',N'''-tetraacetic acid (DOTA) and radiolabeled with 177Lu.  Small-animal SPECT/CT, biodistribution, and radioimmunotherapy (RIT) studies of 177Lu-DOTA-panitumumab (177Lu-Pan) and 177Lu-DOTA-cetuximab (177Lu-Cet) were performed in the UM-SCC-22B tumor model.  Both 177Lu-Pan and 177Lu-Cet exhibited favorable tumor targeting efficacy.  The tumor uptake was 20.92 ± 4.45, 26.10 ± 5.18, and 13.27 ± 1.94% ID/g for 177Lu-Pan, and 15.67 ± 3.84, 15.72 ± 3.49, and 7.82 ± 2.36% ID/g for 177Lu-Cet at 24, 72, and 120 h p.i., resp.  RIT with a single dose of 14.8 MBq of 177Lu-Pan or 177Lu-Cet significantly delayed tumor growth. 177Lu-Pan induced more effective tumor growth inhibition due to a higher tumor uptake.  Our results suggest that panitumumab and cetuximab can function as effective carriers for tumor-targeted delivery of radiation, and that RIT is promising for targeted therapy of EGFR-pos. tumors, esp. for those tumors that are resistant to antibody-based immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgx1hCizrr8LVg90H21EOLACvtfcHk0licz7rPX-OOmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCnu7g%253D&md5=b0990c8fc3d14e611fc74b66e9f6c37b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fmp4005047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp4005047%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DF.%26atitle%3D177Lu-labeled%2520antibodies%2520for%2520EGFR-targeted%2520SPECT%252FCT%2520imaging%2520and%2520radioimmunotherapy%2520in%2520a%2520preclinical%2520head%2520and%2520neck%2520carcinoma%2520model%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D800%26epage%3D807%26doi%3D10.1021%2Fmp4005047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelamanchili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youker, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmarian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pownall, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Vulnerable atherosclerotic plaque imaging by small-molecule high-affinity positron emission tomography radiopharmaceutical</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">1900005</span> <span class="refDoi"> DOI: 10.1002/adtp.201900005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1002%2Fadtp.201900005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&author=Z.+Yangauthor=F.+Liauthor=D.+Yelamanchiliauthor=Z.+Zengauthor=C.+Rosalesauthor=K.+A.+Youkerauthor=H.+Shenauthor=M.+Ferrariauthor=J.+Mahmarianauthor=H.+J.+Pownallauthor=D.+J.+Hamiltonauthor=Z.+Li&title=Vulnerable+atherosclerotic+plaque+imaging+by+small-molecule+high-affinity+positron+emission+tomography+radiopharmaceutical&doi=10.1002%2Fadtp.201900005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fadtp.201900005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadtp.201900005%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DYelamanchili%26aufirst%3DD.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DRosales%26aufirst%3DC.%26aulast%3DYouker%26aufirst%3DK.%2BA.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DFerrari%26aufirst%3DM.%26aulast%3DMahmarian%26aufirst%3DJ.%26aulast%3DPownall%26aufirst%3DH.%2BJ.%26aulast%3DHamilton%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DVulnerable%2520atherosclerotic%2520plaque%2520imaging%2520by%2520small-molecule%2520high-affinity%2520positron%2520emission%2520tomography%2520radiopharmaceutical%26jtitle%3DAdv.%2520Ther.%26date%3D2019%26volume%3D2%26doi%3D10.1002%2Fadtp.201900005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">Precision medicine for cancer with next-generation functional diagnostics</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1038/nrc4015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1038%2Fnrc4015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=26536825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyhtrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=747-756&author=A.+A.+Friedmanauthor=A.+Letaiauthor=D.+E.+Fisherauthor=K.+T.+Flaherty&title=Precision+medicine+for+cancer+with+next-generation+functional+diagnostics&doi=10.1038%2Fnrc4015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Precision medicine for cancer with next-generation functional diagnostics</span></div><div class="casAuthors">Friedman, Adam A.; Letai, Anthony; Fisher, David E.; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">747-756</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Precision medicine is about matching the right drugs to the right patients.  Although this approach is technol. agnostic, in cancer there is a tendency to make precision medicine synonymous with genomics.  However, genome-based cancer therapeutic matching is limited by incomplete biol. understanding of the relationship between phenotype and cancer genotype.  This limitation can be addressed by functional testing of live patient tumor cells exposed to potential therapies.  Recently, several 'next-generation' functional diagnostic technologies have been reported, including novel methods for tumor manipulation, molecularly precise assays of tumor responses and device-based in situ approaches; these address the limitations of the older generation of chemosensitivity tests.  The promise of these new technologies suggests a future diagnostic strategy that integrates functional testing with next-generation sequencing and immunoprofiling to precisely match combination therapies to individual cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruPiW8jX9A2rVg90H21EOLACvtfcHk0lgOm7xQxqAfoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyhtrbE&md5=0399ef5124b61b600f98a3d057944049</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrc4015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc4015%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DA.%2BA.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DPrecision%2520medicine%2520for%2520cancer%2520with%2520next-generation%2520functional%2520diagnostics%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D747%26epage%3D756%26doi%3D10.1038%2Fnrc4015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coates, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhirsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelber, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart-Gebhart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thürlimann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senn, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefoi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiglione-Gertsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coates, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colleoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curigliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejlertsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galimberti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelber, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhirsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huober, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingle, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jassem, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orecchia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent Osborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partridge, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Peña, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart-Gebhart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutgers, E. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedlmayer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semiglazov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thürlimann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Minckwitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span> <span> </span><span class="NLM_article-title">Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1533</span>– <span class="NLM_lpage">1546</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1093%2Fannonc%2Fmdv221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=25939896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BC2MfgsFWrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=1533-1546&author=A.+S.+Coatesauthor=E.+P.+Winerauthor=A.+Goldhirschauthor=R.+D.+Gelberauthor=M.+Gnantauthor=M.+Piccart-Gebhartauthor=B.+Th%C3%BCrlimannauthor=H.+J.+Sennauthor=F.+Andr%C3%A9author=J.+Baselgaauthor=J.+Berghauthor=H.+Bonnefoiauthor=H.+Bursteinauthor=F.+Cardosoauthor=M.+Castiglione-Gertschauthor=A.+S.+Coatesauthor=M.+Colleoniauthor=G.+Curiglianoauthor=N.+E.+Davidsonauthor=A.+Di+Leoauthor=B.+Ejlertsenauthor=J.+F.+Forbesauthor=V.+Galimbertiauthor=R.+D.+Gelberauthor=M.+Gnantauthor=A.+Goldhirschauthor=P.+Goodwinauthor=N.+Harbeckauthor=D.+F.+Hayesauthor=J.+Huoberauthor=C.+A.+Hudisauthor=J.+N.+Ingleauthor=J.+Jassemauthor=Z.+Jiangauthor=P.+Karlssonauthor=M.+Morrowauthor=R.+Orecchiaauthor=C.+Kent+Osborneauthor=A.+H.+Partridgeauthor=L.+de+la+Pe%C3%B1aauthor=M.+J.+Piccart-Gebhartauthor=K.+I.+Pritchardauthor=E.+J.+T.+Rutgersauthor=F.+Sedlmayerauthor=V.+Semiglazovauthor=Z.-M.+Shaoauthor=I.+Smithauthor=B.+Th%C3%BCrlimannauthor=M.+Toiauthor=A.+Tuttauthor=G.+Vialeauthor=G.+von+Minckwitzauthor=T.+Watanabeauthor=T.+Whelanauthor=E.+P.+Winerauthor=B.+Xu&title=Tailoring+therapies%E2%80%94improving+the+management+of+early+breast+cancer%3A+St+Gallen+International+Expert+Consensus+on+the+Primary+Therapy+of+Early+Breast+Cancer+2015&doi=10.1093%2Fannonc%2Fmdv221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015</span></div><div class="casAuthors">Coates A S; Winer E P; Goldhirsch A; Gelber R D; Gnant M; Piccart-Gebhart M; Thurlimann B; Senn H-J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1533-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer.  Further experience has supported the adequacy of tumor margins defined as 'no ink on invasive tumor or DCIS' and the safety of omitting axillary dissection in specific cohorts.  Radiotherapy trials support irradiation of regional nodes in node-positive disease.  Considering subdivisions within luminal disease, the Panel was more concerned with indications for the use of specific therapies, rather than surrogate identification of intrinsic subtypes as measured by multiparameter molecular tests.  For the treatment of HER2-positive disease in patients with node-negative cancers up to 1 cm, the Panel endorsed a simplified regimen comprising paclitaxel and trastuzumab without anthracycline as adjuvant therapy.  For premenopausal patients with endocrine responsive disease, the Panel endorsed the role of ovarian function suppression with either tamoxifen or exemestane for patients at higher risk.  The Panel noted the value of an LHRH agonist given during chemotherapy for premenopausal women with ER-negative disease in protecting against premature ovarian failure and preserving fertility.  The Panel noted increasing evidence for the prognostic value of commonly used multiparameter molecular markers, some of which also carried prognostic information for late relapse.  The Panel noted that the results of such tests, where available, were frequently used to assist decisions about the inclusion of cytotoxic chemotherapy in the treatment of patients with luminal disease, but noted that threshold values had not been established for this purpose for any of these tests.  Multiparameter molecular assays are expensive and therefore unavailable in much of the world.  The majority of new breast cancer cases and breast cancer deaths now occur in less developed regions of the world.  In these areas, less expensive pathology tests may provide valuable information.  The Panel recommendations on treatment are not intended to apply to all patients, but rather to establish norms appropriate for the majority.  Again, economic considerations may require that less expensive and only marginally less effective therapies may be necessary in less resourced areas.  Panel recommendations do not imply unanimous agreement among Panel members.  Indeed, very few of the 200 questions received 100% agreement from the Panel.  In the text below, wording is intended to convey the strength of Panel support for each recommendation, while details of Panel voting on each question are available in supplementary Appendix S2, available at Annals of Oncology online.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2WtDVBdr4Mz0SWnHPWbmmfW6udTcc2eZTRt9pJQ0ldbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfgsFWrsw%253D%253D&md5=b0cb2029f3581a60b86a3894cb26897a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv221%26sid%3Dliteratum%253Aachs%26aulast%3DCoates%26aufirst%3DA.%2BS.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DGoldhirsch%26aufirst%3DA.%26aulast%3DGelber%26aufirst%3DR.%2BD.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DPiccart-Gebhart%26aufirst%3DM.%26aulast%3DTh%25C3%25BCrlimann%26aufirst%3DB.%26aulast%3DSenn%26aufirst%3DH.%2BJ.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DBergh%26aufirst%3DJ.%26aulast%3DBonnefoi%26aufirst%3DH.%26aulast%3DBurstein%26aufirst%3DH.%26aulast%3DCardoso%26aufirst%3DF.%26aulast%3DCastiglione-Gertsch%26aufirst%3DM.%26aulast%3DCoates%26aufirst%3DA.%2BS.%26aulast%3DColleoni%26aufirst%3DM.%26aulast%3DCurigliano%26aufirst%3DG.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DDi%2BLeo%26aufirst%3DA.%26aulast%3DEjlertsen%26aufirst%3DB.%26aulast%3DForbes%26aufirst%3DJ.%2BF.%26aulast%3DGalimberti%26aufirst%3DV.%26aulast%3DGelber%26aufirst%3DR.%2BD.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DGoldhirsch%26aufirst%3DA.%26aulast%3DGoodwin%26aufirst%3DP.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DHuober%26aufirst%3DJ.%26aulast%3DHudis%26aufirst%3DC.%2BA.%26aulast%3DIngle%26aufirst%3DJ.%2BN.%26aulast%3DJassem%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DKarlsson%26aufirst%3DP.%26aulast%3DMorrow%26aufirst%3DM.%26aulast%3DOrecchia%26aufirst%3DR.%26aulast%3DKent%2BOsborne%26aufirst%3DC.%26aulast%3DPartridge%26aufirst%3DA.%2BH.%26aulast%3Dde%2Bla%2BPe%25C3%25B1a%26aufirst%3DL.%26aulast%3DPiccart-Gebhart%26aufirst%3DM.%2BJ.%26aulast%3DPritchard%26aufirst%3DK.%2BI.%26aulast%3DRutgers%26aufirst%3DE.%2BJ.%2BT.%26aulast%3DSedlmayer%26aufirst%3DF.%26aulast%3DSemiglazov%26aufirst%3DV.%26aulast%3DShao%26aufirst%3DZ.-M.%26aulast%3DSmith%26aufirst%3DI.%26aulast%3DTh%25C3%25BCrlimann%26aufirst%3DB.%26aulast%3DToi%26aufirst%3DM.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DViale%26aufirst%3DG.%26aulast%3Dvon%2BMinckwitz%26aufirst%3DG.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DWhelan%26aufirst%3DT.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DXu%26aufirst%3DB.%26atitle%3DTailoring%2520therapies%25E2%2580%2594improving%2520the%2520management%2520of%2520early%2520breast%2520cancer%253A%2520St%2520Gallen%2520International%2520Expert%2520Consensus%2520on%2520the%2520Primary%2520Therapy%2520of%2520Early%2520Breast%2520Cancer%25202015%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26spage%3D1533%26epage%3D1546%26doi%3D10.1093%2Fannonc%2Fmdv221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span> <span> </span><span class="NLM_article-title">The emerging regulation of VEGFR-2 in triple-negative breast cancer</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">159</span> <span class="refDoi"> DOI: 10.3389/fendo.2015.00159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.3389%2Ffendo.2015.00159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=26500608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BC28zlslWnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&author=X.+Zhuauthor=W.+Zhou&title=The+emerging+regulation+of+VEGFR-2+in+triple-negative+breast+cancer&doi=10.3389%2Ffendo.2015.00159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Zhu Xiaoxia; Zhou Wen</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">Vascular endothelial growth factor-A (VEGF) signals vascular development and angiogenesis mainly by binding to VEGF receptor family member 2 (VEGFR-2).  Adaptor proteins mediate many VEGFR-2's functions in the development of blood vessels.  Cancer cells secrete VEGF to activate VEGFR-2 pathway in their neighboring endothelial cells in the process of cancer-related angiogenesis.  Interestingly, activation of VEGFR-2 signaling is found in breast cancer cells, but its role and regulation are not clear.  We highlighted research advances of VEGFR-2, with a focus on VEGFR-2's regulation by mutant p53 in breast cancer.  In addition, we reviewed recent Food and Drug Administration-approved tyrosine kinase inhibitor drugs that can inhibit the function of VEGFR-2.  Ongoing preclinical and clinical studies might prove that pharmaceutically targeting VEGFR-2 could be an effective therapeutic strategy in treating triple-negative breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFUMsAIro3rMULxIEhxUjPfW6udTcc2eaUHtjBIrJEgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zlslWnug%253D%253D&md5=2b4b9beffffd1a05a1463bd8275a37cb</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2015.00159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2015.00159%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DW.%26atitle%3DThe%2520emerging%2520regulation%2520of%2520VEGFR-2%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DFront.%2520Endocrinol.%26date%3D2015%26volume%3D6%26doi%3D10.3389%2Ffendo.2015.00159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Folkman, J.</span></span> <span> </span><span class="NLM_article-title">Tumor angiogenesis: therapeutic implications</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1971</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">1182</span>– <span class="NLM_lpage">1186</span>, <span class="refDoi"> DOI: 10.1056/NEJM197111182852108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1056%2FNEJM197111182852108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=4938153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADyaE38%252FgvVCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1971&pages=1182-1186&author=J.+Folkman&title=Tumor+angiogenesis%3A+therapeutic+implications&doi=10.1056%2FNEJM197111182852108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor angiogenesis: therapeutic implications</span></div><div class="casAuthors">Folkman J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1182-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA0C6odtE1LPxQvRxYU81tfW6udTcc2eaUHtjBIrJEgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE38%252FgvVCqsQ%253D%253D&md5=efdddcba0c04be542edd51fef2ef27b9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1056%2FNEJM197111182852108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197111182852108%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DTumor%2520angiogenesis%253A%2520therapeutic%2520implications%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1971%26volume%3D285%26spage%3D1182%26epage%3D1186%26doi%3D10.1056%2FNEJM197111182852108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Folkman, J.</span></span> <span> </span><span class="NLM_article-title">Angiogenesis: an organizing principle for drug discovery?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1038/nrd2115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1038%2Fnrd2115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=17396134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1SisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=273-286&author=J.+Folkman&title=Angiogenesis%3A+an+organizing+principle+for+drug+discovery%3F&doi=10.1038%2Fnrd2115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis: an organizing principle for drug discovery?</span></div><div class="casAuthors">Folkman, Judah</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">273-286</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Angiogenesis - the process of new blood-vessel growth - has an essential role in development, reprodn. and repair.  However, pathol. angiogenesis occurs not only in tumor formation, but also in a range of non-neoplastic diseases that could be classed together as 'angiogenesis-dependent diseases'.  By viewing the process of angiogenesis as an 'organizing principle' in biol., intriguing insights into the mol. mechanisms of seemingly unrelated phenomena might be gained.  This has important consequences for the clin. use of angiogenesis inhibitors and for drug discovery, not only for optimizing the treatment of cancer, but possibly also for developing therapeutic approaches for various diseases that are otherwise unrelated to each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4BkXDYKVlmLVg90H21EOLACvtfcHk0ljmRiiNNA5Y0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1SisL4%253D&md5=2556d5e3a653c3dcac5b3297e2645c3c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd2115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2115%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAngiogenesis%253A%2520an%2520organizing%2520principle%2520for%2520drug%2520discovery%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D273%26epage%3D286%26doi%3D10.1038%2Fnrd2115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium(iii) metal-based compound</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">4756</span>– <span class="NLM_lpage">4763</span>, <span class="refDoi"> DOI: 10.1039/C7SC00311K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1039%2FC7SC00311K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=28959398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVeltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=4756-4763&author=L.-J.+Liuauthor=W.+Wangauthor=S.-Y.+Huangauthor=Y.+Hongauthor=G.+Liauthor=S.+Linauthor=J.+Tianauthor=Z.+Caiauthor=H.-M.+D.+Wangauthor=D.-L.+Maauthor=C.-H.+Leung&title=Inhibition+of+the+Ras%2FRaf+interaction+and+repression+of+renal+cancer+xenografts+in+vivo+by+an+enantiomeric+iridium%28iii%29+metal-based+compound&doi=10.1039%2FC7SC00311K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium(III) metal-based compound</span></div><div class="casAuthors">Liu, Li-Juan; Wang, Wanhe; Huang, Shi-Ying; Hong, Yanjun; Li, Guodong; Lin, Sheng; Tian, Jinglin; Cai, Zongwei; Wang, Hui-Min David; Ma, Dik-Lung; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4756-4763</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Targeting protein-protein interactions (PPIs) offers tantalizing opportunities for therapeutic intervention for the treatment of human diseases.  Modulating PPI interfaces with org. small mols. has been found to be exceptionally challenging, and few candidates have been successfully developed into clin. drugs.  Meanwhile, the striking array of distinctive properties exhibited by metal compds. renders them attractive scaffolds for the development of bioactive leads.  Here, we report the identification of iridium(III) compds. as inhibitors of the H-Ras/Raf-1 PPI.  The lead iridium(III) compd. 1 exhibited potent inhibitory activity against the H-Ras/Raf-1 interaction and its signaling pathway in vitro and in vivo, and also directly engaged both H-Ras and Raf-1-RBD in cell lysates.  Moreover, 1 repressed tumor growth in a mouse renal xenograft tumor model.  Intriguingly, the Δ-enantiomer of 1 showed superior potency in the biol. assays compared to Λ-1 or racemic 1.  These compds. could potentially be used as starting scaffolds for the development of more potent Ras/Raf PPI inhibitors for the treatment of kidney cancer or other proliferative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr81r1n5s7wkrVg90H21EOLACvtfcHk0ljmRiiNNA5Y0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVeltbk%253D&md5=b1c8c88211bab7eca780eb33b35dc772</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FC7SC00311K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7SC00311K%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.-J.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DS.-Y.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.-M.%2BD.%26aulast%3DMa%26aufirst%3DD.-L.%26aulast%3DLeung%26aufirst%3DC.-H.%26atitle%3DInhibition%2520of%2520the%2520Ras%252FRaf%2520interaction%2520and%2520repression%2520of%2520renal%2520cancer%2520xenografts%2520in%2520vivo%2520by%2520an%2520enantiomeric%2520iridium%2528iii%2529%2520metal-based%2520compound%26jtitle%3DChem.%2520Sci.%26date%3D2017%26volume%3D8%26spage%3D4756%26epage%3D4763%26doi%3D10.1039%2FC7SC00311K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. L.</span></span> <span> </span><span class="NLM_article-title">Interfering with S100B-effector protein interactions for cancer therapy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1754</span>– <span class="NLM_lpage">1761</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2020.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1016%2Fj.drudis.2020.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=32679172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVWhsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=1754-1761&author=K.+J.+Wuauthor=W.+Wangauthor=H.+D.+Wangauthor=C.+H.+Leungauthor=D.+L.+Ma&title=Interfering+with+S100B-effector+protein+interactions+for+cancer+therapy&doi=10.1016%2Fj.drudis.2020.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Interfering with S100B-effector protein interactions for cancer therapy</span></div><div class="casAuthors">Wu, Ke-Jia; Wang, Wanhe; Wang, Hui-Min David; Leung, Chung-Hang; Ma, Dik-Lung</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1754-1761</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  S100 calcium-binding protein B (S100B) is overexpressed in various malignant tumors, where it regulates cancer cell proliferation and metab. by phys. interactions with other mols.  Interfering with S100B-effector protein interactions is a potential strategy to treat malignant tumors.  Although some S100B inhibitors have been discovered by virtual screening (VS), most target the S100B-p53 interaction.  Hence, there is scope for the discovery of other S100B-effector protein interaction modulators for malignant tumors.  In this review, we provide an overview of S100B-effector protein interaction inhibitor discovery using VS and discuss promising S100B-effector protein interaction targets that permit in silico anal. for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvmIh-e_AFDbVg90H21EOLACvtfcHk0li_SjRKs2F6zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVWhsbnI&md5=3461c73b1bb4bbf54d90aaedcddc04ab</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2020.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2020.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%2BD.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26aulast%3DMa%26aufirst%3DD.%2BL.%26atitle%3DInterfering%2520with%2520S100B-effector%2520protein%2520interactions%2520for%2520cancer%2520therapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D1754%26epage%3D1761%26doi%3D10.1016%2Fj.drudis.2020.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span> <span> </span><span class="NLM_article-title">Pretargeted molecular imaging and radioimmunotherapy</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.7150/thno.3582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.7150%2Fthno.3582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=22737190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC38XosVertrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=523-540&author=D.+M.+Goldenbergauthor=C.-H.+Changauthor=E.+A.+Rossiauthor=W.+J.+McBrideauthor=R.+M.+Sharkey&title=Pretargeted+molecular+imaging+and+radioimmunotherapy&doi=10.7150%2Fthno.3582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pretargeted molecular imaging and radioimmunotherapy</span></div><div class="casAuthors">Goldenberg, David M.; Chang, Chien-Hsing; Rossi, Edmund A.; McBride, William J.; Sharkey, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">523-540</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">A review.  Pretargeting is a multi-step process that first has an unlabeled bispecific antibody (bsMAb) localize within a tumor by virtue of its anti-tumor binding site(s) before administering a small, fast-clearing radiolabeled compd. that then attaches to the other portion of the bsMAb.  The compd.'s rapid clearance significantly reduces radiation exposure outside of the tumor and its small size permits speedy delivery to the tumor, creating excellent tumor/nontumor ratios in less than 1 h.  Haptens that bind to an anti-hapten antibody, biotin that binds to streptavidin, or an oligonucleotide binding to a complementary oligonucleotide sequence have all been radiolabeled for use by pretargeting.  This review will focus on a highly flexible anti-hapten bsMAb platform that has been used to target a variety of radionuclides to image (SPECT and PET) as well as treat tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdfeGKgIG2ArVg90H21EOLACvtfcHk0li_SjRKs2F6zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosVertrY%253D&md5=2feba3fec5db97a91f98fc672185e449</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.7150%2Fthno.3582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.3582%26sid%3Dliteratum%253Aachs%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DRossi%26aufirst%3DE.%2BA.%26aulast%3DMcBride%26aufirst%3DW.%2BJ.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26atitle%3DPretargeted%2520molecular%2520imaging%2520and%2520radioimmunotherapy%26jtitle%3DTheranostics%26date%3D2012%26volume%3D2%26spage%3D523%26epage%3D540%26doi%3D10.7150%2Fthno.3582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skora, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blosser, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span> <span> </span><span class="NLM_article-title">Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">11774</span>– <span class="NLM_lpage">11779</span>, <span class="refDoi"> DOI: 10.1073/pnas.1410626111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1073%2Fpnas.1410626111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=25071169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1amsb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=11774-11779&author=K.+Kimauthor=A.+D.+Skoraauthor=Z.+Liauthor=Q.+Liuauthor=A.+J.+Tamauthor=R.+L.+Blosserauthor=L.+A.+Diazauthor=N.+Papadopoulosauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=S.+Zhou&title=Eradication+of+metastatic+mouse+cancers+resistant+to+immune+checkpoint+blockade+by+suppression+of+myeloid-derived+cells&doi=10.1073%2Fpnas.1410626111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells</span></div><div class="casAuthors">Kim, KiBem; Skora, Andrew D.; Li, Zhaobo; Liu, Qiang; Tam, Ada J.; Blosser, Richard L.; Diaz, Luis A. Jr.; Papadopoulos, Nickolas; Kinzler, Kenneth W.; Vogelstein, Bert; Zhou, Shibin</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">11774-11779</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Impressive responses have been obsd. in patients treated with checkpoint inhibitory anti-programmed cell death-1 (PD-1) or anti-cytotoxic T-lymphocyte-assocd. antigen-4 (CTLA-4) antibodies.  However, immunotherapy against poorly immunogenic cancers remains a challenge.  Here we report that treatment with both anti-PD-1 and anti-CTLA-4 antibodies was unable to eradicate large, modestly immunogenic CT26 tumors or metastatic 4T1 tumors.  Cotreatment with epigenetic-modulating drugs and checkpoint inhibitors markedly improved treatment outcomes, curing more than 80% of the tumor-bearing mice.  Functional studies revealed that the primary targets of the epigenetic modulators were myeloid-derived suppressor cells (MDSCs).  A PI3K inhibitor that reduced circulating MDSCs also eradicated 4T1 tumors in 80% of the mice when combined with immune checkpoint inhibitors.  Thus, cancers resistant to immune checkpoint blockade can be cured by eliminating MDSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobXSdogLP7T7Vg90H21EOLACvtfcHk0li_SjRKs2F6zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1amsb%252FL&md5=89ba46cd5660d507aa3e4268033edd4d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1410626111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1410626111%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%26aulast%3DSkora%26aufirst%3DA.%2BD.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DTam%26aufirst%3DA.%2BJ.%26aulast%3DBlosser%26aufirst%3DR.%2BL.%26aulast%3DDiaz%26aufirst%3DL.%2BA.%26aulast%3DPapadopoulos%26aufirst%3DN.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DS.%26atitle%3DEradication%2520of%2520metastatic%2520mouse%2520cancers%2520resistant%2520to%2520immune%2520checkpoint%2520blockade%2520by%2520suppression%2520of%2520myeloid-derived%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D11774%26epage%3D11779%26doi%3D10.1073%2Fpnas.1410626111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perillo, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.-C.</span></span> <span> </span><span class="NLM_article-title">Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1016%2Fj.ccell.2018.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=29438695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=187-201&author=C.-W.+Liauthor=S.-O.+Limauthor=E.+M.+Chungauthor=Y.-S.+Kimauthor=A.+H.+Parkauthor=J.+Yaoauthor=J.-H.+Chaauthor=W.+Xiaauthor=L.-C.+Chanauthor=T.+Kimauthor=S.-S.+Changauthor=H.-H.+Leeauthor=C.-K.+Chouauthor=Y.-L.+Liuauthor=H.-C.+Yehauthor=E.+P.+Perilloauthor=A.+K.+Dunnauthor=C.-W.+Kuoauthor=K.-H.+Khooauthor=J.+L.+Hsuauthor=Y.+Wuauthor=J.-M.+Hsuauthor=H.+Yamaguchiauthor=T.-H.+Huangauthor=A.+A.+Sahinauthor=G.+N.+Hortobagyiauthor=S.+S.+Yooauthor=M.-C.+Hung&title=Eradication+of+triple-negative+breast+cancer+cells+by+targeting+glycosylated+PD-L1&doi=10.1016%2Fj.ccell.2018.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1</span></div><div class="casAuthors">Li, Chia-Wei; Lim, Seung-Oe; Chung, Ezra M.; Kim, Yong-Soo; Park, Andrew H.; Yao, Jun; Cha, Jong-Ho; Xia, Weiya; Chan, Li-Chuan; Kim, Taewan; Chang, Shih-Shin; Lee, Heng-Huan; Chou, Chao-Kai; Liu, Yen-Liang; Yeh, Hsin-Chih; Perillo, Evan P.; Dunn, Andrew K.; Kuo, Chu-Wei; Khoo, Kay-Hooi; Hsu, Jennifer L.; Wu, Yun; Hsu, Jung-Mao; Yamaguchi, Hirohito; Huang, Tzu-Hsuan; Sahin, Aysegul A.; Hortobagyi, Gabriel N.; Yoo, Stephen S.; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-201.e10</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Protein glycosylation provides proteomic diversity in regulating protein localization, stability, and activity; it remains largely unknown whether the sugar moiety contributes to immunosuppression.  In the study of immune receptor glycosylation, we showed that EGF induces programmed death ligand 1 (PD-L1) and receptor programmed cell death protein 1 (PD-1) interaction, requiring β-1,3-N-acetylglucosaminyl transferase (B3GNT3) expression in triple-neg. breast cancer.  Downregulation of B3GNT3 enhances cytotoxic T cell-mediated anti-tumor immunity.  A monoclonal antibody targeting glycosylated PD-L1 (gPD-L1) blocks PD-L1/PD-1 interaction and promotes PD-L1 internalization and degrdn.  In addn. to immune reactivation, drug-conjugated gPD-L1 antibody induces a potent cell-killing effect as well as a bystander-killing effect on adjacent cancer cells lacking PD-L1 expression without any detectable toxicity.  Our work suggests targeting protein glycosylation as a potential strategy to enhance immune checkpoint therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOCUWMg3ECZrVg90H21EOLACvtfcHk0lgMOxK50UngoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSgt78%253D&md5=f8455254b3af2db53721cc7977ec3a6e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.-W.%26aulast%3DLim%26aufirst%3DS.-O.%26aulast%3DChung%26aufirst%3DE.%2BM.%26aulast%3DKim%26aufirst%3DY.-S.%26aulast%3DPark%26aufirst%3DA.%2BH.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DCha%26aufirst%3DJ.-H.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DChan%26aufirst%3DL.-C.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DChang%26aufirst%3DS.-S.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DChou%26aufirst%3DC.-K.%26aulast%3DLiu%26aufirst%3DY.-L.%26aulast%3DYeh%26aufirst%3DH.-C.%26aulast%3DPerillo%26aufirst%3DE.%2BP.%26aulast%3DDunn%26aufirst%3DA.%2BK.%26aulast%3DKuo%26aufirst%3DC.-W.%26aulast%3DKhoo%26aufirst%3DK.-H.%26aulast%3DHsu%26aufirst%3DJ.%2BL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHsu%26aufirst%3DJ.-M.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DT.-H.%26aulast%3DSahin%26aufirst%3DA.%2BA.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DYoo%26aufirst%3DS.%2BS.%26aulast%3DHung%26aufirst%3DM.-C.%26atitle%3DEradication%2520of%2520triple-negative%2520breast%2520cancer%2520cells%2520by%2520targeting%2520glycosylated%2520PD-L1%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D33%26spage%3D187%26epage%3D201%26doi%3D10.1016%2Fj.ccell.2018.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. H.</span></span> <span> </span><span class="NLM_article-title">Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">185</span> <span class="refDoi"> DOI: 10.3389/fphar.2018.00185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.3389%2Ffphar.2018.00185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=29556198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1egsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=Y.+Wangauthor=W.+Dengauthor=N.+Liauthor=S.+Neriauthor=A.+Sharmaauthor=W.+Jiangauthor=S.+H.+Lin&title=Combining+immunotherapy+and+radiotherapy+for+cancer+treatment%3A+current+challenges+and+future+directions&doi=10.3389%2Ffphar.2018.00185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions</span></div><div class="casAuthors">Wang, Yifan; Deng, Weiye; Li, Nan; Neri, Shinya; Sharma, Amrish; Jiang, Wen; Lin, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">185/1-185/11</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the development of anticancer immunotherapy agents has thrived.  The success of many immune-checkpoint inhibitors has drastically changed the landscape of cancer treatment.  For some types of cancer, monotherapy for targeting immune checkpoint pathways has proven more effective than traditional therapies, and combining immunotherapy with current treatment strategies may yield even better outcomes.  Numerous preclin. studies have suggested that combining immunotherapy with radiotherapy could be a promising strategy for synergistic enhancement of treatment efficacy.  Radiation delivered to the tumor site affects both tumor cells and surrounding stromal cells.  Radiation-induced cancer cell damage exposes tumor-specific antigens that make them visible to immune surveillance and promotes the priming and activation of cytotoxic T cells.  Radiation-induced modulation of the tumor microenvironment may also facilitate the recruitment and infiltration of immune cells.  This unique relationship is the rationale for combining radiation with immune checkpoint blockade.  Enhanced tumor recognition and immune cell targeting with checkpoint blockade may unleash the immune system to eliminate the cancer cells.  However, challenges remain to be addressed to maximize the efficacy of this promising combination.  Here we summarize the mechanisms of radiation and immune system interaction, and we discuss current challenges in radiation and immune checkpoint blockade therapy and possible future approaches to boost this combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBtkPZgvdoirVg90H21EOLACvtfcHk0lgMOxK50UngoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1egsLnJ&md5=8b5ae6b55679ba67aa0b103c763f6576</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00185%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DNeri%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DS.%2BH.%26atitle%3DCombining%2520immunotherapy%2520and%2520radiotherapy%2520for%2520cancer%2520treatment%253A%2520current%2520challenges%2520and%2520future%2520directions%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26doi%3D10.3389%2Ffphar.2018.00185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langbein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, R.</span></span> <span> </span><span class="NLM_article-title">Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">529</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=29025984" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=529&author=H.+Kulkarniauthor=C.+Schuchardtauthor=A.+Singhauthor=T.+Langbeinauthor=R.+Baum&title=Early+initiation+of+Lu-177+PSMA+radioligand+therapy+prolongs+overall+survival+in+metastatic+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DH.%26aulast%3DSchuchardt%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DLangbein%26aufirst%3DT.%26aulast%3DBaum%26aufirst%3DR.%26atitle%3DEarly%2520initiation%2520of%2520Lu-177%2520PSMA%2520radioligand%2520therapy%2520prolongs%2520overall%2520survival%2520in%2520metastatic%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0008.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Binding affinity of the targeting agent to VEGFR2 validated by measuring the inhibition of diZD to VEGFR2 protein using VEGFR2 kinase assay (A), saturation binding of <sup>177</sup>Lu-DOTA-diZD to VEGFR2-expressed HUVEC cells (B), and blocking of excessive cold DOTA-diZD to specific binding of <sup>177</sup>Lu-DOTA-diZD to VEGFR2-expressed HUVEC cells (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Structures of <sup>64</sup>Cu-DOTA-diZD and <sup>177</sup>Lu-DOTA-diZD<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Blue color highlights the targeting moieties to VEGFR.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Diagnostic MIP (maximum intensity projection) images of <sup>64</sup>Cu-DOTA-diZD in 4T1 tumor-bearing mice obtained by in vivo PET/CT imaging at 6, 24, and 48 h pi (A), tumor/blood ROI-derived uptake of the radiotracer in the in vivo imaging (B), and biodistribution of the radiotracer among major organs at 48 h pi (C).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Therapies for the 4T1 tumor-bearing Balb/c mice: (A) schematic illustration of the therapy protocol; (B) body weight change; (C) local tumor volume change; and (D) survival of mice treated with saline (group A), cold diZD (group B), anti-PD1 antibody (group C), and <sup>177</sup>Lu-DOTA-diZD (group D) (<i>p</i> < 0.001).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Immunohistochemistry staining of Ki67 on tumor tissues collected from various therapies; (B) western blotting assay for VEGFR2 expression on tumor tissues; (C) flow analyses of PD1 expression on T cells from spleens of healthy Balb/c and 4T1 tumor-bearing Balb/c mice; and (D) flow analyses of CD4<sup>+</sup> and CD8<sup>+</sup> cells activation in tumors treated with various therapies.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/medium/jm0c01957_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Scheme of Precursor DOTA-diZD</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-5/acs.jmedchem.0c01957/20210305/images/large/jm0c01957_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01957&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i28">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54282" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54282" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foulkes, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis-Filho, J. S.</span></span> <span> </span><span class="NLM_article-title">Triple-negative breast cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>363</i></span>,  <span class="NLM_fpage">1938</span>– <span class="NLM_lpage">1948</span>, <span class="refDoi"> DOI: 10.1056/NEJMra1001389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1056%2FNEJMra1001389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=21067385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1938-1948&author=W.+D.+Foulkesauthor=I.+E.+Smithauthor=J.+S.+Reis-Filho&title=Triple-negative+breast+cancer&doi=10.1056%2FNEJMra1001389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer</span></div><div class="casAuthors">Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1938-1948</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiN8P8IsovvLVg90H21EOLACvtfcHk0liDuf3pOaOpyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVCltr7P&md5=641fe4726e6a7118208aa6b3502c9df6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1056%2FNEJMra1001389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMra1001389%26sid%3Dliteratum%253Aachs%26aulast%3DFoulkes%26aufirst%3DW.%2BD.%26aulast%3DSmith%26aufirst%3DI.%2BE.%26aulast%3DReis-Filho%26aufirst%3DJ.%2BS.%26atitle%3DTriple-negative%2520breast%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1938%26epage%3D1948%26doi%3D10.1056%2FNEJMra1001389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cedolini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertozzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Londero, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seriau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Concina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Risaliti, A.</span></span> <span> </span><span class="NLM_article-title">Type of breast cancer diagnosis, screening, and survival</span>. <i>Clin. Breast Cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/j.clbc.2014.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1016%2Fj.clbc.2014.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=24703317" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BC2cngslGhug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=235-240&author=C.+Cedoliniauthor=S.+Bertozziauthor=A.+P.+Londeroauthor=S.+Bernardiauthor=L.+Seriauauthor=S.+Concinaauthor=F.+Cattinauthor=A.+Risaliti&title=Type+of+breast+cancer+diagnosis%2C+screening%2C+and+survival&doi=10.1016%2Fj.clbc.2014.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Type of breast cancer diagnosis, screening, and survival</span></div><div class="casAuthors">Cedolini Carla; Bertozzi Serena; Seriau Luca; Concina Serena; Cattin Federico; Risaliti Andrea; Londero Ambrogio P; Bernardi Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical breast cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-40</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Breast cancer screening is known to reduce mortality.  In the present study, we analyzed the prevalence of breast cancers detected through screening, before and after introduction of an organized screening, and we evaluated the overall survival of these patients in comparison with women with an extrascreening imaging-detected breast cancer or those with palpable breast cancers.  MATERIALS AND METHODS:  We collected data about all women who underwent a breast operation for cancer in our department between 2001 and 2008, focusing on type of tumor diagnosis, tumor characteristics, therapies administered, and patient outcome in terms of overall survival, and recurrences.  Data was analyzed by R (version 2.15.2), and P < .05 was considered significant.  RESULTS:  Among the 2070 cases of invasive breast cancer we considered, 157 were detected by regional mammographic screening (group A), 843 by extrascreening breast imaging (group B: 507 by mammography and 336 by ultrasound), and 1070 by extrascreening breast objective examination (group C).  The 5-year overall survival in groups A, B, and C were, respectively, 99% (95% CI, 98%-100%), 98% (95% CI, 97%-99%), and 91% (95% CI, 90%-93%), with a significant difference between the first 2 groups and the third (P < .05) and a trend between groups A and B (P = .081).  CONCLUSION:  The diagnosis of invasive breast cancer with screening in our population resulted in a survival gain at 5 years from the diagnosis, but a longer follow-up is necessary to confirm this data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSmYGo-TAdgM8AKB7Fa-xrUfW6udTcc2eZnCbjbSqh_gbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cngslGhug%253D%253D&md5=5bad0adebd713661b082b0a4ad66c9f1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.clbc.2014.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clbc.2014.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DCedolini%26aufirst%3DC.%26aulast%3DBertozzi%26aufirst%3DS.%26aulast%3DLondero%26aufirst%3DA.%2BP.%26aulast%3DBernardi%26aufirst%3DS.%26aulast%3DSeriau%26aufirst%3DL.%26aulast%3DConcina%26aufirst%3DS.%26aulast%3DCattin%26aufirst%3DF.%26aulast%3DRisaliti%26aufirst%3DA.%26atitle%3DType%2520of%2520breast%2520cancer%2520diagnosis%252C%2520screening%252C%2520and%2520survival%26jtitle%3DClin.%2520Breast%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D235%26epage%3D240%26doi%3D10.1016%2Fj.clbc.2014.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auguste, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moses, M. A.</span></span> <span> </span><span class="NLM_article-title">Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">18295</span>– <span class="NLM_lpage">18303</span>, <span class="refDoi"> DOI: 10.1073/pnas.1904697116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1073%2Fpnas.1904697116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=31451668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslOhsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2019&pages=18295-18303&author=P.+Guoauthor=J.+Yangauthor=J.+Huangauthor=D.+T.+Augusteauthor=M.+A.+Moses&title=Therapeutic+genome+editing+of+triple-negative+breast+tumors+using+a+noncationic+and+deformable+nanolipogel&doi=10.1073%2Fpnas.1904697116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic genome editing of triple-negative breast tumors using a noncationic and deformable nanolipogel</span></div><div class="casAuthors">Guo, Peng; Yang, Jiang; Huang, Jing; Auguste, Debra T.; Moses, Marsha A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">18295-18303</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC), which has the highest mortality rate of all breast cancer, is in urgent need of a therapeutic that hinders the spread and growth of cancer cells.  CRISPR genome editing holds the promise of a potential cure for many genetic diseases, including TNBC; however, its clin. translation is being challenged by the lack of safe and effective nonviral delivery systems for in vivo therapeutic genome editing.  Here we report the synthesis and application of a noncationic, deformable, and tumor-targeted nanolipogel system (tNLG) for CRISPR genome editing in TNBC tumors.  We have demonstrated that tNLGs mediate a potent CRISPR knockout of Lipocalin 2 (Lcn2), a known breast cancer oncogene, in human TNBC cells in vitro and in vivo.  The loss of Lcn2 significantly inhibits the migration and the mesenchymal phenotype of human TNBC cells and subsequently attenuates TNBC aggressiveness.  In an orthotopic TNBC model, we have shown that systemically administered tNLGs mediated &gt;81% CRISPR knockout of Lcn2 in TNBC tumor tissues, resulting in significant tumor growth suppression (&gt;77%).  Our proof-of-principle results provide exptl. evidence that tNLGs can be used as a safe, precise, and effective delivery approach for in vivo CRISPR genome editing in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjqqx58aJhMbVg90H21EOLACvtfcHk0lhyHPAzTTMNGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslOhsbjP&md5=8c6b27fc6fa491c81ed757fd096a38ff</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1904697116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1904697116%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DAuguste%26aufirst%3DD.%2BT.%26aulast%3DMoses%26aufirst%3DM.%2BA.%26atitle%3DTherapeutic%2520genome%2520editing%2520of%2520triple-negative%2520breast%2520tumors%2520using%2520a%2520noncationic%2520and%2520deformable%2520nanolipogel%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2019%26volume%3D116%26spage%3D18295%26epage%3D18303%26doi%3D10.1073%2Fpnas.1904697116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dent, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trudeau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahn, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawka, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lickley, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlinson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narod, S. A.</span></span> <span> </span><span class="NLM_article-title">Triple-negative breast cancer: clinical features and patterns of recurrence</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">4429</span>– <span class="NLM_lpage">4434</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-06-3045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1158%2F1078-0432.CCR-06-3045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=17671126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BD2svltlShtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=4429-4434&author=R.+Dentauthor=M.+Trudeauauthor=K.+I.+Pritchardauthor=W.+M.+Hannaauthor=H.+K.+Kahnauthor=C.+A.+Sawkaauthor=L.+A.+Lickleyauthor=E.+Rawlinsonauthor=P.+Sunauthor=S.+A.+Narod&title=Triple-negative+breast+cancer%3A+clinical+features+and+patterns+of+recurrence&doi=10.1158%2F1078-0432.CCR-06-3045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Triple-negative breast cancer: clinical features and patterns of recurrence</span></div><div class="casAuthors">Dent Rebecca; Trudeau Maureen; Pritchard Kathleen I; Hanna Wedad M; Kahn Harriet K; Sawka Carol A; Lickley Lavina A; Rawlinson Ellen; Sun Ping; Narod Steven A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">15 Pt 1</span>),
    <span class="NLM_cas:pages">4429-34</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">PURPOSE:  To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer.  EXPERIMENTAL DESIGN:  We studied a cohort of 1,601 patients with breast cancer, diagnosed between January 1987 and December 1997 at Women's College Hospital in Toronto.  Triple-negative breast cancers were defined as those that were estrogen receptor negative, progesterone receptor negative, and HER2neu negative.  The prognostic significance of triple-negative breast cancer was explored.  RESULTS:  The median follow-up time of the 1,601 women was 8.1 years.  One hundred and eighty of 1,601 patients (11.2%) had triple-negative breast cancer.  Compared with other women with breast cancer, those with triple-negative breast cancer had an increased likelihood of distant recurrence (hazard ratio, 2.6; 95% confidence interval, 2.0-3.5; P < 0.0001) and death (hazard ratio, 3.2; 95% confidence interval, 2.3-4.5; P < 0.001) within 5 years of diagnosis but not thereafter.  The pattern of recurrence was also qualitatively different; among the triple-negative group, the risk of distant recurrence peaked at approximately 3 years and declined rapidly thereafter.  Among the "other" group, the recurrence risk seemed to be constant over the period of follow-up.  CONCLUSIONS:  Triple-negative breast cancers have a more aggressive clinical course than other forms of breast cancer, but the adverse effect is transient.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgv_jWdHp-NeIHSmpohpd0fW6udTcc2eZnCbjbSqh_gbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svltlShtQ%253D%253D&md5=7ee3954fe80ef97f1966768b115e6050</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-3045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-3045%26sid%3Dliteratum%253Aachs%26aulast%3DDent%26aufirst%3DR.%26aulast%3DTrudeau%26aufirst%3DM.%26aulast%3DPritchard%26aufirst%3DK.%2BI.%26aulast%3DHanna%26aufirst%3DW.%2BM.%26aulast%3DKahn%26aufirst%3DH.%2BK.%26aulast%3DSawka%26aufirst%3DC.%2BA.%26aulast%3DLickley%26aufirst%3DL.%2BA.%26aulast%3DRawlinson%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DP.%26aulast%3DNarod%26aufirst%3DS.%2BA.%26atitle%3DTriple-negative%2520breast%2520cancer%253A%2520clinical%2520features%2520and%2520patterns%2520of%2520recurrence%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D4429%26epage%3D4434%26doi%3D10.1158%2F1078-0432.CCR-06-3045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fleisher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ait-Oudhia, S.</span></span> <span> </span><span class="NLM_article-title">Current advances in biomarkers for targeted therapy in triple-negative breast cancer</span>. <i>Breast Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.2147/BCTT.S114659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.2147%2FBCTT.S114659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC1cXovFOjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=183-197&author=B.+Fleisherauthor=C.+Clarkeauthor=S.+Ait-Oudhia&title=Current+advances+in+biomarkers+for+targeted+therapy+in+triple-negative+breast+cancer&doi=10.2147%2FBCTT.S114659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Current advances in biomarkers for targeted therapy in triple-negative breast cancer</span></div><div class="casAuthors">Fleisher, Brett; Clarke, Charlotte; Ait-Oudhia, Sihem</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">183-197</span>CODEN:
                <span class="NLM_cas:coden">BCTTA9</span>;
        ISSN:<span class="NLM_cas:issn">1179-1314</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a complex heterogeneous disease characterized by the absence of three hallmark receptors: human epidermal growth factor receptor 2, estrogen receptor, and progesterone receptor.  Compared to other breast cancer subtypes, TNBC is more aggressive, has a higher prevalence in African-Americans, and more frequently affects younger patients.  Currently, TNBC lacks clin. accepted targets for tailored therapy, warranting the need for candidate biomarkers.  BiomarkerBase, an online platform used to find biomarkers reported in clin. trials, was utilized to screen all potential biomarkers for TNBC and select only the ones registered in completed TNBC trials through clinicaltrials.gov.  The selected candidate biomarkers were classified as surrogate, prognostic, predictive, or pharmacodynamic (PD) and organized by location in the blood, on the cell surface, in the cytoplasm, or in the nucleus.  Blood biomarkers include vascular endothelial growth factor/vascular endothelial growth factor receptor and interleukin-8 (IL-8); cell surface biomarkers include EGFR, insulin-like growth factor binding protein, c-Kit, c-Met, and PD-L1; cytoplasm biomarkers include PIK3CA, pAKT/S6/p4E-BP1, PTEN, ALDH1, and the PIK3CA/AKT/mTOR-related metabolites; and nucleus biomarkers include BRCA1, the glucocorticoid receptor, TP53, and Ki67.  Candidate biomarkers were further organized into a "cellular protein network" that demonstrates potential connectivity.  This review provides an inventory and ref. point for promising biomarkers for breakthrough targeted therapies in TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEVZUacaLXTLVg90H21EOLACvtfcHk0litLgwwbPuVGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXovFOjtbY%253D&md5=3d9f5f9599f1e3700c7c04a518fc527e</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2147%2FBCTT.S114659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FBCTT.S114659%26sid%3Dliteratum%253Aachs%26aulast%3DFleisher%26aufirst%3DB.%26aulast%3DClarke%26aufirst%3DC.%26aulast%3DAit-Oudhia%26aufirst%3DS.%26atitle%3DCurrent%2520advances%2520in%2520biomarkers%2520for%2520targeted%2520therapy%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2016%26volume%3D8%26spage%3D183%26epage%3D197%26doi%3D10.2147%2FBCTT.S114659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litton, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moulder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meric-Bernstam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Angulo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ueno, N. T.</span></span> <span> </span><span class="NLM_article-title">Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">12890</span>– <span class="NLM_lpage">12908</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.3849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.18632%2Foncotarget.3849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=25973541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BC2Mfjs12msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=12890-12908&author=F.+Le%0ADuauthor=B.+L.+Eckhardtauthor=B.+Limauthor=J.+K.+Littonauthor=S.+Moulderauthor=F.+Meric-Bernstamauthor=A.+M.+Gonzalez-Anguloauthor=N.+T.+Ueno&title=Is+the+future+of+personalized+therapy+in+triple-negative+breast+cancer+based+on+molecular+subtype%3F&doi=10.18632%2Foncotarget.3849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?</span></div><div class="casAuthors">Le Du Fanny; Eckhardt Bedrich L; Lim Bora; Litton Jennifer K; Moulder Stacy; Gonzalez-Angulo Ana M; Ueno Naoto T; Le Du Fanny; Lim Bora; Litton Jennifer K; Moulder Stacy; Meric-Bernstam Funda; Gonzalez-Angulo Ana M; Ueno Naoto T; Litton Jennifer K; Meric-Bernstam Funda; Gonzalez-Angulo Ana M</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">12890-908</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Significant research has been conducted to better understand the extensive, heterogeneous molecular features of triple-negative breast cancer (TNBC).  We reviewed published TNBC molecular classifications to identify major groupings that have potential for clinical trial development.  With the ultimate aim to streamline translational medicine, we linked these categories of TNBC according to their gene-expression signatures, biological function, and clinical outcome.  To this end, we define five potential clinically actionable groupings of TNBC: 1) basal-like TNBC with DNA-repair deficiency or growth factor pathways; 2) mesenchymal-like TNBC with epithelial-to-mesenchymal transition and cancer stem cell features; 3) immune-associated TNBC; 4) luminal/apocrine TNBC with androgen-receptor overexpression; and 5) HER2-enriched TNBC.  For each defined subtype, we highlight the major biological pathways and discuss potential targeted therapies in TNBC that might abrogate disease progression.  However, many of these potential targets need clinical validation by clinical trials.  We have yet to know how we can enrich the targets by molecular classifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZdPdM90gD3_3jf77P2BG3fW6udTcc2eb9ZaPIJQKS7bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2Mfjs12msA%253D%253D&md5=64bd5a0e4eb949f45eceed1a4a2a5fdd</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.3849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.3849%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BDu%26aufirst%3DF.%26aulast%3DEckhardt%26aufirst%3DB.%2BL.%26aulast%3DLim%26aufirst%3DB.%26aulast%3DLitton%26aufirst%3DJ.%2BK.%26aulast%3DMoulder%26aufirst%3DS.%26aulast%3DMeric-Bernstam%26aufirst%3DF.%26aulast%3DGonzalez-Angulo%26aufirst%3DA.%2BM.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DIs%2520the%2520future%2520of%2520personalized%2520therapy%2520in%2520triple-negative%2520breast%2520cancer%2520based%2520on%2520molecular%2520subtype%253F%26jtitle%3DOncotarget%26date%3D2015%26volume%3D6%26spage%3D12890%26epage%3D12908%26doi%3D10.18632%2Foncotarget.3849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mayer, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abramson, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietenpol, J. A.</span></span> <span> </span><span class="NLM_article-title">New strategies for triple-negative nreast cancer—deciphering the heterogeneity</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">782</span>– <span class="NLM_lpage">790</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-13-0583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1158%2F1078-0432.CCR-13-0583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=24536073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXivVejsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=782-790&author=I.+A.+Mayerauthor=V.+G.+Abramsonauthor=B.+D.+Lehmannauthor=J.+A.+Pietenpol&title=New+strategies+for+triple-negative+nreast+cancer%E2%80%94deciphering+the+heterogeneity&doi=10.1158%2F1078-0432.CCR-13-0583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">New Strategies for Triple-Negative Breast Cancer-Deciphering the Heterogeneity</span></div><div class="casAuthors">Mayer, Ingrid A.; Abramson, Vandana G.; Lehmann, Brian D.; Pietenpol, Jennifer A.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">782-790</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Triple-neg. breast cancer (TNBC) is a heterogeneous disease; gene expression analyses recently identified six distinct TNBC subtypes, each displaying a unique biol.  Exploring novel approaches to treatment of these subtypes is crit. because less than 30% of women with metastatic breast cancer survive five years and virtually all women with metastatic TNBC will ultimately die of their disease despite systemic therapy.  To date, not a single targeted therapy has been approved for the treatment of TNBC and cytotoxic chemotherapy remains the std. treatment.  We discuss the current and upcoming therapeutic strategies being explored in an attempt to "target" TNBC.  Clin Cancer Res; 20(4); 782-90. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdvsR_JjXMyLVg90H21EOLACvtfcHk0litLgwwbPuVGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXivVejsb0%253D&md5=4ce0876cb914096f913a7a637d7b63d5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-13-0583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-13-0583%26sid%3Dliteratum%253Aachs%26aulast%3DMayer%26aufirst%3DI.%2BA.%26aulast%3DAbramson%26aufirst%3DV.%2BG.%26aulast%3DLehmann%26aufirst%3DB.%2BD.%26aulast%3DPietenpol%26aufirst%3DJ.%2BA.%26atitle%3DNew%2520strategies%2520for%2520triple-negative%2520nreast%2520cancer%25E2%2580%2594deciphering%2520the%2520heterogeneity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D782%26epage%3D790%26doi%3D10.1158%2F1078-0432.CCR-13-0583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, H.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uribe, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colpo, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bénard, F.</span></span> <span> </span><span class="NLM_article-title">Enhancing treatment efficacy of 177Lu-PSMA-617 with the conjugation of an albumin-binding motif: preclinical dosimetry and endoradiotherapy studies</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5183</span>– <span class="NLM_lpage">5191</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.8b00720</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.8b00720" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOhsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=5183-5191&author=H.-T.+Kuoauthor=H.+Merkensauthor=Z.+Zhangauthor=C.+F.+Uribeauthor=J.+Lauauthor=C.+Zhangauthor=N.+Colpoauthor=K.-S.+Linauthor=F.+B%C3%A9nard&title=Enhancing+treatment+efficacy+of+177Lu-PSMA-617+with+the+conjugation+of+an+albumin-binding+motif%3A+preclinical+dosimetry+and+endoradiotherapy+studies&doi=10.1021%2Facs.molpharmaceut.8b00720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies</span></div><div class="casAuthors">Kuo, Hsiou-Ting; Merkens, Helen; Zhang, Zhengxing; Uribe, Carlos F.; Lau, Joseph; Zhang, Chengcheng; Colpo, Nadine; Lin, Kuo-Shyan; Benard, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5183-5191</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We designed and evaluated a novel albumin-binder-conjugated 177Lu-PSMA-617 deriv., 177Lu-HTK01169, with an extended blood retention time to maximize the radiation dose delivered to prostate tumors expressing prostate-specific membrane antigen (PSMA).  PSMA-617 and HTK01169 that contained N-[4-(p-iodophenyl)butanoyl]-Glu as an albumin-binding motif were synthesized using the solid-phase approach.  Binding affinity to PSMA was detd. by in vitro competition-binding assay.  77Lu labeling was performed in acetate buffer (pH 4.5) at 90 °C for 15 min.  SPECT/CT imaging, biodistribution, and endoradiotherapy studies were conducted in mice bearing PSMA-expressing LNCaP tumor xenografts.  Radiation dosimetry was calcd. using OLINDA software.  Lu-PSMA-617 and Lu-HTK01169-bound PSMA with high affinity (Ki values = 0.24 and 0.04 nM, resp.).  SPECT imaging and biodistribution studies showed that 177Lu-PSMA-617 and 177Lu-HTK01169 were excreted mainly via the renal pathway.  With fast blood clearance (0.68%ID/g at 1 h postinjection), the tumor uptake of 177Lu-PSMA-617 peaked at 1 h postinjection (15.1%ID/g) and gradually decreased to 7.91%ID/g at 120 h postinjection.  With extended blood retention (16.6 and 2.10%ID/g at 1 and 24 h, resp.), the tumor uptake of 177Lu-HTK01169 peaked at 24 h postinjection (55.9%ID/g) and remained at the same level by the end of the study (120 h).  Based on dosimetry calcns., 177Lu-HTK01169 delivered an 8.3-fold higher radiation dose than 177Lu-PSMA-617 to LNCaP tumor xenografts.  For the endoradiotherapy study, the mice treated with 177Lu-PSMA-617 (18.5 MBq) all reached humane end point (tumor vol. >1000 mm3) by Day 73 with a median survival of 58 days.  Mice treated with 18.5, 9.3, 4.6, or 2.3 MBq of 177Lu-HTK01169 had a median survival of >120, 103, 61, and 28 days, resp.  With greatly enhanced tumor uptake and treatment efficacy compared to 177Lu-PSMA-617 in preclin. studies, 177Lu-HTK01169 warrants further investigation for endoradiotherapy of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJkVyN6KqoFbVg90H21EOLACvtfcHk0litLgwwbPuVGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOhsLjP&md5=3bf3bad467088ab84b51b65285f9db7a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.8b00720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.8b00720%26sid%3Dliteratum%253Aachs%26aulast%3DKuo%26aufirst%3DH.-T.%26aulast%3DMerkens%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DUribe%26aufirst%3DC.%2BF.%26aulast%3DLau%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DColpo%26aufirst%3DN.%26aulast%3DLin%26aufirst%3DK.-S.%26aulast%3DB%25C3%25A9nard%26aufirst%3DF.%26atitle%3DEnhancing%2520treatment%2520efficacy%2520of%2520177Lu-PSMA-617%2520with%2520the%2520conjugation%2520of%2520an%2520albumin-binding%2520motif%253A%2520preclinical%2520dosimetry%2520and%2520endoradiotherapy%2520studies%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2018%26volume%3D15%26spage%3D5183%26epage%3D5191%26doi%3D10.1021%2Facs.molpharmaceut.8b00720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">7948</span>– <span class="NLM_lpage">7960</span>, <span class="refDoi"> DOI: 10.7150/thno.39203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.7150%2Fthno.39203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=31695808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFams7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=7948-7960&author=H.+Chenauthor=L.+Zhaoauthor=K.+Fuauthor=Q.+Linauthor=X.+Wenauthor=O.+Jacobsonauthor=L.+Sunauthor=H.+Wuauthor=X.+Zhangauthor=Z.+Guoauthor=Q.+Linauthor=X.+Chen&title=Integrin+%CE%B1v%CE%B23-targeted+radionuclide+therapy+combined+with+immune+checkpoint+blockade+immunotherapy+synergistically+enhances+anti-tumor+efficacy&doi=10.7150%2Fthno.39203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Integrin αvβ3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy</span></div><div class="casAuthors">Chen, Haojun; Zhao, Liang; Fu, Kaili; Lin, Qiuming; Wen, Xuejun; Jacobson, Orit; Sun, Long; Wu, Hua; Zhang, Xianzhong; Guo, Zhide; Lin, Qin; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">7948-7960</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">Radiotherapy combined with immunotherapy has revealed promising outcomes in both preclin. studies and ongoing clin. trials.  Targeted radionuclide therapy (TRT) is a branch of radiotherapy concerned with the use of radioisotopes, radiolabeled mols. or nanoparticles that deliver particulate radiation to cancer cells.  TRT is a promising approach in cases of metastatic disease where conventional treatments are no longer effective.  The increasing use of TRT raises the question of how to best integrate TRT with immunotherapy.  In this study, we proposed a novel therapeutic regimen that combined programmed death ligand 1 (PD-L1)-based immunotherapy with peptide-based TRT (177Lu as the radionuclide) in the murine colon cancer model.  To explore the most appropriate timing of immunotherapy after radionuclide therapy, the anti-PD-L1 antibody (αPD-L1 mAb) was delivered in a concurrent or sequential manner when 177Lu TRT was given.  The results demonstrated that TRT led to an acute increase in PD-L1 expression on T cells, and TRT in combination with αPD-L1 mAb stimulated the infiltration of CD8+ T cells, which improved local tumor control, overall survival and protection against tumor rechallenge.  Moreover, our data revealed that the time window for this combination therapy may be crit. to outcome.  This therapeutic combination may be a promising approach to treating metastatic tumors in which TRT can be used.  Clin. translation of the result would suggest that concurrent rather than sequential blockade of the PD-1/PD-L1 axis combined with TRT improves overall survival and long-term tumor control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsr0E0ceG7HrVg90H21EOLACvtfcHk0lgF1vxCIAh4aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFams7%252FP&md5=ec320e3cccd676df412d96656f144667</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.7150%2Fthno.39203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.39203%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DFu%26aufirst%3DK.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DJacobson%26aufirst%3DO.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DLin%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DIntegrin%2520%25CE%25B1v%25CE%25B23-targeted%2520radionuclide%2520therapy%2520combined%2520with%2520immune%2520checkpoint%2520blockade%2520immunotherapy%2520synergistically%2520enhances%2520anti-tumor%2520efficacy%26jtitle%3DTheranostics%26date%3D2019%26volume%3D9%26spage%3D7948%26epage%3D7960%26doi%3D10.7150%2Fthno.39203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehlerding, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacognata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theuer, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, W.</span></span> <span> </span><span class="NLM_article-title">Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody</span>. <i>Eur. J. Nucl. Med. Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">123</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1007/s00259-017-3793-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1007%2Fs00259-017-3793-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=28821931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKnurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2018&pages=123-131&author=E.+B.+Ehlerdingauthor=S.+Lacognataauthor=D.+Jiangauthor=C.+A.+Ferreiraauthor=S.+Goelauthor=R.+Hernandezauthor=J.+J.+Jefferyauthor=C.+P.+Theuerauthor=W.+Cai&title=Targeting+angiogenesis+for+radioimmunotherapy+with+a+177Lu-labeled+antibody&doi=10.1007%2Fs00259-017-3793-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody</span></div><div class="casAuthors">Ehlerding, Emily B.; Lacognata, Saige; Jiang, Dawei; Ferreira, Carolina A.; Goel, Shreya; Hernandez, Reinier; Jeffery, Justin J.; Theuer, Charles P.; Cai, Weibo</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Nuclear Medicine and Molecular Imaging</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">123-131</span>CODEN:
                <span class="NLM_cas:coden">EJNMA6</span>;
        ISSN:<span class="NLM_cas:issn">1619-7070</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Increased angiogenesis is a marker of aggressiveness in many cancers.  Targeted radionuclide therapy of these cancers with angiogenesis-targeting agents may curtail this increased blood vessel formation and slow the growth of tumors, both primary and metastatic.  CD105, or endoglin, has a primary role in angiogenesis in a no. of cancers, making this a widely applicable target for targeted radioimmunotherapy.  The anti-CD105 antibody, TRC105 (TRACON Pharmaceuticals), was conjugated with DTPA for radiolabeling with 177Lu (t1/2 6.65 days).  Balb/c mice were implanted with 4T1 mammary carcinoma cells, and five study groups were used: 177Lu only, TRC105 only, 177Lu-DTPA-IgG (a nonspecific antibody), 177Lu-DTPA-TRC105 low-dose, and 177Lu-DTPA-TRC105 high-dose.  Toxicity of the agent was monitored by body wt. measurements and anal. of blood markers.  Biodistribution studies of 177Lu-DTPA-TRC105 were also performed at 1 and 7 days after injection.  Ex vivo histol. studies of various tissues were conducted at 1, 7, and 30 days after injection of high-dose 177Lu-DTPA-TRC105.  Biodistribution studies indicated steady uptake of 177Lu-DTPA-TRC105 in 4T1 tumors between 1 and 7 days after injection (14.3 ± 2.3%ID/g and 11.6 ± 6.1%ID/g, resp.; n = 3) and gradual clearance from other organs.  Significant inhibition of tumor growth was obsd. in the high-dose group, with a corresponding significant increase in survival (p < 0.001, all groups).  In most study groups (all except the nonspecific IgG group), the body wts. of the mice did not decrease by more than 10%, indicating the safety of the injected agents.  Serum alanine transaminase levels remained nearly const. indicating no damage to the liver (a primary clearance organ of the agent), and this was confirmed by ex vivo histol. analyses.  177Lu-DTPA-TRC105, when administered at a sufficient dose, is able to curtail tumor growth and provide a significant survival benefit without off-target toxicity.  Thus, this targeted agent could be used in combination with other treatment options to slow tumor growth allowing the other agents to be more effective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosYqSvEDxgebVg90H21EOLACvtfcHk0lgF1vxCIAh4aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKnurrL&md5=066ae34a2a9074e63b5d4067897476eb</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs00259-017-3793-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00259-017-3793-2%26sid%3Dliteratum%253Aachs%26aulast%3DEhlerding%26aufirst%3DE.%2BB.%26aulast%3DLacognata%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DD.%26aulast%3DFerreira%26aufirst%3DC.%2BA.%26aulast%3DGoel%26aufirst%3DS.%26aulast%3DHernandez%26aufirst%3DR.%26aulast%3DJeffery%26aufirst%3DJ.%2BJ.%26aulast%3DTheuer%26aufirst%3DC.%2BP.%26aulast%3DCai%26aufirst%3DW.%26atitle%3DTargeting%2520angiogenesis%2520for%2520radioimmunotherapy%2520with%2520a%2520177Lu-labeled%2520antibody%26jtitle%3DEur.%2520J.%2520Nucl.%2520Med.%2520Mol.%2520Imaging%26date%3D2018%26volume%3D45%26spage%3D123%26epage%3D131%26doi%3D10.1007%2Fs00259-017-3793-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mittra, E. S.</span></span> <span> </span><span class="NLM_article-title">Neuroendocrine tumor therapy: 177Lu-DOTATATE</span>. <i>Am. J. Roentgenol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>211</i></span>,  <span class="NLM_fpage">278</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.2214/AJR.18.19953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.2214%2FAJR.18.19953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FisVyisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=211&publication_year=2018&pages=278-285&author=E.+S.+Mittra&title=Neuroendocrine+tumor+therapy%3A+177Lu-DOTATATE&doi=10.2214%2FAJR.18.19953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Neuroendocrine Tumor Therapy: (177)Lu-DOTATATE</span></div><div class="casAuthors">Mittra Erik S</div><div class="citationInfo"><span class="NLM_cas:title">AJR. American journal of roentgenology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">211</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">278-285</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  The purposes of this article are to increase understanding of the concepts of theranostics and peptide receptor radionuclide therapy (PRRT) as they apply to neuroendocrine tumors (NETs); review the key 1, 2, and 3 clinical trial data leading to the approval of (177)Lu-tetraazacyclododecanetetraacetic acid-octreotide ((177)Lu-DOTATATE); and foster understanding of the practical aspects and future directions of PRRT for NETs.  CONCLUSION:  In January 2018, (177)Lu-DOTATATE therapy was approved in the United States (previously approved in Europe in September 2017) for adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including those of the foregut, midgut, and hindgut.  The results of the phase 3 Neuroendocrine Tumors Therapy (NETTER-1) trial show favorable outcomes with respect to the primary endpoint of progression-free survival and a host of secondary objectives, including overall survival, objective response rate, and quality of life measures.  Patient selection is based on a number of specific factors and should be sequenced carefully with respect to other available therapies, ideally in multidisciplinary cancer conferences.  Establishing the therapy at a new institution can be somewhat involved, but once it is established, the therapy is fairly straightforward to administer and is well tolerated with limited side-effects and toxicity.  A number of approaches and issues are still to be worked out, and this therapy will continue to be studied and optimized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQVZWXuXntqS_6BottYdIAWfW6udTcc2eYCKxu7BXtzBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FisVyisw%253D%253D&md5=bc9e9550a927a2fa425d63c18f779f5c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.2214%2FAJR.18.19953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2214%252FAJR.18.19953%26sid%3Dliteratum%253Aachs%26aulast%3DMittra%26aufirst%3DE.%2BS.%26atitle%3DNeuroendocrine%2520tumor%2520therapy%253A%2520177Lu-DOTATATE%26jtitle%3DAm.%2520J.%2520Roentgenol.%26date%3D2018%26volume%3D211%26spage%3D278%26epage%3D285%26doi%3D10.2214%2FAJR.18.19953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Strosberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Haddad, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendifar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chasen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunz, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulke, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacene, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bushnell, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dorisio, T. M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>376</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1607427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1056%2FNEJMoa1607427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=28076709" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSnsLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=376&publication_year=2017&pages=125-135&author=J.+Strosbergauthor=G.+El-Haddadauthor=E.+Wolinauthor=A.+Hendifarauthor=J.+Yaoauthor=B.+Chasenauthor=E.+Mittraauthor=P.+L.+Kunzauthor=M.+H.+Kulkeauthor=H.+Jaceneauthor=D.+Bushnellauthor=T.+M.+O%E2%80%99Dorisio&title=Phase+3+trial+of+177Lu-dotatate+for+midgut+neuroendocrine+tumors&doi=10.1056%2FNEJMoa1607427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors</span></div><div class="casAuthors">Strosberg, J.; El-Haddad, G.; Wolin, E.; Hendifar, A.; Yao, J.; Chasen, B.; Mittra, E.; Kunz, P. L.; Kulke, M. H.; Jacene, H.; Bushnell, D.; O'Dorisio, T. M.; Baum, R. P.; Kulkarni, H. R.; Caplin, M.; Lebtahi, R.; Hobday, T.; Delpassand, E.; Van Cutsem, E.; Benson, A.; Srirajaskanthan, R.; Pavel, M.; Mora, J.; Berlin, J.; Grande, E.; Reed, N.; Seregni, E.; Oeberg, K.; Sierra, M. Lopera; Santoro, P.; Thevenet, T.; Erion, J. L.; Ruszniewski, P.; Kwekkeboom, D.; Krenning, E.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">376</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-135</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analog therapy have limited therapeutic options.  This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-pos. midgut neuroendocrine tumors.  METHODS We randomly assigned 229 patients who had well-differentiated, metastatic midgut neuroendocrine tumors to receive either 177Lu-Dotatate (116 patients) at a dose of 7.4 GBq every 8 wk (four i.v. infusions, plus best supportive care including octreotide long-acting repeatable [LAR] administered i.m. at a dose of 30 mg) (177Lu-Dotatate group) or octreotide LAR alone (113 patients) administered i.m. at a dose of 60 mg every 4 wk (control group).  The primary end point was progression-free survival.  Secondary end points included the objective response rate, overall survival, safety, and the side-effect profile.  The final anal. of overall survival will be conducted in the future as specified in the protocol; a prespecified interim anal. of overall survival was conducted and is reported here.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKr440jwrnEbVg90H21EOLACvtfcHk0liZILPvbvrnZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSnsLnM&md5=58f9b06cf2877e354899a6a26af138fd</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1607427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1607427%26sid%3Dliteratum%253Aachs%26aulast%3DStrosberg%26aufirst%3DJ.%26aulast%3DEl-Haddad%26aufirst%3DG.%26aulast%3DWolin%26aufirst%3DE.%26aulast%3DHendifar%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DChasen%26aufirst%3DB.%26aulast%3DMittra%26aufirst%3DE.%26aulast%3DKunz%26aufirst%3DP.%2BL.%26aulast%3DKulke%26aufirst%3DM.%2BH.%26aulast%3DJacene%26aufirst%3DH.%26aulast%3DBushnell%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Dorisio%26aufirst%3DT.%2BM.%26atitle%3DPhase%25203%2520trial%2520of%2520177Lu-dotatate%2520for%2520midgut%2520neuroendocrine%2520tumors%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2017%26volume%3D376%26spage%3D125%26epage%3D135%26doi%3D10.1056%2FNEJMoa1607427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barber, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niepsch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, R. P.</span></span> <span> </span><span class="NLM_article-title">Clinical outcomes of 177Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">955</span>– <span class="NLM_lpage">962</span>, <span class="refDoi"> DOI: 10.2967/jnumed.118.216820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.2967%2Fjnumed.118.216820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=30683770" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpslaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2019&pages=955-962&author=T.+W.+Barberauthor=A.+Singhauthor=H.+R.+Kulkarniauthor=K.+Niepschauthor=B.+Billahauthor=R.+P.+Baum&title=Clinical+outcomes+of+177Lu-PSMA+radioligand+therapy+in+earlier+and+later+phases+of+metastatic+castration-resistant+prostate+cancer+grouped+by+previous+taxane+chemotherapy&doi=10.2967%2Fjnumed.118.216820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical outcomes of 177Lu-PSMA radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy</span></div><div class="casAuthors">Barber, Thomas W.; Singh, Aviral; Kulkarni, Harshad R.; Niepsch, Karin; Billah, Baki; Baum, Richard P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">955-962</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy using PSMA-617 and PSMA-I&T ligands (177Lu-PRLT) is an emerging treatment in metastatic castration-resistant prostate cancer (mCRPC).  This retrospective study evaluates clin. outcomes of 177Lu-PRLT in earlier and later phases of mCRPC grouped by previous taxane chemotherapy.  A retrospective anal. was performed on 167 patients with mCRPC who underwent 177Lu-PRLT between March 2013 and Dec. 2016.  Patients were classified as either taxane chemotherapy pretreated (T-pretreated) or naive (T-naive) depending on whether they had received taxane-based chemotherapy prior to 177Lu-PRLT.  Clin. outcome for T-pretreated and T-naive patients was assessed by overall survival (OS), radiog. progression- free survival, and prostate-specific antigen (PSA) response rate.  Univariate and multivariable analyses were performed for both Tpretreated and T-naive patients to det. predictors of outcome.  Toxicity was categorized by the Common Terminol. Criteria for Adverse Events (version 4.03).  Of the 167 patients treated with 177Lu-PRLT, 83 were T-pretreated and 84 were T-naive.  At baseline, T-pretreated patients had overall poorer performance status, a higher prevalence of bone metastases, higher PSA levels, lower Hb levels, higher alk. phosphatase (ALP) levels and had received more addnl. therapies compared with T-naive patients.  Median OS was 10.7 mo for T-pretreated patients and 27.1 mo for T-naive patients.  Median radiog. progression-free survival was 6.0 mo for T-pretreated patients and 8.8 mo for T-naive patients.  PSA response assessment was evaluable in 132 patients and seen in 25 of 62 (40%) T-pretreated patients and 40 of 70 (57%) T-naive patients.  Significant determinates of inferior OS in multivariable anal. for T-pretreated patients were poorer performance status, lower cumulative administered activity, and lower baseline Hb.  Higher baseline alk. phosphatase was the only significant determinate of inferior OS in multivariable anal. for T-naive patients.  Overall 177Lu-PRLT was safe, with minimal adverse effects evident during follow-up in both T-pretreated and T-naive patients.  177Lu-PRLT is a promising therapy in mCRPC, with encouraging outcomes and minimal assocd. toxicity seen in both our T-naive and heavily pretreated patient cohorts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQlOH_-eDNvLVg90H21EOLACvtfcHk0liZILPvbvrnZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpslaqtw%253D%253D&md5=f042fc9d466570e85bfac4465a8d5df6</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.118.216820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.118.216820%26sid%3Dliteratum%253Aachs%26aulast%3DBarber%26aufirst%3DT.%2BW.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DKulkarni%26aufirst%3DH.%2BR.%26aulast%3DNiepsch%26aufirst%3DK.%26aulast%3DBillah%26aufirst%3DB.%26aulast%3DBaum%26aufirst%3DR.%2BP.%26atitle%3DClinical%2520outcomes%2520of%2520177Lu-PSMA%2520radioligand%2520therapy%2520in%2520earlier%2520and%2520later%2520phases%2520of%2520metastatic%2520castration-resistant%2520prostate%2520cancer%2520grouped%2520by%2520previous%2520taxane%2520chemotherapy%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2019%26volume%3D60%26spage%3D955%26epage%3D962%26doi%3D10.2967%2Fjnumed.118.216820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szajek, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiesewetter, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Single low-dose injection of evans blue modified PSMA-617 radioligand therapy eliminates prostate-specific membrane antigen positive tumors</span>. <i>Bioconjugate Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">3213</span>– <span class="NLM_lpage">3221</span>, <span class="refDoi"> DOI: 10.1021/acs.bioconjchem.8b00556</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.bioconjchem.8b00556" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVylsrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2018&pages=3213-3221&author=Z.+Wangauthor=R.+Tianauthor=G.+Niuauthor=Y.+Maauthor=L.+Langauthor=L.+P.+Szajekauthor=D.+O.+Kiesewetterauthor=O.+Jacobsonauthor=X.+Chen&title=Single+low-dose+injection+of+evans+blue+modified+PSMA-617+radioligand+therapy+eliminates+prostate-specific+membrane+antigen+positive+tumors&doi=10.1021%2Facs.bioconjchem.8b00556"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors</span></div><div class="casAuthors">Wang, Zhantong; Tian, Rui; Niu, Gang; Ma, Ying; Lang, Lixin; Szajek, Lawrence P.; Kiesewetter, Dale O.; Jacobson, Orit; Chen, Xiaoyuan</div><div class="citationInfo"><span class="NLM_cas:title">Bioconjugate Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3213-3221</span>CODEN:
                <span class="NLM_cas:coden">BCCHES</span>;
        ISSN:<span class="NLM_cas:issn">1043-1802</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Prostate cancer is the most frequently diagnosed malignant tumor in men worldwide.  Prostate-specific membrane antigen (PSMA) is a surface mol. specifically expressed by prostate tumors that has been shown to be a valid target for internal radionuclide therapy in both preclin. and clin. settings.  The most common radiotherapeutic agent is the small mol. 177Lu-PSMA-617, which is under clin. evaluation in multiple countries.  Nevertheless, its efficacy in causing tumor regression is still suboptimal, even when administered in several cycles per patient, perhaps due to poor pharmacokinetics (PK), which limits uptake by the tumor cells.  We postulated that the addn. of the Evans blue (EB) moiety to PSMA-617 would improve the PK by extending circulation half-life, which would increase tumor uptake and improve radiotherapeutic efficacy.  PSMA-617 was modified by conjugation of a 2-thiol acetate group onto the primary amine and thereafter reacted with a maleimide functional group of an EB deriv., to give EB-PSMA-617.  The PK and radiotherapeutic efficacy of 90Y- or 177Lu-EB-PSMA-617 was compared to the clin. used radiopharmaceutical 90Y- or 177Lu- PSMA-617 in PC3-PIP tumor-bearing mice.  EB-PSMA-617 retained binding to serum albumin as well as a high internalization rate by tumor cells.  Upon injection, metal-labeled EB-PSMA-617 demonstrated an extended blood half-life compared to PSMA-617 and, thereby, prolonged the time window for binding to PSMA.  The improved PK of EB-PSMA-617 resulted in significantly higher accumulation in PSMA+ tumors and highly effective radiotherapeutic efficacy.  Remarkably, a single dose of 1.85 MBq of 90Y- or 177Lu-EB-PSMA-617 was sufficient to eradicate established PMSA+ tumors in mice.  No significant body wt. loss was obsd., suggesting little to no gross toxicity.  The construct described here, EB-PSMA-617, may improve the radiotherapeutic efficacy for patients with PSMA-pos. tumors by reducing both the amt. of activity needed for therapy as well as the frequency of administration, as compared to PSMA-617.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVIct9lbcQfrVg90H21EOLACvtfcHk0liZILPvbvrnZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVylsrvO&md5=66a04f13d479e0fc7c4d7097ce148d31</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.bioconjchem.8b00556&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.bioconjchem.8b00556%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTian%26aufirst%3DR.%26aulast%3DNiu%26aufirst%3DG.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DLang%26aufirst%3DL.%26aulast%3DSzajek%26aufirst%3DL.%2BP.%26aulast%3DKiesewetter%26aufirst%3DD.%2BO.%26aulast%3DJacobson%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DSingle%2520low-dose%2520injection%2520of%2520evans%2520blue%2520modified%2520PSMA-617%2520radioligand%2520therapy%2520eliminates%2520prostate-specific%2520membrane%2520antigen%2520positive%2520tumors%26jtitle%3DBioconjugate%2520Chem.%26date%3D2018%26volume%3D29%26spage%3D3213%26epage%3D3221%26doi%3D10.1021%2Facs.bioconjchem.8b00556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, T. P.</span></span> <span> </span><span class="NLM_article-title">Peptide-targeted radionuclide therapy for melanoma</span>. <i>Crit. Rev Oncol./Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2008.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1016%2Fj.critrevonc.2008.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=18387816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BD1cnis1Ckuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2008&pages=213-228&author=Y.+Miaoauthor=T.+P.+Quinn&title=Peptide-targeted+radionuclide+therapy+for+melanoma&doi=10.1016%2Fj.critrevonc.2008.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide-targeted radionuclide therapy for melanoma</span></div><div class="casAuthors">Miao Yubin; Quinn Thomas P</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">213-28</span>
        ISSN:<span class="NLM_cas:issn">1040-8428</span>.
    </div><div class="casAbstract">Melanocortin-1 receptor (MC1-R) and melanin are two attractive melanoma-specific targets for peptide-targeted radionuclide therapy for melanoma.  Radiolabeled peptides targeting MC1-R/melanin can selectively and specifically target cytotoxic radiation generated from therapeutic radionuclides to melanoma cells for cell killing, while sparing the normal tissues and organs.  This review highlights the recent advances of peptide-targeted radionuclide therapy of melanoma targeting MC1-R and melanin.  The promising therapeutic efficacies of 188Re-(Arg(11))CCMSH (188Re-[Cys(3,4,10), D-Phe(7),Arg(11)]-alpha-MSH(3-13)), 177Lu- and 212Pb-labeled DOTA-Re(Arg(11))CCMSH (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-[ReO-(Cys(3,4,10), D-Phe(7), Arg(11))]-alpha-MSH(3-13)) and 188Re-HYNIC-4B4 (188Re-hydrazinonicotinamide-Tyr-Glu-Arg-Lys-Phe-Trp-His-Gly-Arg-His) in preclinical melanoma-bearing models demonstrate an optimistic outlook for peptide-targeted radionuclide therapy for melanoma.  Peptide-targeted radionuclide therapy for melanoma will likely contribute in an adjuvant setting, once the primary tumor has been surgically removed, to treat metastatic deposits and for treatment of end-stage disease.  The lack of effective treatments for metastatic melanoma and end-stage disease underscores the necessity to develop and implement new treatment strategies, such as peptide-targeted radionuclide therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRiJPWW4Lb-mMuCWE5mhx1RfW6udTcc2eYhgJcY11yvy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnis1Ckuw%253D%253D&md5=f1b8b2536ade387be4ce52e369b54637</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2008.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2008.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DMiao%26aufirst%3DY.%26aulast%3DQuinn%26aufirst%3DT.%2BP.%26atitle%3DPeptide-targeted%2520radionuclide%2520therapy%2520for%2520melanoma%26jtitle%3DCrit.%2520Rev%2520Oncol.%252FHematol.%26date%3D2008%26volume%3D67%26spage%3D213%26epage%3D228%26doi%3D10.1016%2Fj.critrevonc.2008.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wei, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span> <span> </span><span class="NLM_article-title">Fundamental mechanisms of immune checkpoint blockade therapy</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1069</span>– <span class="NLM_lpage">1086</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-18-0367</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1158%2F2159-8290.CD-18-0367" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=30115704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BB3c7ovV2lug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=1069-1086&author=S.+C.+Weiauthor=C.+R.+Duffyauthor=J.+P.+Allison&title=Fundamental+mechanisms+of+immune+checkpoint+blockade+therapy&doi=10.1158%2F2159-8290.CD-18-0367"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Fundamental Mechanisms of Immune Checkpoint Blockade Therapy</span></div><div class="casAuthors">Wei Spencer C; Duffy Colm R; Allison James P; Allison James P</div><div class="citationInfo"><span class="NLM_cas:title">Cancer discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1069-1086</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Immune checkpoint blockade is able to induce durable responses across multiple types of cancer, which has enabled the oncology community to begin to envision potentially curative therapeutic approaches.  However, the remarkable responses to immunotherapies are currently limited to a minority of patients and indications, highlighting the need for more effective and novel approaches.  Indeed, an extraordinary amount of preclinical and clinical investigation is exploring the therapeutic potential of negative and positive costimulatory molecules.  Insights into the underlying biological mechanisms and functions of these molecules have, however, lagged significantly behind.  Such understanding will be essential for the rational design of next-generation immunotherapies.  Here, we review the current state of our understanding of T-cell costimulatory mechanisms and checkpoint blockade, primarily of CTLA4 and PD-1, and highlight conceptual gaps in knowledge.Significance: This review provides an overview of immune checkpoint blockade therapy from a basic biology and immunologic perspective for the cancer research community.  Cancer Discov; 8(9); 1069-86. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQlpKqONKSUIwqdek-gHSrIfW6udTcc2eYhgJcY11yvy7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7ovV2lug%253D%253D&md5=fceabad6a29a522d25051d90ed3a3c44</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-18-0367&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-18-0367%26sid%3Dliteratum%253Aachs%26aulast%3DWei%26aufirst%3DS.%2BC.%26aulast%3DDuffy%26aufirst%3DC.%2BR.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26atitle%3DFundamental%2520mechanisms%2520of%2520immune%2520checkpoint%2520blockade%2520therapy%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26spage%3D1069%26epage%3D1086%26doi%3D10.1158%2F2159-8290.CD-18-0367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettigrew, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Single-molecule force measurement guides the design of multivalent ligand with picomolar affinity</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">5326</span>– <span class="NLM_lpage">5330</span>, <span class="refDoi"> DOI: 10.1002/ange.201814347</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1002%2Fange.201814347" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2019&pages=5326-5330&author=Z.+Yangauthor=S.+Jiangauthor=F.+Liauthor=Y.+Qiuauthor=J.+Guauthor=R.+I.+Pettigrewauthor=M.+Ferrariauthor=D.+J.+Hamiltonauthor=Z.+Li&title=Single-molecule+force+measurement+guides+the+design+of+multivalent+ligand+with+picomolar+affinity&doi=10.1002%2Fange.201814347"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fange.201814347&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fange.201814347%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DQiu%26aufirst%3DY.%26aulast%3DGu%26aufirst%3DJ.%26aulast%3DPettigrew%26aufirst%3DR.%2BI.%26aulast%3DFerrari%26aufirst%3DM.%26aulast%3DHamilton%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DSingle-molecule%2520force%2520measurement%2520guides%2520the%2520design%2520of%2520multivalent%2520ligand%2520with%2520picomolar%2520affinity%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2019%26volume%3D131%26spage%3D5326%26epage%3D5330%26doi%3D10.1002%2Fange.201814347" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">A tyrosine kinase inhibitor–based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1525</span>– <span class="NLM_lpage">1531</span>, <span class="refDoi"> DOI: 10.2967/jnumed.114.138925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.2967%2Fjnumed.114.138925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=24970912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVSrurrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=1525-1531&author=F.+Liauthor=S.+Jiangauthor=Y.+Zuauthor=D.+Y.+Leeauthor=Z.+Li&title=A+tyrosine+kinase+inhibitor%E2%80%93based+high-affinity+PET+radiopharmaceutical+targets+vascular+endothelial+growth+factor+receptor&doi=10.2967%2Fjnumed.114.138925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor</span></div><div class="casAuthors">Li, Feng; Jiang, Sheng; Zu, Youli; Lee, Daniel Y.; Li, Zheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1525-1531</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">Tyrosine kinase receptors including vascular endothelial growth factor receptor (VEGFR) have gained significant attention as pharmacol. targets.  However, clin. evaluation of small-mol. drugs or biologics that target these pathways has so far yielded mixed results in a variety of solid tumors.  The reasons for response variability remain unknown, including the temporal and spatial patterns of receptor tyrosine kinase expression.  Methods to detect and quantify the presence of such cellular receptors would greatly facilitate drug development and therapy response assessment.  We aimed to generate specific imaging agents as potential companion diagnostics that could also be used for targeted radionuclide therapy.  Here, we report on the synthesis and initial preclin. performance of 64Cu-labeled probes that were based on the kinase inhibitor already in clin. use, vandetanib (ZD6474), as a VEGFR-selective theranostic radiopharmaceutical.  Methods: A monomeric (ZD-G1) and a dimeric (ZD-G2) deriv. of ZD6474 were synthesized and conjugated with DOTA for chelation with 64Cu to produce the probes 64Cu-DOTA-ZD-G1 and 64Cu-DOTA-ZD-G2.  The binding affinity and specificity to VEGFR were measured using U-87 MG cells known to overexpress VEGFR.  Small-animal PET and biodistribution studies were performed with 64Cu-labeled probes (3-4 MBq) i.v. administered in U-87 MG tumor-bearing mice with or without coinjection of unlabeled ZD-G2 for up to 24 h after injection.  Results: Receptor-binding assays yielded a mean equil. dissocn. const. of 44.7 and 0.45 nM for monomeric and dimeric forms, resp., indicating a synergistic effect in VEGFR affinity by multivalency.  Small-animal PET/CT imaging showed rapid tumor accumulation of 64Cu-DOTA-ZD-G2, with excellent tumor-to-normal tissue contrast by 24 h.  Coinjection of the 64Cu-DOTA-ZD-G2 with 50 nmol (60 μg) of nonradioactive ZD-G2 effectively blocked tumor uptake.  Conclusion: A 64Cu-labeled probe derived from an approved oncol. drug selective for VEGFR demonstrates excellent tumor targeting, particularly for the dimeric form.  The multivalent probe yielded a 100-fold improvement in receptor affinity while maintaining pharmacokinetic and biodistribution properties well suited for PET imaging in our preclin. model.  These results indicate that a clin. relevant theranostic platform can be rapidly developed from known small mols. that target key cellular receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiDkS3tF9BU7Vg90H21EOLACvtfcHk0ljws2et7YxK3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVSrurrN&md5=2fe2cbca18a5366002a0ab70e450ced2</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.114.138925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.114.138925%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DZu%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DD.%2BY.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DA%2520tyrosine%2520kinase%2520inhibitor%25E2%2580%2593based%2520high-affinity%2520PET%2520radiopharmaceutical%2520targets%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2014%26volume%3D55%26spage%3D1525%26epage%3D1531%26doi%3D10.2967%2Fjnumed.114.138925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span> <span> </span><span class="NLM_article-title">177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">800</span>– <span class="NLM_lpage">807</span>, <span class="refDoi"> DOI: 10.1021/mp4005047</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp4005047" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlCnu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=800-807&author=Z.+Liuauthor=T.+Maauthor=H.+Liuauthor=Z.+Jinauthor=X.+Sunauthor=H.+Zhaoauthor=J.+Shiauthor=B.+Jiaauthor=F.+Liauthor=F.+Wang&title=177Lu-labeled+antibodies+for+EGFR-targeted+SPECT%2FCT+imaging+and+radioimmunotherapy+in+a+preclinical+head+and+neck+carcinoma+model&doi=10.1021%2Fmp4005047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">177Lu-Labeled Antibodies for EGFR-Targeted SPECT/CT Imaging and Radioimmunotherapy in a Preclinical Head and Neck Carcinoma Model</span></div><div class="casAuthors">Liu, Zhaofei; Ma, Teng; Liu, Hao; Jin, Zhongxia; Sun, Xianlei; Zhao, Huiyun; Shi, Jiyun; Jia, Bing; Li, Fang; Wang, Fan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">800-807</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) has been well characterized as an important target for cancer therapy.  Immunotherapy based on EGFR-specific antibodies (e.g., panitumumab and cetuximab) has shown great clin. promise.  However, increasing evidence has indicated that only a subgroup of patients receiving these antibodies will benefit from them, and even patients who do initially experience a major response may eventually develop therapeutic resistance.  In this study, we investigated whether panitumumab and cetuximab can serve as delivery vehicles for tumor-targeted radionuclide therapy in a preclin. tumor model that did not respond to immunotherapy.  The in vitro toxicity and cell binding properties of panitumumab and cetuximab were characterized.  Both antibodies were conjugated with 1,4,7,10-tetraazadodecane-N,N',N'',N'''-tetraacetic acid (DOTA) and radiolabeled with 177Lu.  Small-animal SPECT/CT, biodistribution, and radioimmunotherapy (RIT) studies of 177Lu-DOTA-panitumumab (177Lu-Pan) and 177Lu-DOTA-cetuximab (177Lu-Cet) were performed in the UM-SCC-22B tumor model.  Both 177Lu-Pan and 177Lu-Cet exhibited favorable tumor targeting efficacy.  The tumor uptake was 20.92 ± 4.45, 26.10 ± 5.18, and 13.27 ± 1.94% ID/g for 177Lu-Pan, and 15.67 ± 3.84, 15.72 ± 3.49, and 7.82 ± 2.36% ID/g for 177Lu-Cet at 24, 72, and 120 h p.i., resp.  RIT with a single dose of 14.8 MBq of 177Lu-Pan or 177Lu-Cet significantly delayed tumor growth. 177Lu-Pan induced more effective tumor growth inhibition due to a higher tumor uptake.  Our results suggest that panitumumab and cetuximab can function as effective carriers for tumor-targeted delivery of radiation, and that RIT is promising for targeted therapy of EGFR-pos. tumors, esp. for those tumors that are resistant to antibody-based immunotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgx1hCizrr8LVg90H21EOLACvtfcHk0liPIhAh_34F_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlCnu7g%253D&md5=b0990c8fc3d14e611fc74b66e9f6c37b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fmp4005047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp4005047%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DF.%26atitle%3D177Lu-labeled%2520antibodies%2520for%2520EGFR-targeted%2520SPECT%252FCT%2520imaging%2520and%2520radioimmunotherapy%2520in%2520a%2520preclinical%2520head%2520and%2520neck%2520carcinoma%2520model%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D800%26epage%3D807%26doi%3D10.1021%2Fmp4005047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yelamanchili, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youker, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmarian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pownall, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamilton, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Vulnerable atherosclerotic plaque imaging by small-molecule high-affinity positron emission tomography radiopharmaceutical</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>2</i></span>, <span class="NLM_elocation-id">1900005</span> <span class="refDoi"> DOI: 10.1002/adtp.201900005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1002%2Fadtp.201900005" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2019&author=Z.+Yangauthor=F.+Liauthor=D.+Yelamanchiliauthor=Z.+Zengauthor=C.+Rosalesauthor=K.+A.+Youkerauthor=H.+Shenauthor=M.+Ferrariauthor=J.+Mahmarianauthor=H.+J.+Pownallauthor=D.+J.+Hamiltonauthor=Z.+Li&title=Vulnerable+atherosclerotic+plaque+imaging+by+small-molecule+high-affinity+positron+emission+tomography+radiopharmaceutical&doi=10.1002%2Fadtp.201900005"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fadtp.201900005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadtp.201900005%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DYelamanchili%26aufirst%3DD.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DRosales%26aufirst%3DC.%26aulast%3DYouker%26aufirst%3DK.%2BA.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DFerrari%26aufirst%3DM.%26aulast%3DMahmarian%26aufirst%3DJ.%26aulast%3DPownall%26aufirst%3DH.%2BJ.%26aulast%3DHamilton%26aufirst%3DD.%2BJ.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DVulnerable%2520atherosclerotic%2520plaque%2520imaging%2520by%2520small-molecule%2520high-affinity%2520positron%2520emission%2520tomography%2520radiopharmaceutical%26jtitle%3DAdv.%2520Ther.%26date%3D2019%26volume%3D2%26doi%3D10.1002%2Fadtp.201900005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flaherty, K. T.</span></span> <span> </span><span class="NLM_article-title">Precision medicine for cancer with next-generation functional diagnostics</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">747</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1038/nrc4015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1038%2Fnrc4015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=26536825" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyhtrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=747-756&author=A.+A.+Friedmanauthor=A.+Letaiauthor=D.+E.+Fisherauthor=K.+T.+Flaherty&title=Precision+medicine+for+cancer+with+next-generation+functional+diagnostics&doi=10.1038%2Fnrc4015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Precision medicine for cancer with next-generation functional diagnostics</span></div><div class="casAuthors">Friedman, Adam A.; Letai, Anthony; Fisher, David E.; Flaherty, Keith T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">747-756</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Precision medicine is about matching the right drugs to the right patients.  Although this approach is technol. agnostic, in cancer there is a tendency to make precision medicine synonymous with genomics.  However, genome-based cancer therapeutic matching is limited by incomplete biol. understanding of the relationship between phenotype and cancer genotype.  This limitation can be addressed by functional testing of live patient tumor cells exposed to potential therapies.  Recently, several 'next-generation' functional diagnostic technologies have been reported, including novel methods for tumor manipulation, molecularly precise assays of tumor responses and device-based in situ approaches; these address the limitations of the older generation of chemosensitivity tests.  The promise of these new technologies suggests a future diagnostic strategy that integrates functional testing with next-generation sequencing and immunoprofiling to precisely match combination therapies to individual cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruPiW8jX9A2rVg90H21EOLACvtfcHk0liPIhAh_34F_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyhtrbE&md5=0399ef5124b61b600f98a3d057944049</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnrc4015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc4015%26sid%3Dliteratum%253Aachs%26aulast%3DFriedman%26aufirst%3DA.%2BA.%26aulast%3DLetai%26aufirst%3DA.%26aulast%3DFisher%26aufirst%3DD.%2BE.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26atitle%3DPrecision%2520medicine%2520for%2520cancer%2520with%2520next-generation%2520functional%2520diagnostics%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2015%26volume%3D15%26spage%3D747%26epage%3D756%26doi%3D10.1038%2Fnrc4015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coates, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhirsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelber, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart-Gebhart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thürlimann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senn, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">André, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnefoi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castiglione-Gertsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coates, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colleoni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curigliano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Leo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ejlertsen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forbes, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galimberti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelber, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldhirsch, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goodwin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harbeck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huober, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudis, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingle, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jassem, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orecchia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent Osborne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Partridge, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Peña, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccart-Gebhart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rutgers, E. J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sedlmayer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semiglazov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Z.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thürlimann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Minckwitz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whelan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winer, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, B.</span></span> <span> </span><span class="NLM_article-title">Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1533</span>– <span class="NLM_lpage">1546</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdv221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1093%2Fannonc%2Fmdv221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=25939896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BC2MfgsFWrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2015&pages=1533-1546&author=A.+S.+Coatesauthor=E.+P.+Winerauthor=A.+Goldhirschauthor=R.+D.+Gelberauthor=M.+Gnantauthor=M.+Piccart-Gebhartauthor=B.+Th%C3%BCrlimannauthor=H.+J.+Sennauthor=F.+Andr%C3%A9author=J.+Baselgaauthor=J.+Berghauthor=H.+Bonnefoiauthor=H.+Bursteinauthor=F.+Cardosoauthor=M.+Castiglione-Gertschauthor=A.+S.+Coatesauthor=M.+Colleoniauthor=G.+Curiglianoauthor=N.+E.+Davidsonauthor=A.+Di+Leoauthor=B.+Ejlertsenauthor=J.+F.+Forbesauthor=V.+Galimbertiauthor=R.+D.+Gelberauthor=M.+Gnantauthor=A.+Goldhirschauthor=P.+Goodwinauthor=N.+Harbeckauthor=D.+F.+Hayesauthor=J.+Huoberauthor=C.+A.+Hudisauthor=J.+N.+Ingleauthor=J.+Jassemauthor=Z.+Jiangauthor=P.+Karlssonauthor=M.+Morrowauthor=R.+Orecchiaauthor=C.+Kent+Osborneauthor=A.+H.+Partridgeauthor=L.+de+la+Pe%C3%B1aauthor=M.+J.+Piccart-Gebhartauthor=K.+I.+Pritchardauthor=E.+J.+T.+Rutgersauthor=F.+Sedlmayerauthor=V.+Semiglazovauthor=Z.-M.+Shaoauthor=I.+Smithauthor=B.+Th%C3%BCrlimannauthor=M.+Toiauthor=A.+Tuttauthor=G.+Vialeauthor=G.+von+Minckwitzauthor=T.+Watanabeauthor=T.+Whelanauthor=E.+P.+Winerauthor=B.+Xu&title=Tailoring+therapies%E2%80%94improving+the+management+of+early+breast+cancer%3A+St+Gallen+International+Expert+Consensus+on+the+Primary+Therapy+of+Early+Breast+Cancer+2015&doi=10.1093%2Fannonc%2Fmdv221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015</span></div><div class="casAuthors">Coates A S; Winer E P; Goldhirsch A; Gelber R D; Gnant M; Piccart-Gebhart M; Thurlimann B; Senn H-J</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1533-46</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The 14th St Gallen International Breast Cancer Conference (2015) reviewed substantial new evidence on locoregional and systemic therapies for early breast cancer.  Further experience has supported the adequacy of tumor margins defined as 'no ink on invasive tumor or DCIS' and the safety of omitting axillary dissection in specific cohorts.  Radiotherapy trials support irradiation of regional nodes in node-positive disease.  Considering subdivisions within luminal disease, the Panel was more concerned with indications for the use of specific therapies, rather than surrogate identification of intrinsic subtypes as measured by multiparameter molecular tests.  For the treatment of HER2-positive disease in patients with node-negative cancers up to 1 cm, the Panel endorsed a simplified regimen comprising paclitaxel and trastuzumab without anthracycline as adjuvant therapy.  For premenopausal patients with endocrine responsive disease, the Panel endorsed the role of ovarian function suppression with either tamoxifen or exemestane for patients at higher risk.  The Panel noted the value of an LHRH agonist given during chemotherapy for premenopausal women with ER-negative disease in protecting against premature ovarian failure and preserving fertility.  The Panel noted increasing evidence for the prognostic value of commonly used multiparameter molecular markers, some of which also carried prognostic information for late relapse.  The Panel noted that the results of such tests, where available, were frequently used to assist decisions about the inclusion of cytotoxic chemotherapy in the treatment of patients with luminal disease, but noted that threshold values had not been established for this purpose for any of these tests.  Multiparameter molecular assays are expensive and therefore unavailable in much of the world.  The majority of new breast cancer cases and breast cancer deaths now occur in less developed regions of the world.  In these areas, less expensive pathology tests may provide valuable information.  The Panel recommendations on treatment are not intended to apply to all patients, but rather to establish norms appropriate for the majority.  Again, economic considerations may require that less expensive and only marginally less effective therapies may be necessary in less resourced areas.  Panel recommendations do not imply unanimous agreement among Panel members.  Indeed, very few of the 200 questions received 100% agreement from the Panel.  In the text below, wording is intended to convey the strength of Panel support for each recommendation, while details of Panel voting on each question are available in supplementary Appendix S2, available at Annals of Oncology online.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR2WtDVBdr4Mz0SWnHPWbmmfW6udTcc2eapS_RxwEaSPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfgsFWrsw%253D%253D&md5=b0cb2029f3581a60b86a3894cb26897a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdv221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdv221%26sid%3Dliteratum%253Aachs%26aulast%3DCoates%26aufirst%3DA.%2BS.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DGoldhirsch%26aufirst%3DA.%26aulast%3DGelber%26aufirst%3DR.%2BD.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DPiccart-Gebhart%26aufirst%3DM.%26aulast%3DTh%25C3%25BCrlimann%26aufirst%3DB.%26aulast%3DSenn%26aufirst%3DH.%2BJ.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DBaselga%26aufirst%3DJ.%26aulast%3DBergh%26aufirst%3DJ.%26aulast%3DBonnefoi%26aufirst%3DH.%26aulast%3DBurstein%26aufirst%3DH.%26aulast%3DCardoso%26aufirst%3DF.%26aulast%3DCastiglione-Gertsch%26aufirst%3DM.%26aulast%3DCoates%26aufirst%3DA.%2BS.%26aulast%3DColleoni%26aufirst%3DM.%26aulast%3DCurigliano%26aufirst%3DG.%26aulast%3DDavidson%26aufirst%3DN.%2BE.%26aulast%3DDi%2BLeo%26aufirst%3DA.%26aulast%3DEjlertsen%26aufirst%3DB.%26aulast%3DForbes%26aufirst%3DJ.%2BF.%26aulast%3DGalimberti%26aufirst%3DV.%26aulast%3DGelber%26aufirst%3DR.%2BD.%26aulast%3DGnant%26aufirst%3DM.%26aulast%3DGoldhirsch%26aufirst%3DA.%26aulast%3DGoodwin%26aufirst%3DP.%26aulast%3DHarbeck%26aufirst%3DN.%26aulast%3DHayes%26aufirst%3DD.%2BF.%26aulast%3DHuober%26aufirst%3DJ.%26aulast%3DHudis%26aufirst%3DC.%2BA.%26aulast%3DIngle%26aufirst%3DJ.%2BN.%26aulast%3DJassem%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DKarlsson%26aufirst%3DP.%26aulast%3DMorrow%26aufirst%3DM.%26aulast%3DOrecchia%26aufirst%3DR.%26aulast%3DKent%2BOsborne%26aufirst%3DC.%26aulast%3DPartridge%26aufirst%3DA.%2BH.%26aulast%3Dde%2Bla%2BPe%25C3%25B1a%26aufirst%3DL.%26aulast%3DPiccart-Gebhart%26aufirst%3DM.%2BJ.%26aulast%3DPritchard%26aufirst%3DK.%2BI.%26aulast%3DRutgers%26aufirst%3DE.%2BJ.%2BT.%26aulast%3DSedlmayer%26aufirst%3DF.%26aulast%3DSemiglazov%26aufirst%3DV.%26aulast%3DShao%26aufirst%3DZ.-M.%26aulast%3DSmith%26aufirst%3DI.%26aulast%3DTh%25C3%25BCrlimann%26aufirst%3DB.%26aulast%3DToi%26aufirst%3DM.%26aulast%3DTutt%26aufirst%3DA.%26aulast%3DViale%26aufirst%3DG.%26aulast%3Dvon%2BMinckwitz%26aufirst%3DG.%26aulast%3DWatanabe%26aufirst%3DT.%26aulast%3DWhelan%26aufirst%3DT.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DXu%26aufirst%3DB.%26atitle%3DTailoring%2520therapies%25E2%2580%2594improving%2520the%2520management%2520of%2520early%2520breast%2520cancer%253A%2520St%2520Gallen%2520International%2520Expert%2520Consensus%2520on%2520the%2520Primary%2520Therapy%2520of%2520Early%2520Breast%2520Cancer%25202015%26jtitle%3DAnn.%2520Oncol.%26date%3D2015%26volume%3D26%26spage%3D1533%26epage%3D1546%26doi%3D10.1093%2Fannonc%2Fmdv221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span> <span> </span><span class="NLM_article-title">The emerging regulation of VEGFR-2 in triple-negative breast cancer</span>. <i>Front. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">159</span> <span class="refDoi"> DOI: 10.3389/fendo.2015.00159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.3389%2Ffendo.2015.00159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=26500608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADC%252BC28zlslWnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&author=X.+Zhuauthor=W.+Zhou&title=The+emerging+regulation+of+VEGFR-2+in+triple-negative+breast+cancer&doi=10.3389%2Ffendo.2015.00159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Zhu Xiaoxia; Zhou Wen</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in endocrinology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159</span>
        ISSN:<span class="NLM_cas:issn">1664-2392</span>.
    </div><div class="casAbstract">Vascular endothelial growth factor-A (VEGF) signals vascular development and angiogenesis mainly by binding to VEGF receptor family member 2 (VEGFR-2).  Adaptor proteins mediate many VEGFR-2's functions in the development of blood vessels.  Cancer cells secrete VEGF to activate VEGFR-2 pathway in their neighboring endothelial cells in the process of cancer-related angiogenesis.  Interestingly, activation of VEGFR-2 signaling is found in breast cancer cells, but its role and regulation are not clear.  We highlighted research advances of VEGFR-2, with a focus on VEGFR-2's regulation by mutant p53 in breast cancer.  In addition, we reviewed recent Food and Drug Administration-approved tyrosine kinase inhibitor drugs that can inhibit the function of VEGFR-2.  Ongoing preclinical and clinical studies might prove that pharmaceutically targeting VEGFR-2 could be an effective therapeutic strategy in treating triple-negative breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSFUMsAIro3rMULxIEhxUjPfW6udTcc2eapS_RxwEaSPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28zlslWnug%253D%253D&md5=2b4b9beffffd1a05a1463bd8275a37cb</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.3389%2Ffendo.2015.00159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffendo.2015.00159%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DW.%26atitle%3DThe%2520emerging%2520regulation%2520of%2520VEGFR-2%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DFront.%2520Endocrinol.%26date%3D2015%26volume%3D6%26doi%3D10.3389%2Ffendo.2015.00159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Folkman, J.</span></span> <span> </span><span class="NLM_article-title">Tumor angiogenesis: therapeutic implications</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1971</span>,  <span class="NLM_volume"><i>285</i></span>,  <span class="NLM_fpage">1182</span>– <span class="NLM_lpage">1186</span>, <span class="refDoi"> DOI: 10.1056/NEJM197111182852108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1056%2FNEJM197111182852108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=4938153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A280%3ADyaE38%252FgvVCqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=285&publication_year=1971&pages=1182-1186&author=J.+Folkman&title=Tumor+angiogenesis%3A+therapeutic+implications&doi=10.1056%2FNEJM197111182852108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Tumor angiogenesis: therapeutic implications</span></div><div class="casAuthors">Folkman J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1971</span>),
    <span class="NLM_cas:volume">285</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1182-6</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRA0C6odtE1LPxQvRxYU81tfW6udTcc2eYbElBB3ZDG5Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE38%252FgvVCqsQ%253D%253D&md5=efdddcba0c04be542edd51fef2ef27b9</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1056%2FNEJM197111182852108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM197111182852108%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DTumor%2520angiogenesis%253A%2520therapeutic%2520implications%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1971%26volume%3D285%26spage%3D1182%26epage%3D1186%26doi%3D10.1056%2FNEJM197111182852108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Folkman, J.</span></span> <span> </span><span class="NLM_article-title">Angiogenesis: an organizing principle for drug discovery?</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">286</span>, <span class="refDoi"> DOI: 10.1038/nrd2115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1038%2Fnrd2115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=17396134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs1SisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=273-286&author=J.+Folkman&title=Angiogenesis%3A+an+organizing+principle+for+drug+discovery%3F&doi=10.1038%2Fnrd2115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Angiogenesis: an organizing principle for drug discovery?</span></div><div class="casAuthors">Folkman, Judah</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">273-286</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Angiogenesis - the process of new blood-vessel growth - has an essential role in development, reprodn. and repair.  However, pathol. angiogenesis occurs not only in tumor formation, but also in a range of non-neoplastic diseases that could be classed together as 'angiogenesis-dependent diseases'.  By viewing the process of angiogenesis as an 'organizing principle' in biol., intriguing insights into the mol. mechanisms of seemingly unrelated phenomena might be gained.  This has important consequences for the clin. use of angiogenesis inhibitors and for drug discovery, not only for optimizing the treatment of cancer, but possibly also for developing therapeutic approaches for various diseases that are otherwise unrelated to each other.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4BkXDYKVlmLVg90H21EOLACvtfcHk0ljKIpO_sUkEYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs1SisL4%253D&md5=2556d5e3a653c3dcac5b3297e2645c3c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrd2115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2115%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAngiogenesis%253A%2520an%2520organizing%2520principle%2520for%2520drug%2520discovery%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D273%26epage%3D286%26doi%3D10.1038%2Fnrd2115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.-M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C.-H.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium(iii) metal-based compound</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">4756</span>– <span class="NLM_lpage">4763</span>, <span class="refDoi"> DOI: 10.1039/C7SC00311K</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1039%2FC7SC00311K" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=28959398" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVeltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=4756-4763&author=L.-J.+Liuauthor=W.+Wangauthor=S.-Y.+Huangauthor=Y.+Hongauthor=G.+Liauthor=S.+Linauthor=J.+Tianauthor=Z.+Caiauthor=H.-M.+D.+Wangauthor=D.-L.+Maauthor=C.-H.+Leung&title=Inhibition+of+the+Ras%2FRaf+interaction+and+repression+of+renal+cancer+xenografts+in+vivo+by+an+enantiomeric+iridium%28iii%29+metal-based+compound&doi=10.1039%2FC7SC00311K"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the Ras/Raf interaction and repression of renal cancer xenografts in vivo by an enantiomeric iridium(III) metal-based compound</span></div><div class="casAuthors">Liu, Li-Juan; Wang, Wanhe; Huang, Shi-Ying; Hong, Yanjun; Li, Guodong; Lin, Sheng; Tian, Jinglin; Cai, Zongwei; Wang, Hui-Min David; Ma, Dik-Lung; Leung, Chung-Hang</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4756-4763</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Targeting protein-protein interactions (PPIs) offers tantalizing opportunities for therapeutic intervention for the treatment of human diseases.  Modulating PPI interfaces with org. small mols. has been found to be exceptionally challenging, and few candidates have been successfully developed into clin. drugs.  Meanwhile, the striking array of distinctive properties exhibited by metal compds. renders them attractive scaffolds for the development of bioactive leads.  Here, we report the identification of iridium(III) compds. as inhibitors of the H-Ras/Raf-1 PPI.  The lead iridium(III) compd. 1 exhibited potent inhibitory activity against the H-Ras/Raf-1 interaction and its signaling pathway in vitro and in vivo, and also directly engaged both H-Ras and Raf-1-RBD in cell lysates.  Moreover, 1 repressed tumor growth in a mouse renal xenograft tumor model.  Intriguingly, the Δ-enantiomer of 1 showed superior potency in the biol. assays compared to Λ-1 or racemic 1.  These compds. could potentially be used as starting scaffolds for the development of more potent Ras/Raf PPI inhibitors for the treatment of kidney cancer or other proliferative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr81r1n5s7wkrVg90H21EOLACvtfcHk0ljKIpO_sUkEYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVeltbk%253D&md5=b1c8c88211bab7eca780eb33b35dc772</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1039%2FC7SC00311K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC7SC00311K%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.-J.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DS.-Y.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DTian%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DH.-M.%2BD.%26aulast%3DMa%26aufirst%3DD.-L.%26aulast%3DLeung%26aufirst%3DC.-H.%26atitle%3DInhibition%2520of%2520the%2520Ras%252FRaf%2520interaction%2520and%2520repression%2520of%2520renal%2520cancer%2520xenografts%2520in%2520vivo%2520by%2520an%2520enantiomeric%2520iridium%2528iii%2529%2520metal-based%2520compound%26jtitle%3DChem.%2520Sci.%26date%3D2017%26volume%3D8%26spage%3D4756%26epage%3D4763%26doi%3D10.1039%2FC7SC00311K" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D. L.</span></span> <span> </span><span class="NLM_article-title">Interfering with S100B-effector protein interactions for cancer therapy</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1754</span>– <span class="NLM_lpage">1761</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2020.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1016%2Fj.drudis.2020.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=32679172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVWhsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=1754-1761&author=K.+J.+Wuauthor=W.+Wangauthor=H.+D.+Wangauthor=C.+H.+Leungauthor=D.+L.+Ma&title=Interfering+with+S100B-effector+protein+interactions+for+cancer+therapy&doi=10.1016%2Fj.drudis.2020.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Interfering with S100B-effector protein interactions for cancer therapy</span></div><div class="casAuthors">Wu, Ke-Jia; Wang, Wanhe; Wang, Hui-Min David; Leung, Chung-Hang; Ma, Dik-Lung</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1754-1761</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  S100 calcium-binding protein B (S100B) is overexpressed in various malignant tumors, where it regulates cancer cell proliferation and metab. by phys. interactions with other mols.  Interfering with S100B-effector protein interactions is a potential strategy to treat malignant tumors.  Although some S100B inhibitors have been discovered by virtual screening (VS), most target the S100B-p53 interaction.  Hence, there is scope for the discovery of other S100B-effector protein interaction modulators for malignant tumors.  In this review, we provide an overview of S100B-effector protein interaction inhibitor discovery using VS and discuss promising S100B-effector protein interaction targets that permit in silico anal. for drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvmIh-e_AFDbVg90H21EOLACvtfcHk0ljKIpO_sUkEYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVWhsbnI&md5=3461c73b1bb4bbf54d90aaedcddc04ab</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2020.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2020.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%2BD.%26aulast%3DLeung%26aufirst%3DC.%2BH.%26aulast%3DMa%26aufirst%3DD.%2BL.%26atitle%3DInterfering%2520with%2520S100B-effector%2520protein%2520interactions%2520for%2520cancer%2520therapy%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2020%26volume%3D25%26spage%3D1754%26epage%3D1761%26doi%3D10.1016%2Fj.drudis.2020.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McBride, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, R. M.</span></span> <span> </span><span class="NLM_article-title">Pretargeted molecular imaging and radioimmunotherapy</span>. <i>Theranostics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">523</span>– <span class="NLM_lpage">540</span>, <span class="refDoi"> DOI: 10.7150/thno.3582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.7150%2Fthno.3582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=22737190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC38XosVertrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=523-540&author=D.+M.+Goldenbergauthor=C.-H.+Changauthor=E.+A.+Rossiauthor=W.+J.+McBrideauthor=R.+M.+Sharkey&title=Pretargeted+molecular+imaging+and+radioimmunotherapy&doi=10.7150%2Fthno.3582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Pretargeted molecular imaging and radioimmunotherapy</span></div><div class="casAuthors">Goldenberg, David M.; Chang, Chien-Hsing; Rossi, Edmund A.; McBride, William J.; Sharkey, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Theranostics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">523-540</span>CODEN:
                <span class="NLM_cas:coden">THERDS</span>;
        ISSN:<span class="NLM_cas:issn">1838-7640</span>.
    
            (<span class="NLM_cas:orgname">Ivyspring International Publisher</span>)
        </div><div class="casAbstract">A review.  Pretargeting is a multi-step process that first has an unlabeled bispecific antibody (bsMAb) localize within a tumor by virtue of its anti-tumor binding site(s) before administering a small, fast-clearing radiolabeled compd. that then attaches to the other portion of the bsMAb.  The compd.'s rapid clearance significantly reduces radiation exposure outside of the tumor and its small size permits speedy delivery to the tumor, creating excellent tumor/nontumor ratios in less than 1 h.  Haptens that bind to an anti-hapten antibody, biotin that binds to streptavidin, or an oligonucleotide binding to a complementary oligonucleotide sequence have all been radiolabeled for use by pretargeting.  This review will focus on a highly flexible anti-hapten bsMAb platform that has been used to target a variety of radionuclides to image (SPECT and PET) as well as treat tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdfeGKgIG2ArVg90H21EOLACvtfcHk0lgZAqyRpl6rTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosVertrY%253D&md5=2feba3fec5db97a91f98fc672185e449</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.7150%2Fthno.3582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fthno.3582%26sid%3Dliteratum%253Aachs%26aulast%3DGoldenberg%26aufirst%3DD.%2BM.%26aulast%3DChang%26aufirst%3DC.-H.%26aulast%3DRossi%26aufirst%3DE.%2BA.%26aulast%3DMcBride%26aufirst%3DW.%2BJ.%26aulast%3DSharkey%26aufirst%3DR.%2BM.%26atitle%3DPretargeted%2520molecular%2520imaging%2520and%2520radioimmunotherapy%26jtitle%3DTheranostics%26date%3D2012%26volume%3D2%26spage%3D523%26epage%3D540%26doi%3D10.7150%2Fthno.3582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skora, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blosser, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinzler, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogelstein, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span> <span> </span><span class="NLM_article-title">Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">11774</span>– <span class="NLM_lpage">11779</span>, <span class="refDoi"> DOI: 10.1073/pnas.1410626111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1073%2Fpnas.1410626111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=25071169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1amsb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=11774-11779&author=K.+Kimauthor=A.+D.+Skoraauthor=Z.+Liauthor=Q.+Liuauthor=A.+J.+Tamauthor=R.+L.+Blosserauthor=L.+A.+Diazauthor=N.+Papadopoulosauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=S.+Zhou&title=Eradication+of+metastatic+mouse+cancers+resistant+to+immune+checkpoint+blockade+by+suppression+of+myeloid-derived+cells&doi=10.1073%2Fpnas.1410626111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells</span></div><div class="casAuthors">Kim, KiBem; Skora, Andrew D.; Li, Zhaobo; Liu, Qiang; Tam, Ada J.; Blosser, Richard L.; Diaz, Luis A. Jr.; Papadopoulos, Nickolas; Kinzler, Kenneth W.; Vogelstein, Bert; Zhou, Shibin</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">11774-11779</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Impressive responses have been obsd. in patients treated with checkpoint inhibitory anti-programmed cell death-1 (PD-1) or anti-cytotoxic T-lymphocyte-assocd. antigen-4 (CTLA-4) antibodies.  However, immunotherapy against poorly immunogenic cancers remains a challenge.  Here we report that treatment with both anti-PD-1 and anti-CTLA-4 antibodies was unable to eradicate large, modestly immunogenic CT26 tumors or metastatic 4T1 tumors.  Cotreatment with epigenetic-modulating drugs and checkpoint inhibitors markedly improved treatment outcomes, curing more than 80% of the tumor-bearing mice.  Functional studies revealed that the primary targets of the epigenetic modulators were myeloid-derived suppressor cells (MDSCs).  A PI3K inhibitor that reduced circulating MDSCs also eradicated 4T1 tumors in 80% of the mice when combined with immune checkpoint inhibitors.  Thus, cancers resistant to immune checkpoint blockade can be cured by eliminating MDSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobXSdogLP7T7Vg90H21EOLACvtfcHk0lgZAqyRpl6rTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1amsb%252FL&md5=89ba46cd5660d507aa3e4268033edd4d</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1410626111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1410626111%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%26aulast%3DSkora%26aufirst%3DA.%2BD.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DTam%26aufirst%3DA.%2BJ.%26aulast%3DBlosser%26aufirst%3DR.%2BL.%26aulast%3DDiaz%26aufirst%3DL.%2BA.%26aulast%3DPapadopoulos%26aufirst%3DN.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DS.%26atitle%3DEradication%2520of%2520metastatic%2520mouse%2520cancers%2520resistant%2520to%2520immune%2520checkpoint%2520blockade%2520by%2520suppression%2520of%2520myeloid-derived%2520cells%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2014%26volume%3D111%26spage%3D11774%26epage%3D11779%26doi%3D10.1073%2Fpnas.1410626111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S.-O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, H.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perillo, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M.-C.</span></span> <span> </span><span class="NLM_article-title">Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2018.01.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.1016%2Fj.ccell.2018.01.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=29438695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2018&pages=187-201&author=C.-W.+Liauthor=S.-O.+Limauthor=E.+M.+Chungauthor=Y.-S.+Kimauthor=A.+H.+Parkauthor=J.+Yaoauthor=J.-H.+Chaauthor=W.+Xiaauthor=L.-C.+Chanauthor=T.+Kimauthor=S.-S.+Changauthor=H.-H.+Leeauthor=C.-K.+Chouauthor=Y.-L.+Liuauthor=H.-C.+Yehauthor=E.+P.+Perilloauthor=A.+K.+Dunnauthor=C.-W.+Kuoauthor=K.-H.+Khooauthor=J.+L.+Hsuauthor=Y.+Wuauthor=J.-M.+Hsuauthor=H.+Yamaguchiauthor=T.-H.+Huangauthor=A.+A.+Sahinauthor=G.+N.+Hortobagyiauthor=S.+S.+Yooauthor=M.-C.+Hung&title=Eradication+of+triple-negative+breast+cancer+cells+by+targeting+glycosylated+PD-L1&doi=10.1016%2Fj.ccell.2018.01.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1</span></div><div class="casAuthors">Li, Chia-Wei; Lim, Seung-Oe; Chung, Ezra M.; Kim, Yong-Soo; Park, Andrew H.; Yao, Jun; Cha, Jong-Ho; Xia, Weiya; Chan, Li-Chuan; Kim, Taewan; Chang, Shih-Shin; Lee, Heng-Huan; Chou, Chao-Kai; Liu, Yen-Liang; Yeh, Hsin-Chih; Perillo, Evan P.; Dunn, Andrew K.; Kuo, Chu-Wei; Khoo, Kay-Hooi; Hsu, Jennifer L.; Wu, Yun; Hsu, Jung-Mao; Yamaguchi, Hirohito; Huang, Tzu-Hsuan; Sahin, Aysegul A.; Hortobagyi, Gabriel N.; Yoo, Stephen S.; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-201.e10</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Protein glycosylation provides proteomic diversity in regulating protein localization, stability, and activity; it remains largely unknown whether the sugar moiety contributes to immunosuppression.  In the study of immune receptor glycosylation, we showed that EGF induces programmed death ligand 1 (PD-L1) and receptor programmed cell death protein 1 (PD-1) interaction, requiring β-1,3-N-acetylglucosaminyl transferase (B3GNT3) expression in triple-neg. breast cancer.  Downregulation of B3GNT3 enhances cytotoxic T cell-mediated anti-tumor immunity.  A monoclonal antibody targeting glycosylated PD-L1 (gPD-L1) blocks PD-L1/PD-1 interaction and promotes PD-L1 internalization and degrdn.  In addn. to immune reactivation, drug-conjugated gPD-L1 antibody induces a potent cell-killing effect as well as a bystander-killing effect on adjacent cancer cells lacking PD-L1 expression without any detectable toxicity.  Our work suggests targeting protein glycosylation as a potential strategy to enhance immune checkpoint therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOCUWMg3ECZrVg90H21EOLACvtfcHk0lgZAqyRpl6rTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSgt78%253D&md5=f8455254b3af2db53721cc7977ec3a6e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2018.01.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2018.01.009%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.-W.%26aulast%3DLim%26aufirst%3DS.-O.%26aulast%3DChung%26aufirst%3DE.%2BM.%26aulast%3DKim%26aufirst%3DY.-S.%26aulast%3DPark%26aufirst%3DA.%2BH.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DCha%26aufirst%3DJ.-H.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DChan%26aufirst%3DL.-C.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DChang%26aufirst%3DS.-S.%26aulast%3DLee%26aufirst%3DH.-H.%26aulast%3DChou%26aufirst%3DC.-K.%26aulast%3DLiu%26aufirst%3DY.-L.%26aulast%3DYeh%26aufirst%3DH.-C.%26aulast%3DPerillo%26aufirst%3DE.%2BP.%26aulast%3DDunn%26aufirst%3DA.%2BK.%26aulast%3DKuo%26aufirst%3DC.-W.%26aulast%3DKhoo%26aufirst%3DK.-H.%26aulast%3DHsu%26aufirst%3DJ.%2BL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHsu%26aufirst%3DJ.-M.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DT.-H.%26aulast%3DSahin%26aufirst%3DA.%2BA.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DYoo%26aufirst%3DS.%2BS.%26aulast%3DHung%26aufirst%3DM.-C.%26atitle%3DEradication%2520of%2520triple-negative%2520breast%2520cancer%2520cells%2520by%2520targeting%2520glycosylated%2520PD-L1%26jtitle%3DCancer%2520Cell%26date%3D2018%26volume%3D33%26spage%3D187%26epage%3D201%26doi%3D10.1016%2Fj.ccell.2018.01.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. H.</span></span> <span> </span><span class="NLM_article-title">Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">185</span> <span class="refDoi"> DOI: 10.3389/fphar.2018.00185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=10.3389%2Ffphar.2018.00185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=29556198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1egsLnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&author=Y.+Wangauthor=W.+Dengauthor=N.+Liauthor=S.+Neriauthor=A.+Sharmaauthor=W.+Jiangauthor=S.+H.+Lin&title=Combining+immunotherapy+and+radiotherapy+for+cancer+treatment%3A+current+challenges+and+future+directions&doi=10.3389%2Ffphar.2018.00185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Combining immunotherapy and radiotherapy for cancer treatment: current challenges and future directions</span></div><div class="casAuthors">Wang, Yifan; Deng, Weiye; Li, Nan; Neri, Shinya; Sharma, Amrish; Jiang, Wen; Lin, Steven H.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">185/1-185/11</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the development of anticancer immunotherapy agents has thrived.  The success of many immune-checkpoint inhibitors has drastically changed the landscape of cancer treatment.  For some types of cancer, monotherapy for targeting immune checkpoint pathways has proven more effective than traditional therapies, and combining immunotherapy with current treatment strategies may yield even better outcomes.  Numerous preclin. studies have suggested that combining immunotherapy with radiotherapy could be a promising strategy for synergistic enhancement of treatment efficacy.  Radiation delivered to the tumor site affects both tumor cells and surrounding stromal cells.  Radiation-induced cancer cell damage exposes tumor-specific antigens that make them visible to immune surveillance and promotes the priming and activation of cytotoxic T cells.  Radiation-induced modulation of the tumor microenvironment may also facilitate the recruitment and infiltration of immune cells.  This unique relationship is the rationale for combining radiation with immune checkpoint blockade.  Enhanced tumor recognition and immune cell targeting with checkpoint blockade may unleash the immune system to eliminate the cancer cells.  However, challenges remain to be addressed to maximize the efficacy of this promising combination.  Here we summarize the mechanisms of radiation and immune system interaction, and we discuss current challenges in radiation and immune checkpoint blockade therapy and possible future approaches to boost this combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBtkPZgvdoirVg90H21EOLACvtfcHk0lhAXoe7JMWl5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1egsLnJ&md5=8b5ae6b55679ba67aa0b103c763f6576</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.00185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.00185%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DNeri%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DS.%2BH.%26atitle%3DCombining%2520immunotherapy%2520and%2520radiotherapy%2520for%2520cancer%2520treatment%253A%2520current%2520challenges%2520and%2520future%2520directions%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26doi%3D10.3389%2Ffphar.2018.00185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuchardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langbein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, R.</span></span> <span> </span><span class="NLM_article-title">Early initiation of Lu-177 PSMA radioligand therapy prolongs overall survival in metastatic prostate cancer</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">529</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;key=29025984" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=529&author=H.+Kulkarniauthor=C.+Schuchardtauthor=A.+Singhauthor=T.+Langbeinauthor=R.+Baum&title=Early+initiation+of+Lu-177+PSMA+radioligand+therapy+prolongs+overall+survival+in+metastatic+prostate+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DH.%26aulast%3DSchuchardt%26aufirst%3DC.%26aulast%3DSingh%26aufirst%3DA.%26aulast%3DLangbein%26aufirst%3DT.%26aulast%3DBaum%26aufirst%3DR.%26atitle%3DEarly%2520initiation%2520of%2520Lu-177%2520PSMA%2520radioligand%2520therapy%2520prolongs%2520overall%2520survival%2520in%2520metastatic%2520prostate%2520cancer%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2018%26volume%3D59%26spage%3D529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i24"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01957">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_03473"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01957?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01957</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">NMR and MS spectra of representative compounds and stability validation of the investigated radiotracers (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES formula of each tested compound and associated biochemical data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_002.csv">CSV</a>)</p></li><li><p class="inline">Scheme 1 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_003.cdx">CDX</a>)</p></li><li><p class="inline">Scheme 2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_004.cdx">CDX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_001.pdf">jm0c01957_si_001.pdf (694.86 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_002.csv">jm0c01957_si_002.csv (1.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_003.cdx">jm0c01957_si_003.cdx (25.25 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01957/suppl_file/jm0c01957_si_004.cdx">jm0c01957_si_004.cdx (24.53 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01957&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01957%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01957" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799354359ba3d5a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
